Advantageous Anti-hcv combination therapy

TWI945223BActive Publication Date: 2026-11-11ATEA PHARMACEUTICALS INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
TW111122743
Authority / Receiving Office
TW · TW
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-06-17
Filing Date
2022-06-17
Publication Date
2026-11-11
Estimated Expiration
2042-06-16

AI Technical Summary

Technical Problem

There is a strong medical need for anti-HCV therapies that are safe, effective, and well-tolerated, as existing treatments face challenges with drug resistance and varying responses across different HCV genotypes, and current combination therapies have shown suboptimal efficacy and adverse events.

Method used

A synergistic combination of a potent pan-genotypic NS5B polymerase inhibitor (AT-527 or benibuvir) and an NS5A inhibitor (ruzasvir or MK-8408) is administered in fixed-dose or separate dosage forms to achieve overlapping pharmacokinetics, enhancing antiviral activity and reducing drug resistance.

Benefits of technology

The combination achieves high synergy, effectively reducing HCV viral load in both cirrhotic and non-cirrhotic patients within a shorter treatment duration, limiting drug resistance and adverse events.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure TWG2TB001919968_001
    Figure TWG2TB001919968_001
  • Figure TWG2TB001919968_002
    Figure TWG2TB001919968_002
  • Figure TWG2TB001919968_003
    Figure TWG2TB001919968_003
Patent Text Reader

Abstract

A synergistic pharmaceutical combination of compound 1 or a pharmaceutically acceptable salt thereof (e.g., compound 1-A) and compound 2 or a pharmaceutically acceptable salt thereof, and its use in treating hepatitis C or hepatitis C-related symptoms, and a method for manufacturing the pharmaceutical combination:
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This invention relates to a pharmaceutical combination of a specific NS5B polymerase inhibitor and a specific NS5A inhibitor for use in a beneficial and synergistic HCV therapy. [Previous Technology]

[0002] Hepatitis C (HCV) is an RNA single-stranded virus and a member of the hepatovirus genus. It is estimated that most cases of liver disease are caused by HCV. HCV infection can lead to cirrhosis and liver cancer, and if left untreated, it can lead to liver failure, which may require a liver transplant.

[0003] RNA polymerase is a key target for drug development against single-stranded RNA viruses. The HCV non-structural protein NS5B is a key enzyme in the RNA-dependent RNA polymerase system responsible for initiating and catalyzing viral RNA synthesis. There are two main subclasses of NS5B inhibitors: nucleoside analogs and non-nucleoside inhibitors (NNIs). Nucleoside analogs are metabolized into active triphosphates that act as alternative acceptors for the polymerase. Non-nucleoside inhibitors (NNIs) bind to the isotopic region on the protein. Nucleoside or nucleotide inhibitors mimic the native polymerase acceptor and act as chain terminators. They inhibit the initiation of RNA transcription and / or the elongation of nascent RNA chains.

[0004] In addition to targeting RNA polymerase, other RNA virus proteins can also be targeted for treatment. Examples of other HCV proteins that can be targeted for therapeutic purposes include NS3 / 4A (serine protease) and NS5A (a non-structural protein that is an essential component of HCV replicase and plays a series of effects along the cellular pathway).

[0005] In December 2013, the first nucleoside NS5B polymerase inhibitor, sofosbuvir (Sovaldi®, Gilead Sciences), was approved. Sovaldi® is a prodrug of uridine phosphatase, which is absorbed by hepatocytes and activated intracellularly to yield its active metabolite, 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphosphate. Sovaldi® 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphosphate

[0006] Sovaldi® is the first drug proven safe and effective for treating certain types of HCV infection without co-administration of interferon. Sovaldi® is the third drug to receive FDA Breakthrough Therapy designation.

[0007] Several fixed-dose drug combinations have been approved for the treatment of HCV. In 2014, the U.S. FDA approved Harvoni® (ledipasvir, an NS5A inhibitor, and sofosbuvir) for the treatment of chronic hepatitis C virus genotype 1 infection. Harvoni® was the first combination pill approved for the treatment of chronic HCV genotype 1 infection. It was also the first approved regimen that did not require co-administration with interferon or ribavirin. In addition, the FDA approved the combination of simeprevir (Olysio™) and sofosbuvir (Sovaldi®) as a once-daily, all-oral, interferon- and ribavirin-free treatment for adults with genotype 1 HCV infection.

[0008] In 2014, the U.S. FDA also approved AbbVie's VIEKIRA Pak™, a multi-pill pack containing dasabuvir (a non-nucleoside NS5B polymerase inhibitor), ombitasvir (an NS5A inhibitor), paritaprevir (an NS3 / 4A inhibitor), and ritonavir. VIEKIRA Pak™ can be used, with or without ribavirin, to treat patients with genotype 1 HCV infection, including those with compensated cirrhosis. VIEKIRA Pak™ does not require interferon co-therapy.

[0009] In July 2015, the U.S. FDA approved Technivie™ and Daklinza™ for the treatment of HCV genotype 4 and HCV genotype 3, respectively. Technivie™ (opitivvir / paripvir / ritonavir) was approved in combination with ribavirin for the treatment of HCV genotype 4 in patients without scarring or cirrhosis, and was the first option for HCV-4 infection patients that did not require co-administration with interferon. Daklinza™ was approved in combination with Sovaldi® for the treatment of HCV genotype 3 infection. Daklinza™ was the first drug to demonstrate safety and efficacy in treating HCV genotype 3 without co-administration of interferon or ribavirin. In October 2015, the U.S. FDA warned that HCV treatment with Viekira Pak and Technivie could cause serious liver damage primarily in patients with underlying advanced liver disease and requested additional safety information to be added to the label.

[0010] In August 2017, Mavyret® (glecaprevir / pibrentasvir) was approved by the U.S. FDA for the treatment of patients with all major genotypes (genotypes 1 to 6) of HCV. This treatment was also approved for patients without sclerosis or with mild sclerosis, patients on dialysis, and patients with genotype 1 infection who had previously been treated with a regimen containing an NS5A or NS3 / 4A inhibitor. Mavyret® was used for an 8-week course of treatment in previously untreated, non-sclerotic patients. In 2019, the FDA approved an 8-week course of treatment in patients with compensated sclerosis who had previously been untreated.

[0011] Epclusa®, together with Mavyret®, is another therapeutic agent for the treatment of HCV. Epclusa, developed by Gilead, is a fixed-dose combination therapy containing sofosbuvir (an NS5B inhibitor) and velpatasvir (an NS5A inhibitor). Epclusa® was approved in 2016 for the treatment of adults with chronic HCV infection of all major genotypes (genotypes 1 to 6) in patients without cirrhosis or with compensated cirrhosis, in a 12-week prescription. For patients with decompensated cirrhosis, Epclusa® is approved for use in combination with ribavirin.

[0012] Other approved therapies for HCV include interferon alpha-2b or pegylated interferon alpha-2b (Pegintron®), which can be administered in combination with ribavirin (Rebetol®), NS3 / 4A telaprevir (Incivek®, Vertex and Johnson & Johnson), boceprevir (Victrelis™, Merck), cimetidine (Olysio™, Johnson & Johnson), pariprevir (AbbVie), opiativir (AbbVie), and NNI dasabuvir (ABT-333).

[0013] U.S. and WO applications describing nucleoside polymerase inhibitors for the treatment of flaviviridae (including HCV) include those filed by: Idenix Pharmaceuticals (6,812,219; 6,914,054; 7,105,493; 7,138,376; 7,148,206; 7,157,441; 7,163,929; 7,169,766; 7,192,936; 7,365,057; 7,384,924; 7,456,155; 7,547,700). 4; 7,582,618; 7,608,597; 7,608,600; 7,625,875; 7,635,689; 7,662,798; 7,824,851; 7,902,202; 7,932,240; 7,951,789; 8,193,372; 8,299,038; 8,343,9 37; 8,362,068; 8,507,460; 8,637,475; 8,674,085; 8,680,071; 8,691,788, 8 ,742,101, 8,951,985; 9,109,001; 9,243,025; US2016 / 0002281; US2013 / 0064 794; WO / 2015 / 095305; WO / 2015 / 081133; WO / 2015 / 061683; WO / 2013 / 177219; W O / 2013 / 039920; WO / 2014 / 137930; WO / 2014 / 052638; WO / 2012 / 154321); Merck (6,777,395; 7,105,499; 7,125,855; 7,202,224; 7,323,449; 7,339,054; 7,534,767; 7,632,821; 7,879,815; 8,071,568; 8,148,349; 8,470,834; 8,481,712; 8,541,434; 8,697,694; 8,715,638; 9,061,041; 9,156,872 and WO / 2013 / 009737); Emory University U.S. 2014 / 0212382; and WO2014 / 1244430); Gilead Sciences / Pharmasset Inc. (7,842,672;7,973,013; 8,008,264; 8,012,941; 8,012,942; 8,318,682; 8,324,179; 8,415,308; 8,455,451; 8,563,530; 8,841,275; 8,853,171; 8,871,785; 8,877,733; 8,889,1 59;8,906,880;8,912,321;8,957,045;8,957,046;9,045,520;9,085,573;9,090, 642; and 9,139,604) and (6,908,924; 6,949,522; 7,094,770; 7,211,570; 7,429,572; 7, 601,820; 7,638,502; 7,718,790; 7,772,208; RE42,015; 7,919,247; 7,964,580; 8 ,093,380;8,114,997;8,173,621;8,334,270;8,415,322;8,481,713;8,492,539; 8,551,973; 8,580,765; 8,618,076; 8,629,263; 8,633,309; 8,642,756; 8,716,262 ;8,716,263;8,735,345;8,735,372;8,735,569;8,759,510 and 8,765,710);Hoffman La-Roche (6,660,721), Roche (6,784,166; 7,608,599, 7,608,601 and 8,071,567); Alios BioPharma Inc. (8,895,723; 8,877,731; 8,871,737, 8,846,896, 8,772,474; 8,980,865; 9,012,427; US 2015 / 0105341; US ​​2015 / 0011497; US 2010 / 0249068; US2012 / 0070411; WO 2015 / 054465; WO 2014 / 209979; WO 2014 / 100505; WO 2014 / 100498;WO 2013 / 142159;WO 2013 / 142157;WO 2013 / 096680;WO 2013 / 088155;WO 2010 / 108135) 8,575,119; 8,846,638; 9,085,599; WO 2013 / 044030;WO 2012 / 125900), Biota (7,268,119; 7,285,658; 7,713,941; 8,119,607; 8,415,309; 8,501,699 and 8,802,840), Biocryst Pharmaceuticals (7,388,002; 7,429,571; 7,514,410; 7,560,434; 7,994,139; 8,133,870; 8,163,703; 8,242,085 and 8,440,813), Alla Chem, LLC (8,889,701 and WO 2015 / 053662), Inhibitex (8,759,318 and WO / 2012 / 092484), Janssen Products (8,399,429; 8,431,588, 8,481,510, 8,552,021, 8,933,052; 9,006,29 and 9,012,428), the University of Georgia Foundation (6,348,587; 7,307,065; 7,662,938; 8,168,583; 8,673,926, 8,816,074; 8,921,384 and 8,946,244), RFS Pharma, LLC (8,895,531; 8,859,595; 8,815,829; 8,609,627; 7,560,550; US 2014 / 0066395; US 2014 / 0235566; US 2010 / 0279969; WO / 2010 / 091386 and WO 2012 / 158811), University College Cardiff Consultants Limited (WO / 2014 / 076490, WO 2010 / 081082;WO / 2008 / 062206), Achillion Pharmaceuticals, Inc. (WO / 2014 / 169278 and WO 2014 / 169280), Cocrystal Pharma, Inc. (US 9,173,893), Katholieke Universiteit Leuven (WO 2015 / 158913), Catabasis (WO 2013 / 090420), and the Regents of the University of Minnesota (WO 2006 / 004637).

[0014] Elbasvir is an HCV NS5A inhibitor approved by the FDA in 2016, as a component of a fixed-dose combination with grazoprevir (an NS3 / 4A protease inhibitor). This combination (Zepatier®) is approved for the treatment of naïve and previously treated patients with a normal treatment duration of 12 weeks. However, in patients with HCV genotype 1a mutations at positions 28, 30, 31, and / or 93, Zepatier® must be administered in conjunction with ribavirin for 16 weeks to be effective. Ribavirin carries several FDA box-cutting warnings, including the risks of hemolytic anemia and teratogenicity. Elbasvir (MK-8742)

[0015] Ruzasvir (MK-8408) is an oral, pan-genotypic NS5A inhibitor that has been clinically evaluated for the treatment of chronic HCV infection. Ruzasvir has sub-picomolar to low-picomolar affinity for HCV NS5A across a wide range of HCV genotypes and common clinical mutants (including HCV genotype 1 with Y93H, Q30R, L31V, and Y93C mutations). (Tong et al., "Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms" J. Med. Chem. 2017, 60, 290-306). WO 2014 / 110705 and U.S. Patent No. 9,555,038, assigned to Merck and Company, disclose luzazilvir, pharmaceutical compositions comprising luzazilvir, and methods of use thereof. Luzazilvir (MK-8408)

[0016] In 2015, Merck, Sharp & Dohme sponsored a clinical trial to determine the efficacy of gzopivir and uprifosbuvir in combination with elbasvir or ruzazalvir in patients with HCV genotypes. After 12 weeks, this three-drug regimen achieved a sustained virological response in 85 to 100% of patients infected with a range of HCV genotypes. (See, for example, NCT02332707, NCT02332720, Lawitz, E. "Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomized, phase 2, open-label trials" 2017, Lancet Gastroenterol Hepatol, doi:10.1016 / S2468-1253(17)30163-2). Gzoprevir (one component of the three-drug regimen) is an NS3 / 4A protease inhibitor. Such treatments can lead to drug-drug interactions and elevated levels of hepatic transaminases.

[0017] In 2016, Merck initiated a Phase II open-label clinical trial of a two-drug regimen of ruzazevir and the NS5B inhibitor upplibvir, without an NS3 / 4A inhibitor. At the study dose of 60 mg ruzazevir and 450 mg upplibvir daily, the combination was well tolerated but suboptimal efficacy was observed, and the clinical trial was terminated (C-BREEZE 1; NCT02759315). The same combination, but at higher doses (180 mg ruzazevir and 450 mg upplibvir), achieved a sustained virological response in over 90% of participants infected with HCV GT1, GT2, GT4, GT5, and GT6. However, the response rate was only 73.8% in participants infected with GT3. Furthermore, over 30% of trial participants experienced drug-related adverse events (C-BREEZE 2; NCT02956629; Lawitz, E., "Efficacy and Safety of Two-Drug Direct-Acting Antiviral Agent Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, or 6", 2019, J. Viral Hepat. 26, 9, 1127-1138). This second higher-dose trial was also terminated.

[0018] Atea Pharmaceuticals, Inc. has discovered nucleophosphatidylcholine phosphatidylcholine, a 2-modified-N6-(mono- and dimethyl)purine nucleotide with a favorable structure for the treatment of HCV. (US Patent Nos. 9,828,410, 10,000,523, 10,005,811, 10,239,911, 10,519,186, 10,815,266, 10,870,672, 10,870,673, 10,875,885, 10,894,804, 10,906,928 and US Applications US 2021-0015841 and US 2020-0179415). In particular, ((S)-(((2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphatidyl)-L-alanylaminoate isopropyl hemisulfate (AT-527, bemnifosbuvir) has remarkable benefits, such as high bioavailability, target organ selectivity, and high titer against all HCV genotypes (including GT3) (WO2018 / 144640). Benibuzvir (AT-527)

[0019] In the phase I trial, in the multi-dose group, benibuvir reduced viral load by 4.5 log10 IU / mL in non-cirrhotic participants and by 4.6 log10 IU / mL in cirrhotic participants. In the cirrhotic group, it was also effective against a range of genotypes, including refractory GT3 (GT1b: 4.0, 4.0, 4.5; GT2: 5.0; GT3: 4.8, 5.2) (NCT03219957; Berliba, E. et al. "Safety, Pharmacokinics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis" 2019, Antimicrob Agents Chemother, 63 (12): e01201-19).

[0020] In a combination trial of benibuvir and the first-generation HCV NS5A inhibitor daclatasvir, all ten individuals achieved HCV RNA levels below the lower limit of quantification. 90% of the individuals experienced persistent undetectable viral load (SVR12) 12 weeks after treatment. One individual who did not experience SVR12 had a series of resistance-related variants (NS5A: R30Q, NS5B: L159F / A218S / C316N) (NCT04019717; Mungur, O. et al., "A combination of AT-527, a potent pan-genotypic guanosine nucleotide prodrug and daclatasvir was well-tolerated and effective in HCV-infected subjects", 2020, Poster THU438, The International Liver Congress meeting). However, the trial was terminated.

[0021] There remains a strong medical need to develop safe, effective, and well-tolerated anti-HCV therapies. Potential drug resistance exacerbates this need. HCV RNA polymerase exhibits a high replication rate, which contributes to the generation of potential resistance single- and double-point mutations and the maintenance of viral quasispecies throughout the genome. Resistance mutations have been identified both in vitro and in vivo following almost all single-agent treatments.

[0022] Therefore, one object of the present invention is to provide compounds, pharmaceutical compositions, methods and dosage forms for treating and / or preventing HCV infection. [Summary of the Invention]

[0023] The present invention provides compound 1, which is a potent pangenotypic NS5B polymerase inhibitor or a pharmaceutically acceptable salt thereof (e.g., AT-527, benibuvir), and compound 2, which is a combination of an NS5A inhibitor or a pharmaceutically acceptable salt thereof (luzazvir, MK-8408), the combination being highly synergistic for the treatment of hepatitis C infection in a host (typically a human).

[0024] Compound 1 is ((S)-(((2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphatyl)-L-propanol isopropyl ester: Compound 1

[0025] Compound 1 was previously described in U.S. Patent Nos. 9,828,410, 10,000,523, 10,005,811, 10,239,911, 10,815,266, 10,80,672, 10,870,673, 10,875,885, and PCT Applications WO 2016 / 21276 and WO 2019 / 200005, assigned to Atea Pharmaceuticals.

[0026] The hemisulfate of compound 1 is shown below as compound 1-A: Compound 1-A

[0027] Compound 1-A is disclosed in U.S. Patent Nos. 10,519,186, 10,906,928, 10,894,804, and PCT Applications WO 2018 / 144640 and WO 2019 / 200005, assigned to Atea Pharmaceuticals.

[0028] Compound 2 is ruzasvir (N,N′-([(6S)-6-(2-cyclopropyl-1,3-thiazo-5-yl)-1-fluoro-6H-indolo[1,2-c][1,3]benzoxazine-3,10-diyl]bis{1H-imidazol-5,2-diyl-(2S)-pyrrolidone-2,1-diyl[(2S)-3-methyl-1-butane-1,2-diyl]})diaminocarbamate): Compound 2

[0029] In one embodiment, compound 2 is an amorphous solid. In yet another embodiment, compound 2 is a crystalline solid. In one embodiment, compound 2 is administered with its pharmaceutically acceptable salt.

[0030] The previous clinical trial of the combination of ruzasvir and the NS5B inhibitor uplibvir was terminated due to lack of efficacy. Against this backdrop, it was found that the combination of compound 1 (e.g., AT-527) and ruzasvir was highly synergistic when tested at multiple doses (see Example 30 and Figure 34). At each combination dose, the expected additive antiviral protection was subtracted from the experimentally observed antiviral activity, yielding a positive (synergistic), zero (additive), or negative (antagonistic) value. A synergistic volume of -50 to 50 μM 2% was considered additive, 50 to 100 μM 2% indicated a slight synergistic effect, and a volume greater than 100 μM 2% was considered highly synergistic. The combination of compound 1 and compound 2 was evaluated at a series of doses and confirmed a high synergistic effect. The synergistic effect of each compound against dose is shown in Figure 34. At 40 nM for compound 1 and 0.008 nM for compound 2, the synergistic volume was 255 μM2%, which is more than five times the synergistic effect cutoff and falls into the highly synergistic category.

[0031] Such a synergistic combination of two anti-HCV agents acting through different mechanisms can be administered systemically, for example orally, in two or more separate dosage forms or in combination. If administered separately, the agents should be delivered in a manner that allows the host to receive the benefits of the two active agents acting in a synergistic biological manner, for example, by achieving overlapping pharmacokinetics, plasma and / or AUC. In addition to effectively treating the virus, combination therapy is particularly advantageous in limiting the development of drug resistance.

[0032] In a non-limiting embodiment, compound 1 is provided as a hemisulfate.

[0033] In one embodiment, this fixed-dose combination is intended to achieve a sustained viral response in about or less than 12 weeks, such as about or less than 10 weeks, 8 weeks, or 6 weeks or less. In addition to effectively treating the virus, combination drug therapy is helpful in limiting the development of drug resistance.

[0034] Unless otherwise specifically stated, the weight of the active compound in the dosage form described herein is relative to the free or salt form of the compound. For example, 600 mg of compound 1-A is equivalent to 550 mg of compound 1.

[0035] In a typical embodiment, compound 1 is administered at a dose between about 300 and 1000 mg (relative to or not relative to the weight of the salt), more typically between 400 or 500 and 600 or 800 mg, or between 500 and 750 mg. In some embodiments, compound 1 is administered at a dose between about 500 and about 1,500 mg. In one example, 550 mg of compound 1 is administered at a dose of about 600 mg of compound 1-A. In an alternative embodiment, 1,100 mg of compound 1 is administered at a dose of about 1,200 mg of compound 1-A.

[0036] In a typical embodiment, compound 2 or a pharmaceutically acceptable salt thereof is administered in dosage forms ranging from about 20 to 500 mg, more typically from 40 to 250 mg, including (but not limited to) doses of at least 60, 70, 75, 100, 125, 150, 180, 200, 225, 250, 270, 300, 350, or 400 mg. In some embodiments, compound 2 is administered in dosage forms containing at least about 90, 180, 270, or 340 mg.

[0037] In some embodiments, the combination comprises 550 mg of compound 1-A and about 90, 180, 270 or 340 mg of compound 2 or a pharmaceutically acceptable salt thereof (e.g., 180 mg). In some embodiments, the combination is provided once, twice or three times daily.

[0038] As recommended by a healthcare professional, the combination therapy may be administered once, twice, three times, or more daily. In some embodiments, the combination therapy is provided once daily. In other embodiments, the combination therapy is provided twice daily. In yet another embodiment, the combination therapy is provided three times daily.

[0039] In some embodiments, compound 1-a is provided in a solid dose of 600 mg / day and compound 2 is provided in combination or as a standalone dosage form at 180 mg / day.

[0040] In various formulations, compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof are formulated together into a single dosage form or provided in several dosage forms (e.g., two or more doses, each of which has two active agents or one dose has one active agent and another dose has another active agent). In an alternative embodiment, compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof are provided in separate dosage forms but in a manner that allows them to act in concert (e.g., synergistically) in the host. For example, separate dosage forms may be administered to allow for overlapping AUC or other pharmacokinetic parameters indicating that the active agents work together against the virus.

[0041] In one embodiment of the present invention, compound 1 and compound 2 are provided as separate pills and administered at approximately the same time or simultaneously within a day.

[0042] The combination of compound 1 (or a pharmaceutically acceptable salt thereof, such as compound 1-A) and compound 2 (or a pharmaceutically acceptable salt thereof) may also be used to treat related conditions such as positive anti-HCV antibody and antigen symptoms, virus-based chronic liver inflammation, liver cancer (hepatocellular carcinoma (HCC)) due to advanced hepatitis C, cirrhosis, chronic or acute hepatitis C, fulminant hepatitis C, chronic persistent hepatitis C and anti-HCV-based fatigue.

[0043] In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof (e.g., compound 1-A) and compound 2 or a pharmaceutically acceptable salt thereof are administered for up to 24 weeks, up to 12 weeks, up to 10 weeks, up to 8 weeks, up to 6 weeks, or up to 4 weeks. In alternative embodiments, compound 1 or a pharmaceutically acceptable salt thereof (e.g., compound 1-A) and compound 2 or a pharmaceutically acceptable salt thereof are administered for at least 4 weeks, at least 6 weeks, at least 8 weeks, at least 10 weeks, at least 12 weeks, or at least 24 weeks. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof are administered at least once a day or every other day. In alternative embodiments, compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof are administered twice a day. In alternative embodiments, compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof are administered three times a day or more.

[0044] In some embodiments, the patient is non-sclerotic. In some embodiments, the patient is sclerotic. In another embodiment, the host with sclerosis has compensated sclerosis. In an alternative embodiment, the host with sclerosis has decompensated sclerosis. In one embodiment, the host has Child-Pugh A sclerosis. In an alternative embodiment, the host has Child-Pugh B or Child-Pugh C sclerosis.

[0045] The above combinations can also be used to treat a range of HCV genotypes. At least six distinct HCV genotypes have been identified globally, each with multiple subtypes. Genotypes 1 to 3 are globally prevalent, while genotypes 4, 5, and 6 are geographically more localized. Genotype 4 is common in the Middle East and Africa. Genotype 5 is mostly found in South Africa. Genotype 6 is primarily found in Southeast Asia. Although genotype 1 is the most common genotype in the United States, defining genotypes and subtypes can help determine the type and duration of treatment. For example, different genotypes respond differently to different medications. The optimal treatment time varies depending on the genotype of infection. Within a genotype, subtypes such as genotype 1a and genotype 1b also respond differently to treatment. Infection with one genotype does not preclude later infection with a different genotype.

[0046] In one embodiment, a combination of compound 1 or a pharmaceutically acceptable salt thereof (e.g., compound 1-A) and compound 2 or a pharmaceutically acceptable salt thereof is used to treat HCV genotype 1, HCV genotype 2, HCV genotype 3, HCV genotype 4, HCV genotype 5, or HCV genotype 6. In one embodiment, compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof are used to treat HCV genotype 1a. In one embodiment, compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof are used to treat HCV genotype 1b. In one embodiment, compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof are used to treat HCV genotype 2a. In one embodiment, compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof are used to treat HCV genotype 2b. In one embodiment, compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof are used to treat HCV genotype 3a. In one embodiment, compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof are used to treat HCV genotype 3b. In one embodiment, compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof are used to treat HCV genotype 4a. In one embodiment, compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof are used to treat HCV genotype 4d. In one embodiment, compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof are used to treat HCV genotype 5a. In one embodiment, compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof are used to treat HCV genotype 6a. In one embodiment, compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof are used to treat HCV genotypes 6b, 6c, 6d, 6e, 6f, 6g, 6h, 6i, 6j, 6k, 6l, 6m, 6n, 6o, 6p, 6q, 6r, 6s, 6t, or 6u.

[0047] The present invention also includes specific combinations and dosage forms, wherein compound 1-A may be in the form of an amorphous or crystalline salt and independently, compound 2 may be crystalline or amorphous.

[0048] Therefore, the present invention includes at least the following embodiments:

[0049] (a) An effective combination of compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof;

[0050] (b) An effective solid dosage form of a combination of compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof;

[0051] (c) Example (a) or (b), wherein compound 1 is compound 1-A;

[0052] (d) Examples (a) to (c), wherein a third anti-HCV active agent is used in the combination;

[0053] (e) Example (d), wherein the third anti-HCV agent works through a mechanism different from that of compound 1, compound 1-A or compound 2;

[0054] (f) A pharmaceutical composition comprising a combination of any of the excipients in pharmaceutically acceptable form, such as those in Examples (a) to (e).

[0055] (g) Example (f), wherein the combination is in the form of a combination pharmaceutical composition;

[0056] (h) Example (f), wherein the combination is in the form of an independent pharmaceutical dosage form for each active agent, and is used in a synergistic manner;

[0057] (i) Pharmaceutical dosage forms such as (f) to (h) are suitable for oral delivery;

[0058] (j) The dosage form as in (i) is in the form of pills, tablets or gels;

[0059] (k) Pharmaceutical dosage forms such as (f) to (h) are suitable for non-enteral delivery;

[0060] (l) Pharmaceutical dosage forms such as (f) to (h) are suitable for intravenous delivery;

[0061] (m) Use of any of the claims (a) to (l) in the manufacture of a medicament for treating hepatitis C virus infection in patients in need;

[0062] (n) A method for manufacturing a medicament intended for the therapeutic use of treating hepatitis C virus infection in patients in need, characterized in that the manufacture uses an effective combination of any one of Examples (a) to (l);

[0063] (o) A method for treating hepatitis C virus infection, comprising administering to a patient in need an effective combination of any one of Examples (a) to (l);

[0064] (p) A method for curing hepatitis C virus infection, comprising administering to a patient in need an effective combination of any one of Examples (a) to (l);

[0065] (q) A method for the preventive treatment of a patient at risk of hepatitis C virus infection, comprising administering to the patient in need an effective combination of any one of Examples (a) to (l);

[0066] (r) A method for treating symptoms associated with hepatitis C virus infection, the symptoms being selected from virus-based chronic liver inflammation, liver cancer (hepatocellular carcinoma (HCC)) due to advanced hepatitis C, cirrhosis, chronic or acute hepatitis C, fulminant hepatitis C, chronic persistent hepatitis C, and anti-HCV-based fatigue, the method comprising administering to a patient in need an effective combination of any one of Examples (a) to (l);

[0067] (s) As in any one of Examples (m) to (r), wherein the patient has sclerosis.

[0068] (t) As in any of Examples (m) to (r), wherein the patient is non-sclerotic.

[0069] (u) As in any of Examples (m) to (t), wherein the HCV infection is genotype 1.

[0070] (v) As in any of Examples (m) to (t), wherein the HCV infection is genotype 2.

[0071] (w) As in any of Examples (m) to (t), wherein the HCV infection is genotype 3.

[0072] (x) As in any of Examples (m) to (t), wherein the HCV infection is genotype 4.

[0073] (y) As in any of Examples (m) to (t), wherein the HCV infection is genotype 5.

[0074] (z) As in any of Examples (m) to (t), wherein the HCV infection is genotype 6.

[0075] In this invention, compound 1-A may be provided in crystalline form in a synergistic combination therapy, or alternatively, the crystalline form may be used in a spray-drying manufacturing process. Figures 1 to 15 depict the physical form of compound 1-A characterized by XRPD, DSC, and TGA. Compound 1-A can be isolated in crystalline form, which facilitates synthesis and processing.

[0076] The pharmacokinetics of compound 1-A are crucial for the success of combination therapy. Figure 16 depicts the favorable biodistribution properties of compound 1-A. This compound concentrates in the liver (a target organ for HCV infection), exceeding that in the heart. Due to the high concentration in the liver, combination therapy with liver involvement is beneficial.

[0077] Similarly, Figures 17 to 24 depict the pharmacokinetic properties of compound 1-A and its major metabolite. Although compound 1-A is metabolized within 8 hours, the active metabolite persists for up to 24 hours. During this 24-hour period of metabolite presence, inhibition of HCV viral RNA was observed. At a dose of 300 mg, the plasma concentration of the compound 1-A metabolite was higher than the EC95 of HCV GT1b. These pharmacokinetic and pharmacodynamic properties contribute to successful combination therapy.

[0078] Figures 25 to 31 depict the metabolites of compound 1 and the HCV viral RNA content in sclerotic hosts treated with compound 1. Figure 27 highlights that in these hosts, compound 1 is equally effective in sclerotic patients as in non-sclerotic patients. A combination of compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof can be used to treat HCV in both sclerotic and non-sclerotic patients. A pharmaceutical composition containing compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof can be formulated into an oral dosage form. Figure 32 depicts an example process by which a tablet for oral administration can be prepared. Compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof are combined, sieved, blended, and tableted to provide the combination in an oral dosage form.

Implementation Method

[0138] Cross-reference to related applications

[0139] This application claims the benefit of Provisional U.S. Application No. 63 / 212,047, filed June 17, 2021. The entire contents of this application are incorporated herein by reference for all purposes.

[0140] The present invention provides a highly active synergistic combination of a specific NS5B polymerase inhibitor and a specific NS5A inhibitor for the beneficial treatment of hepatitis C infection in a host (usually a human).

[0141] The anti-HCV compound used in this combination therapy is: 1) an NS5B inhibitor ((S)-(((2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphatidyl)-L-propanoic acid isopropyl ester (compound 1) or a pharmaceutically acceptable salt thereof; and 2) NS5A inhibitor ruzasvir (N,N′-([(6S)-6-(2-cyclopropyl-1,3-thiazolyl-5-yl)-1-fluoro-6H-indolo[1,2-c][1,3]benzoxazine-3,10-diyl]bis{1H-imidazol-5,2-diyl-(2S)-pyrrolidone-2,1-diyl[(2S)-3-methyl-1-sideoxybutane-1,2-diyl]}) diaminocarbamate) (compound 2) or a pharmaceutically acceptable salt thereof. In a typical embodiment, compound 1 is administered as a hemisulfate derivative (compound 1-A).

[0142] In one embodiment, the combination of drugs is administered in a fixed-dose dosage form such as a pill or tablet. In an alternative embodiment, the two compounds are administered in a manner that requires the host to synergistically receive the benefits of both compounds, as determined by standard pharmacokinetic methods. Compound 1 and Compound 1-A

[0143] Compound 1 (((S)-(((2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphatidyl)-L-propanylaminoate) isopropyl ester previously described in U.S. Patent Nos. 9,828,410, 10,000,523, 10,005,811, and 10,239,911, and PCT Applications WO 2016 / 21276 and WO 2019 / 200005, assigned to Atea Pharmaceuticals. The synthesis of Compound 1 is described in Example 1 below.

[0144] Compound 1-A was previously disclosed in US 2018-0215776 and PCT applications WO 2018 / 144640 and WO 2019 / 200005, assigned to Atea Pharmaceuticals. The synthesis of Compound 1-A (((S)-(((2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purine-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphatidyl)-L-propanoic acid isopropyl hemisulfate) is described in Example 2 below. In one embodiment, Compound 1-A is provided as a pharmaceutically acceptable composition or a solid dosage form thereof. In another embodiment, Compound 1-A is an amorphous solid. In one embodiment, Compound 1-A is a crystalline solid. Figures 1 to 15 depict the physical form of compound 1-A characterized by XRPD, DSC, and TGA.

[0145] As described above, compound 1-A has completed a phase 1b / 2a clinical trial in patients infected with HCV. This multipart study evaluated the effects of single and multiple doses of compound 1-A in healthy individuals, patients with non-sclerotic HCV infection, and patients with sclerotic HCV infection. When administered to all tested HCV infection groups, compound 1-A induced a significant reduction in antiviral activity. Strong antiviral activity was observed with once-daily (QD) administration of compound 1-A over a seven-day period. In non-sclerotic HCV-infected patients given 600 mg QD of compound 1-A (equivalent to 550 mg of compound 1), the mean maximum reduction in HCV RNA was 4.4 log10 IU / mL in HCV GT1-infected patients and 4.6 log10 IU / mL in HCV GT3-infected patients. The antiviral reduction effect of compound 1-A also extended to patients with refractory sclerotic disease. In patients with HCV GT1 or HCV GT3 infection and CPA cirrhosis, the mean maximum HCV RNA reduction was 4.4 log10 IU / mL after seven days of QD administration (Zhou, X. et al., "AT-527, a pan-genotypic purine nucleotide prodrug, exhibits potent antiviral activity in subjects with chronic hepatitis C", presented at The International Liver Congress 2018; April 13, 2018; Paris, France). Figures 25-31 depict the metabolites of compound 1 and HCV viral RNA levels in cirrhotic patients administered compound 1. Figure 27 highlights that compound 1 was as effective in cirrhotic patients as it was in non-cirrhotic patients.

[0146] Unless otherwise specified, compound 1, or a pharmaceutically acceptable salt thereof (e.g., compound 1-A), is provided in the β-D-configuration. In an alternative embodiment, compound 1, or a pharmaceutically acceptable salt thereof (e.g., compound 1-A), may be provided in the β-L-configuration. Phosphoramide salts of compound 1, or pharmaceutically acceptable salts thereof (e.g., compound 1-A), may be provided as R or S panotropic phosphorus derivatives or mixtures thereof (including racemic or diastereomer mixtures). All combinations of these stereoconfigurations are alternative embodiments of the invention described herein.

[0147] These alternative configurations include (but are not limited to): One additional alternative configuration includes:

[0148] In one embodiment, any of the above stereoisomers or pharmaceutically acceptable salts thereof are used as compound 1 in any form of the present invention herein. In another embodiment, any one of the above stereoisomers or pharmaceutically acceptable salts thereof is used as compound 1-A in any form of the present invention herein.

[0149] In one alternative embodiment, compound 1-A is provided as a hemisulfate of a phosphatamine salt other than the specific phosphatamine salt described in the compound description. In another alternative embodiment, compound 1 or a pharmaceutically acceptable salt thereof is provided as a phosphatamine salt other than the specific phosphatamine salt described in the compound description. Those skilled in the art know a wide range of phosphatamine salts that can be selected as needed to provide the active compound as described herein. For example, the phosphatamine salt of compound 1, or its pharmaceutically acceptable salt, includes compounds of formula A or their pharmaceutically acceptable salts, wherein: R7 is hydrogen, a C1-6 alkyl group (including methyl, ethyl, propyl, and isopropyl), a C3-7 cycloalkyl group, or an aryl group (including phenyl and naphthyl); R8 is hydrogen or a C1-6 alkyl group (including methyl, ethyl, propyl, and isopropyl); R9a and R9b are independently selected from hydrogen, a C1-6 alkyl group (including methyl, ethyl, propyl, and isopropyl), or a C3-7 cycloalkyl group; and R10 is hydrogen, a C1-6 alkyl group (including methyl, ethyl, propyl, and isopropyl), a C1-6 haloalkyl group, or a C3-7 cycloalkyl group.

[0150] In alternative, non-limiting embodiments, the present invention includes Compound 1 as an oxalate (Compound 1-B), an HCl salt (Compound 1-C), or a sulfate (Compound 1-D).

[0151] The metabolism of compounds 1 and 1-A involves the production of 5'-monophosphate and the subsequent synergistic metabolism of the N6-methyl-2,6-diaminopurine base (1-3) to produce ((2R,3R,4R,5R)-5-(2-amino-6-sideoxy-1,6-dihydro-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methyl dihydrophosphate (1-4) as 5'-monophosphate. The monophosphate is then further synergistically metabolized to the active triphosphate: 5'-triphosphate (1-6). The 5'-triphosphate can be further metabolized to produce 2-amino-9-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one (1-7). Figures 17-24 depict the pharmacokinetic properties of compound 1-A and its major metabolites. Although compound 1-A is metabolized within 8 hours, the active metabolite persists for up to 24 hours. During this 24-hour period of metabolite presence, inhibition of HCV viral RNA was observed. At a dose of 300 mg, the plasma concentration of the compound 1-A metabolite was higher than the EC95 of HCV GT1b. Figure 16 depicts the favorable biodistribution characteristics of compound 1-A. The compound is concentrated in the liver (the target organ of HCV infection), exceeding the heart. Due to the high liver concentration, a lower dose can be used. This effect is not species-specific and was observed in three different preclinical species. Figure 24 shows a comparison of the EC95 of compound 1 and sofosbuvir against various HCV genotypes. Sofosbuvir has a variable EC95 based on genotype, while the EC95 of compound 1 exhibits minimal genotype-based variation.

[0152] Alternatively, 5'-monophosphate 1-2 can be metabolized to produce purine bases 1-8. The metabolic pathway of ((S)-(((2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphatidyl)-L-alanine isopropyl ester is described in Scheme 1:

[0153] Atea Pharmaceuticals, Inc. has disclosed in U.S. Patent Nos. 9,828,410, 10,000,523, 10,005,811, 10,239,911 and US2018-0215776; and PCT Application Nos. WO 2016 / 144918, WO 2018 / 048937, WO 2018 / 013937 and WO 2018 / 144640 a β-D-2'-deoxy-2'-α-fluoro-2'-β-C-substituted 2-modified-N6-(mono- and dimethyl)purine nucleotides for the treatment of HCV. Atea has also disclosed β-D-2'-deoxy-2'-substituted-4'-substituted-2-N6-substituted-6-aminopurine nucleotides for the treatment of paramyxovirus and orthomyxovirus infections in U.S. Patent No. 10,202,412 and PCT Application No. WO 2018 / 009623.

[0154] Compound 2 is disclosed in WO 2014 / 110705, assigned to Merck and Company, and U.S. Patent No. 9,555,038. In one embodiment, Compound 2 is administered as a pharmaceutically acceptable salt. In one embodiment, Compound 2 is used in solid form. In one embodiment, the solid form of Compound 2 is a crystalline solid.

[0155] The synthesis of lucazasvir (N,N′-([(6S)-6-(2-cyclopropyl-1,3-thiazolyl-5-yl)-1-fluoro-6H-indolo[1,2-c][1,3]benzoxazine-3,10-diyl]bis{1H-imidazol-5,2-diyl-(2S)-pyrrolidone-2,1-diyl[(2S)-3-methyl-1-sideoxybutane-1,2-diyl]}) dimethyl diaminoformate, compound 2) is known in this art. Non-limiting examples of synthetic methods that can be used to synthesize compound 2 include those reported therein in WO 2016 / 196932 assigned to Merck. Definition

[0156] The term "D-configuration" as used in the context of this invention refers to the natural configuration of the sugar moiety rather than the principle configuration of a non-naturally occurring nucleotide or "L" configuration. The term "β" or "β-mutant isomer" is used in reference to nucleotide analogs in which the nucleotide bases are configured (set) above the plane of the furanose moiety in the nucleotide analog.

[0157] The term "co-administration" or combination therapy is used to describe the administration of a combination of compound 1 or a pharmaceutically acceptable salt thereof according to the invention and compound 2 or a pharmaceutically acceptable salt thereof. In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof (e.g., compound 1-A) and compound 2 or a pharmaceutically acceptable salt thereof are administered together with at least one other active agent (e.g., at least one additional anti-HCV agent where appropriate). The timing of co-administration is optimally determined by a medical expert treating the patient. Sometimes it is preferred that the agents be administered at the same time or at least in a manner that allows for overlapping pharmacological effects of the two drugs in the treated patient. Alternatively, the drugs selected for combination therapy may be administered to the patient at different times. Of course, when more than one virus or other infection or other symptom is present, the compounds of the invention may be combined with other agents to treat the other infection or symptom as needed.

[0158] The term "host," as used herein, refers to a single-celled or multicellular organism in which HCV virus can replicate, including cell lines and animals, and is generally human. The term "host" specifically refers to infected cells, cells transfected with all or part of the HCV genome, and animals, particularly primates (including chimpanzees) and humans, carrying an HCV genome or a portion thereof capable of being treated with the combination therapies described herein. In most animal applications of the invention, the host is a human patient, including (but not limited to) dosing regimens with overlapping pharmacokinetics. However, in some indications, the invention (such as in chimpanzees) is clearly contemplated for veterinary applications. The host may be, for example, cattle, equines, birds, canines, felines, etc., which can be viral hosts.

[0159] "Pharmaceutically acceptable salts" are derivatives of the disclosed compounds, wherein the parent compound is modified to form inorganic and organic, acidic or basic addition salts without excessive toxicity. Salts of the compounds of the present invention can be synthesized from parent compounds having a basic or acidic moiety by known chemical methods. Generally, such salts can be prepared by reacting the free acidic form of these compounds with a stoichiometric amount of a suitable base (such as Na, Ca, Mg, or K hydroxide; Na, Ca, Mg, or K carbonate; Na, Ca, Mg, or K bicarbonate; or similar), or by reacting the free basic form of these compounds with a stoichiometric amount of a suitable acid. Such reactions are typically carried out in water, in an organic solvent, or in a mixture of both. Generally, non-aqueous media, such as ethers, ethyl acetate, ethanol, isopropanol, or acetonitrile, are typical where feasible. Salts of the compounds of the present invention may be provided as solvates if desired.

[0160] Examples of pharmaceutically acceptable salts include (but are not limited to) inorganic or organic acid salts of basic residues, such as amines; basic or organic salts of acidic residues, such as carboxylic acids; and the like. Pharmaceutically acceptable salts include, for example, known salts of parent compounds formed from inorganic or organic acids that are not excessively toxic, and quaternary ammonium salts. For example, known salts include those derived from inorganic acids (such as hydrochloric acid, hydrobromic acid, sulfuric acid, ammonium sulfonic acid, phosphoric acid, nitric acid, and the like); and salts prepared from organic acids (such as acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, maleic acid, tartaric acid, citric acid, ascorbic acid, pyric acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, methanesulfonic acid, ethylsulfonic acid, benzenesulfonic acid, sulfanilic acid, 2-acetoxybenzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, oxalic acid, hydroxyethanesulfonic acid, HOOC-(CH2)n-COOH (where n is 0 to 4) and the like) or using different acids that produce the same counterion. Further lists of suitable salts can be found, for example, in Remington's Pharmaceutical Sciences, 17th edition, Mack Publishing Company, Easton, Pa., page 1418 (1985).

[0161] The compound can be delivered in any molar ratio to achieve the desired result. For example, the compound can be provided in a molar equivalent of the counterion, such as in the form of a hemisulfate. Alternatively, the compound can be provided in a molar equivalent of the counterion, such as in the form of a disulfate. Non-limiting examples of the molar ratio of the compound to the counterion include 1:0.25, 1:0.5, 1:1, and 1:2. Isotope substitution

[0162] This invention includes combinations of compound 1 or a pharmaceutically acceptable salt thereof (e.g., compound 1-A) and compound 2 or a pharmaceutically acceptable salt thereof, wherein one or both of these compounds have desired isotopic substitutions of atoms in an amount (i.e., enriched) higher than the natural abundance of the isotope. Isotopes are atoms having the same number of atoms but different mass numbers, i.e., the same number of protons but different numbers of neutrons. By general example and without limitation, isotopes of hydrogen, such as deuterium (2H) and tritium (3H), may be used anywhere in the described structure. Alternatively, isotopes of carbon, such as 13C and 14C, may be used. A preferred isotopic substitution involves replacing hydrogen with deuterium at one or more positions on the molecule to improve the properties of the drug. Deuterium may bind at bond-breaking sites during metabolism (α-deuterium kinetic isotope effect) or adjacent to or near bond-breaking sites (β-deuterium kinetic isotope effect). Achillion Pharmaceuticals, Inc. (WO / 2014 / 169278 and WO / 2014 / 169280) describes the deuteration of nucleotides to improve their pharmacokinetics or pharmacodynamics, including at the 5 position of the molecule.

[0163] Substitution with an isotope such as deuterium can provide certain therapeutic advantages due to greater metabolic stability (such as, for example, increased in vivo half-life or reduced dose requirements). Replacing hydrogen with deuterium at a metabolic breakdown site can reduce the rate of metabolism at that bond or eliminate metabolism at that bond. At any position in a compound where a hydrogen atom may be present, that hydrogen atom may be any isotope of hydrogen, including protium (¹H), deuterium (²H), and tritium (³H). Therefore, unless the context clearly indicates otherwise, references to compounds herein encompass all potential isotopic forms.

[0164] The term "isotopically labeled" analogue refers to an analogue that is "deuterated," "13C-labeled," or "deuterated / 13C-labeled." The term "deuterated analogue" means a compound described herein in which an H-isotope (i.e., hydrogen / protium (1H)) is substituted with an H-isotope (i.e., deuterium (2H)). The deuteration substitution may be partial or complete. Partial deuteration substitution means that at least one hydrogen atom is substituted with at least one deuterium atom. In some embodiments, the isotope is 90, 95, or 99% or more enriched at any site of interest. In some embodiments, 90, 95, or 99% enriched at the desired site is deuterium. Unless otherwise indicated, at the selected site, deuteration is at least 80%. The deuteration of nucleosides can occur at any displaceable hydrogen atom that provides the desired result. Treatment Methods

[0165] Treatment, as used herein, refers to administering an effective amount of the combination of the present invention to a host, such as a human infected with HCV virus or capable of becoming infected with HCV virus. In one embodiment, the treatment method includes administering an effective amount of compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof to a host, such as a human or a human capable of becoming infected with HCV virus. In another embodiment, the treatment method includes administering compounds 1-A and compound 2 to a host, such as a human infected with HCV virus or capable of becoming infected with HCV virus.

[0166] The terms "prophylactic" or "preventative" are used to refer to the combination of the present invention administered to prevent or reduce the likelihood of viral illness. In one alternative embodiment, the present invention includes both therapeutic and prophylactic / preventative therapies. In one embodiment, the combination is administered to a host who has been exposed to and is therefore at risk of infection with hepatitis C virus.

[0167] This invention relates to a method for treating hepatitis C virus by administering an effective amount of a synergistic combination of compound 1 (such as 1-A) and compound 2, which includes drug resistance and multidrug resistance forms of HCV and disease states, symptoms, or complications associated with HCV infection, including cirrhosis and related hepatotoxicity, and other symptoms secondary to HCV infection, such as weakness, loss of appetite, weight loss, gynecomastia (especially in men), rash (especially on the palms), blood clotting difficulties, spider veins on the skin, altered mental status, coma (encephalopathy), fluid accumulation in the abdominal cavity (ascites), esophageal varices, portal hypertension, renal failure, splenomegaly, cytopenia, anemia, thrombocytopenia, jaundice, and hepatocellular carcinoma, etc. The method includes administering an effective amount of the combination described herein to a host (usually a human) in need, combining it as needed with at least one other bioactive agent, such as another anti-HCV agent, and further combining it as needed with pharmaceutically acceptable carriers and / or excipients. In another embodiment, the method includes administering an effective amount of the combination of the present invention to a patient at risk of HCV infection. In another embodiment, the combination described above may be used in combination with a pharmaceutically acceptable carrier, additive, or excipient, as needed, in conjunction with a third anti-HCV agent. In another embodiment, the combination of the present invention may be administered to a patient after a hepatitis-related liver transplant to protect the new organ.

[0168] This combination therapy and dosage form can also be used to treat conditions related to or caused by HCV virus exposure. For example, the active compound can be used to treat HCV antibody-positive and HCV antigen-positive conditions, virus-based chronic liver inflammation, liver cancer due to advanced hepatitis C (e.g., hepatocellular carcinoma), cirrhosis, acute hepatitis C, fulminant hepatitis C, chronic persistent hepatitis C, and anti-HCV-based fatigue. This combination can also be used prophylactically to prevent or limit the progression of clinical disease in individuals who are anti-HCV antibody- or antigen-positive or have been exposed to hepatitis C. Pharmaceutical Compositions and Dosage Forms

[0169] The administration of compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof may be carried out in any desired form, including (but not limited to) oral, topical, non-enteric, intramuscular, intravenous, subcutaneous, transdermal (which may include a penetration enhancer), buccal, and suppository administration, and other routes of administration. In one embodiment, the active compound or combination of compounds is provided in a solid dosage form known in the art and further described below. Enteric-coated oral tablets may also be used to enhance the bioavailability of compounds administered via the oral route. The most effective dosage form will depend on the bioavailability / pharmacokinetics of the particular agent selected and the severity of the disease in the patient. Oral dosage forms are preferred due to ease of administration and anticipated benefits to patient compliance.

[0170] In some embodiments, the pharmaceutical composition according to the present invention comprises individual or combined amounts of compound 1 or a pharmaceutically acceptable salt thereof as described herein and compound 2 or a pharmaceutically acceptable salt thereof, as needed, in combination with a pharmaceutically acceptable carrier, additive or excipient, and further as needed, in combination with or alternating with at least one other active compound.

[0171] In one embodiment, the combination comprises a solid dosage form of compound 1 or a pharmaceutically acceptable salt thereof (e.g., compound 1-A) and compound 2 or a pharmaceutically acceptable salt thereof contained in a pharmaceutically acceptable carrier. The pharmaceutical composition may contain compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof, or the compounds may be in a standalone dosage form administered in a manner that allows the host to synergistically receive the benefits of both compounds (e.g., as determined by standard pharmacokinetics).

[0172] Those skilled in the art will recognize that the effective therapeutic dose will vary depending on the infection or symptom to be treated, its severity, the intended treatment regimen, the pharmacokinetics of the drug used, and the patient or individual (animal or human) to be treated, and that such therapeutic dose can be determined by the attending physician or specialist.

[0173] Compound 1 or a pharmaceutically acceptable salt thereof (e.g., compound 1-A) and compound 2 or a pharmaceutically acceptable salt thereof may be formulated into a mixture with one or more pharmaceutically acceptable carriers. Generally, it is preferred to administer the pharmaceutical composition in an orally administered form, and specifically, in one or more solid dosage forms, such as pills or tablets. Some formulations may be administered via non-enteral, intravenous, intramuscular, topical, transdermal, buccal, subcutaneous, suppository, or other routes (including nasal spray). Intravenous and intramuscular formulations are often administered in sterile saline. Those skilled in the art can modify formulations to make them more soluble in water or another medium, for example, this can be easily achieved by minor modifications (salt formulations, esterification, etc.) clearly within the scope of the art. Modifying the administration routes and dosage regimens of compound 1 or its pharmaceutically acceptable salts (e.g., compound 1-A) and compound 2 or its pharmaceutically acceptable salts to manage the pharmacokinetics of the compounds to achieve the maximum beneficial effect in patients is also clearly within the technical scope of regular practitioners.

[0174] In certain pharmaceutical dosage forms, the prodrug forms of these compounds, including acetylated (acetylated or otherwise), and ether (alkyl and related) derivatives, phosphate esters, thiophosphatamine salts, phosphatamine salts, and various salts of the compound, can be used to achieve the desired effect. Those skilled in the art will recognize how easily the compound can be modified into a prodrug form to facilitate the delivery of the active compound to the target site in the host organism or patient. Those skilled in the art will also utilize the favorable pharmacokinetic parameters of the prodrug form, where appropriate, in maximizing the desired effect of the compound by delivering it to the target site in the host organism or patient.

[0175] The amounts mentioned in this invention generally refer to the free form (i.e., the non-salt, hydrate, or solvate form). The typical values ​​described herein represent the free form equivalent, i.e., the amount as if it were to be added to the free form. If it is to be added to a salt, the amount needs to be calculated based on the molecular weight ratio between the salt and the free form.

[0176] The amounts of compound 1 or a pharmaceutically acceptable salt thereof (e.g., compound 1-A) and compound 2 or a pharmaceutically acceptable salt thereof contained in the therapeutically active formulation according to the invention are effective amounts to achieve the desired results according to the invention, for example, for treating HCV infection, reducing the likelihood of HCV infection, or inhibiting, reducing and / or eliminating HCV or its secondary effects (including disease states, symptoms and / or complications) secondary to HCV. Generally, the therapeutically effective amount of the compound in a pharmaceutical dosage form may, for example, be in the range of about 0.001 mg / kg to about 100 mg / kg / day or more. Compound 1 or compound 1-A may, for example, be administered to a patient at a dose of about 0.1 mg / kg to about 15 mg / kg per day, depending on the pharmacokinetics of the formulation in the patient.

[0177] In some embodiments, 600 mg of compound 1-A (which is 550 mg of compound 1) is provided in a dosage form.

[0178] In some embodiments, the pharmaceutical composition is in a dosage form containing, in addition to a pharmaceutically acceptable salt of compound 2 or an equivalent amount of compound 2, in units of about 1 mg to about 2000 mg, about 10 mg to about 1000 mg, about 100 mg to about 800 mg, about 200 mg to about 600 mg, about 300 mg to about 500 mg, or about 400 mg to about 450 mg, ...450 mg.

[0179] In an alternative embodiment, the pharmaceutical composition is in a dosage form containing, in addition to a pharmaceutically acceptable salt of compound 2 or an equivalent amount of compound 2, in units of about 500 mg to about 600 mg, about 550 mg to about 750 mg, about 600 mg to about 800 mg, about 350 mg to about 300 mg, or about 350 mg to about 400 mg, about 500 mg to about 600 mg, about 550 mg to about 750 mg, about 600 mg to about 800 mg, or about 1,000 mg to about 1,300 mg, about 1,000 mg to about 1,300 mg.

[0180] In some embodiments, the pharmaceutical composition is in a dosage form, such as a solid dosage form, containing as many as about 10, about 50, about 100, about 125, about 150, about 175, about 200, about 225, about 250, about 275, about 300, about 325, about 350, about 375, about 400, about 425, about 450, about 475, about 500, about 525, about 550, about 575, about 600, about 625, about 650, about 675, about 700, about 725, about 750, about 775, about 800, about 825, about 850, about 875, about 900, about 925, about 950, about 975, or about 1000 mg or more of compound 1 or an equivalent amount of compound 1-A in a unit dosage form.

[0181] In some embodiments, the pharmaceutical composition is in a dosage form, such as a solid dosage form, containing as many as about 10, about 50, about 60, about 100, about 125, about 150, about 175, about 200, about 225, about 250, about 275, about 300, about 325, about 350, about 375, about 400, about 425, about 450, about 475, about 500, about 525, about 550, about 575, about 600, about 625, about 650, about 675, about 700, about 725, about 750, about 775, about 800, about 825, about 850, about 875, about 900, about 925, about 950, about 975, or about 1000 mg or more of a pharmaceutically acceptable salt of compound 2 or an equivalent amount of compound 2.

[0182] In an alternative embodiment, the pharmaceutical composition is in a dosage form, such as a solid dosage form, containing up to about 90, about 180, about 270 or about 360 mg of compound 2 or an equivalent amount of a pharmaceutically acceptable salt of compound 2.

[0183] In one embodiment, once daily, the patient may consume a compound 1 or an equivalent amount of compound 1-A containing up to about 800 mg, up to about 700 mg, up to about 600 mg, up to about 550 mg, up to about 500 mg, up to about 400 mg, up to about 300 mg, up to about 200 mg, or up to about 100 mg, and up to about 360 mg, up to about 270 mg, up to about 180 mg, up to about 145 mg, up to about 130 mg, up to about 125 mg, up to about 110 mg, up to about 100 mg, up to about 90 mg, up to about 75 mg, up to about 70 mg, up to about 65 mg, up to about 60 mg, up to about 55 mg, up to about 50 mg, up to about 45 mg, up to about 40 mg, up to about 35 mg, up to about 30 mg, up to about 25 mg, up to about 20 mg, up to about 15 mg, up to about 10 mg, or up to about 5 mg. Administer a solid dosage form of compound 2 in mg or an equivalent amount of a pharmaceutically acceptable salt of compound 2 to the host in need of treatment for HCV.

[0184] In one embodiment, once daily, the patient is given a compound 1 or an effective amount of compound 1-A containing at least about 100 mg, at least about 200 mg, at least about 300 mg, at least about 400 mg, at least about 500 mg, at least about 550 mg, at least about 600 mg, at least about 700 mg, at least about 750 mg, or at least about 1,100 mg, and at least about 5 mg, at least about 10 mg, at least about 15 mg, at least about 20 mg, at least about 25 mg, at least about 30 mg, at least about 35 mg, at least about 40 mg, at least about 45 mg, at least about 50 mg, at least about 55 mg, at least about 60 mg, at least about 65 mg, at least about 70 mg, at least about 75 mg, at least about 90 mg, at least about 100 mg, at least about 110 mg, at least about 125 mg, at least about 130 mg, at least about 145 mg, at least about 180 mg, at least about 270 mg, at least about 360 mg, or at least about 100 mg. Administer a solid dosage form of compound 2, or an equivalent amount of a pharmaceutically acceptable salt thereof, in the host in need of treatment for HCV, at least 400 mg or at least 500 mg.

[0185] In an alternative embodiment, a solid dosage form containing up to about 1,100, up to about 750 mg or up to about 550 mg of compound 1 or an equivalent amount of compound 1-A and up to about 360 mg, up to about 270 mg, up to about 180 mg or up to about 90 mg of compound 2 or an equivalent amount of compound 2 is administered once daily to the host in need to treat HCV.

[0186] In an alternative embodiment, a solid dosage form containing at least about 500 mg, at least about 550 mg, at least about 750 mg or at least about 1,100 mg of compound 1 or an equivalent amount of compound 1-A and at least about 90 mg, at least about 180 mg, at least about 270 mg or at least about 360 mg of compound 2 or an equivalent amount of compound 2 is administered twice daily to the host in need to treat HCV.

[0187] In one embodiment, the combination of compounds as described herein is administered as a single tablet containing up to about 600 mg of compound 1-A and up to about 90, 180, 270 or 340 mg of compound 2 or an equivalent amount of a pharmaceutically acceptable salt of compound 2.

[0188] In an alternative embodiment, the combination of compounds as described herein is administered as a single tablet containing up to about 600 mg of compound 1-A and up to about 180 mg of compound 2 or an equivalent amount of a pharmaceutically acceptable salt of compound 2.

[0189] In an alternative embodiment, the combination of compounds as described herein is administered as a single tablet containing up to about 600 mg of compound 1-A and up to about 270 mg of compound 2 or an equivalent amount of a pharmaceutically acceptable salt of compound 2.

[0190] In an alternative embodiment, the combination of compounds as described herein is administered as a single tablet containing up to about 600 mg of compound 1-A and up to about 360 mg of compound 2 or an equivalent amount of a pharmaceutically acceptable salt of compound 2.

[0191] In an alternative embodiment, the combination of compounds as described herein is administered as a single tablet containing up to about 750 mg of compound 1-A and up to about 180 mg of compound 2 or an equivalent amount of a pharmaceutically acceptable salt of compound 2.

[0192] In an alternative embodiment, the combination of compounds as described herein is administered as a single tablet containing up to about 750 mg of compound 1-A and up to about 270 mg of compound 2 or an equivalent amount of a pharmaceutically acceptable salt of compound 2.

[0193] In an alternative embodiment, the combination of compounds as described herein is administered as a single tablet containing up to about 750 mg of compound 1-A and up to about 360 mg of compound 2 or an equivalent amount of a pharmaceutically acceptable salt of compound 2.

[0194] In an alternative embodiment, the combination of compounds as described herein is administered as a single tablet containing up to about 1,200 mg of compound 1-A and up to about 180 mg of compound 2 or an equivalent amount of a pharmaceutically acceptable salt of compound 2.

[0195] In an alternative embodiment, the combination of compounds as described herein is administered as a single tablet containing up to about 1,200 mg of compound 1-A and up to about 270 mg of compound 2 or an equivalent amount of a pharmaceutically acceptable salt of compound 2.

[0196] In an alternative embodiment, the combination of compounds as described herein is administered as a single tablet containing up to about 1,200 mg of compound 1-A and up to about 360 mg of compound 2 or an equivalent amount of a pharmaceutically acceptable salt of compound 2.

[0197] Alternatively, a solid dosage form of compound 1-A or an equivalent amount of compound 1 may be administered in combination with a separate solid dosage form containing compound 2 or an equivalent amount of compound 2-A. This combination may be administered once, twice, three times, or up to four times daily as directed by a healthcare provider. In one embodiment, compound 1-A or compound 1 may be administered in a regimen independent of compound 2. For example, compound 1 or an equivalent amount of compound 1-A may be administered twice daily while compound 2 may be administered only once daily, or vice versa: compound 2 may be administered multiple times daily while compound 1 or an equivalent amount of compound 1-A may be administered only once daily.

[0198] In one embodiment, once daily administration of compound 1 or an equivalent amount of compound 1-A containing up to about 800 mg, up to about 700 mg, up to about 600 mg, up to about 500 mg, up to about 400 mg, up to about 300 mg, up to about 200 mg, or up to about 100 mg, and once daily administration of compound 1-A containing up to about 145 mg, up to about 130 mg, up to about 125 mg, up to about 110 mg, up to about 100 mg, up to about 90 mg, up to about 75 mg, up to about 70 mg, up to about 65 mg, up to about 60 mg, up to about 55 mg, up to about 50 mg, up to about 45 mg, up to about 40 mg, up to about 35 mg, up to about 30 mg, up to about 25 mg, up to about 20 mg, up to about 15 mg, up to about 10 mg, or up to about 5 mg. Administer a single solid dosage form of compound 2, or an equivalent amount of a pharmaceutically acceptable salt of compound 2, to the host in need of treating HCV.

[0199] In one embodiment, once daily administration of compound 1 or an equivalent amount of compound 1-A containing at least about 100 mg, at least about 200 mg, at least about 300 mg, at least about 400 mg, at least about 500 mg, at least about 600 mg, at least about 700 mg, or at least about 800 mg, and once daily administration of compound 1-A containing at least about 5 mg, at least about 10 mg, at least about 15 mg, at least about 20 mg, at least about 25 mg, at least about 30 mg, at least about 35 mg, at least about 40 mg, at least about 45 mg, at least about 50 mg, at least about 55 mg, at least about 60 mg, at least about 65 mg, at least about 70 mg, at least about 75 mg, at least about 80 mg, at least about 90 mg, at least about 100 mg, at least about 110 mg, at least about 125 mg, at least about 130 mg, or at least about 145 mg, is permitted. Administer a mg dose of compound 2 or an equivalent dose of a pharmaceutically acceptable salt of compound 2 in a stand-alone solid dosage form to the host in need of treating HCV.

[0200] In some embodiments, a combination of compounds as described herein is administered to a host in need, in the following manner (either as two active agents in independent doses or as a combination of two active compounds): (1) a single dosage form; (2) two dosage forms; (3) three or more dosage forms; (4) a kit comprising two dosage forms; (5) a kit comprising three or more dosage forms; wherein each of the dosage forms in Examples (1) to (5) comprises: (a) about 500 or 550 mg to about 1100 mg of compound 1-A and an effective amount of compound 2; (b) about 400 mg to about 1,500 mg of compound 1-A and an effective amount of compound 2; (c) about 550 to about 650 mg of compound 1-A and an effective amount of compound 2; (d) about 500 to about 750 mg of compound 1-A and an effective amount of compound 2; (e) about 1,000 to about 1,300 mg of compound 1-A and an effective amount of compound 2. (f) at least about 600 mg of compound 1-A and an effective amount of compound 2; (g) at least about 750 mg of compound 1-A and an effective amount of compound 2; (h) at least about 1,100 mg of compound 1-A and an effective amount of compound 2; (i) as in any of Examples (a) to (h), wherein about 60 mg to about 500 mg of compound 2 is present; (j) as in any of Examples (a) to (h), wherein about 150 mg to about 200 mg of compound 2 is present; (k) as in any of Examples (a) to (h), wherein about 250 mg to about 300 mg of compound 2 is present; (l) as in any of Examples (a) to (h), wherein about 350 mg to about 400 mg of compound 2 is present; (m) as in any of Examples (a) to (h), wherein at least about 90 mg of compound 2 is present; (n) (a) of any one of Examples (a) to (h), wherein at least about 180 mg of compound 2 is present; (o) of any one of Examples (a) to (h), wherein at least about 270 mg of compound 2 is present; (p) of any one of Examples (a) to (h), wherein at least about 360 mg of compound 2 is present; (q) of any one of Examples (1) to (5) and (a) to (h), wherein the dosage form is administered once daily; (r) of any one of Examples (1) to (5) and (a) to (h), wherein the dosage form is administered twice daily; (s) of any one of Examples (1) to (5) and (a) to (h), wherein the dosage form is administered three or more times daily; (t) of any one of Examples (1) to (5) and (a) to (s), wherein the dosage form is administered orally;(u) As in any of Examples (1) to (5) and (a) to (t), wherein the host is a human.

[0201] In an alternative embodiment, a certain amount of compound 1 may be provided to a host in need, resulting in a plasma concentration of compound 1 of about 0.15 nM to about 1 nM. In one embodiment, a certain amount of compound 1 may be provided to a host in need, resulting in a plasma concentration of compound 1 of about 0.25 to about 40 nM. In one embodiment, a certain amount of compound 1 may be provided to a host in need, resulting in a plasma concentration of compound 1 of about 40 to about 200 nM. In one embodiment, a certain amount of compound 1 may be provided to a host in need, resulting in a plasma concentration of compound 2 of about 0.001 nM to about 0.008 nM.

[0202] The compounds in this combination are usually administered orally, but may also be administered non-enterally, topically or in suppository form, and intranasally, as a nasal spray or in other forms described herein. More generally, these compounds may be administered in one or more tablets, capsules, injections, intravenous preparations, suspensions, liquids, emulsions, implants, granules, spheres, creams, ointments, suppositories, inhalable forms, transdermal forms, buccal, sublingual, topical, gels, mucosal, and similar forms.

[0203] In some embodiments, the combination is administered at least once daily for up to 24 weeks. In some embodiments, the combination is administered at least once daily for up to 12 weeks. In some embodiments, the combination is administered at least once daily for up to 10 weeks. In some embodiments, the combination is administered at least once daily for up to 8 weeks. In some embodiments, the combination is administered at least once daily for up to 6 weeks. In some embodiments, the combination is administered at least once daily for up to 4 weeks. In some embodiments, the combination is administered at least once daily for at least 4 weeks. In some embodiments, the combination is administered at least once daily for at least 6 weeks. In some embodiments, the combination is administered at least once daily for at least 8 weeks. In some embodiments, the combination is administered at least once daily for at least 10 weeks. In some embodiments, the combination is administered at least once daily for at least 12 weeks. In some embodiments, the combination is administered at least once daily for at least 24 weeks. In some embodiments, the combination is administered at least every other day for up to 24 weeks, 12 weeks, up to 10 weeks, up to 8 weeks, up to 6 weeks, or up to 4 weeks. In some embodiments, the combination is administered at least every other day for at least 4 weeks, at least 6 weeks, at least 8 weeks, at least 10 weeks, at least 12 weeks, or at least 24 weeks.

[0204] For the purposes of this invention, the prophylactically effective amount of the composition according to the invention falls within the same concentration range as described above for the therapeutic effective amount and is generally the same as the therapeutic effective amount.

[0205] To prepare the pharmaceutical composition according to the present invention, a therapeutically effective amount of compound 1 or a pharmaceutically acceptable salt thereof (e.g., compound 1-A) and compound 2 or a pharmaceutically acceptable salt thereof may be tightly mixed with a pharmaceutically acceptable carrier to produce a certain dose, according to conventional pharmaceutical compounding techniques. The carrier may be in various forms depending on the desired formulation for administration (e.g., oral or non-enteral). In preparing pharmaceutical compositions in oral dosage forms, any common pharmaceutical medium may be used. Thus, for liquid oral formulations such as suspensions, elixirs, and solutions, suitable carriers and additives may be used, including water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like. For solid oral formulations such as powders, tablets, capsules, and for solid formulations such as suppositories, suitable carriers and additives may be used, including starch, sugar carriers (such as dextrose, manifold, lactose, and related carriers), diluents, granulating agents, lubricants, binders, disintegrants, and the like. If desired, tablets or capsules can be enteric-coated or use standard techniques for sustained release. The use of these dosage forms can significantly improve the bioavailability of the compound in patients.

[0206] For non-enteral formulations, the carrier will typically contain sterile water or an aqueous sodium chloride solution, although other components may also be included, including those that aid in dispersion. Of course, if sterile water is intended to be used and maintained as sterile, the composition and carrier must also be sterilized. Injectable suspensions can also be prepared, in which case suitable liquid carriers, suspending agents, and the like may be used.

[0207] Liposome suspensions (including liposomes targeting viral antigens) can also be prepared by conventional methods to produce pharmaceutically acceptable carriers. This is applicable to the delivery of nucleoside, aceto / alkyl nucleoside, or phosphate prodrug forms of the nucleoside compounds according to the present invention.

[0208] In a typical embodiment of the present invention, the pharmaceutical composition is used to treat, prevent, or delay HCV infection or secondary disease states, symptoms, or complications of HCV. Solid dosage form

[0209] A fixed dosage form of an active compound (alone or in combination) or a pharmaceutically acceptable salt thereof (as required, a combined fixed dosage form).

[0210] Any one or both compounds may be provided in crystalline or amorphous form. In some embodiments, they are provided alone or in the same oral dosage form, such as soft capsules, solid form, spray-dried dispersion, tablets, capsules or other pellet forms.

[0211] In one embodiment, the fixed-dose combination comprises a spray-dried solid dispersion of at least one of the compounds or two of the compounds (either in the form of a pharmaceutically acceptable salt) and the composition is suitable for oral delivery. In one embodiment, the fixed-dose combination comprises compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof, wherein at least one of the compounds is in the form of a spray-dried solid dispersion.

[0212] In another embodiment, the fixed-dose combination is a granulated solid dispersion of at least one of the compounds or a pharmaceutically acceptable salt thereof, and the composition is suitable for oral delivery. An exemplary process for preparing a solid dosage form for oral delivery is shown in FIG32. In one embodiment, the fixed-dose combination is a granulated solid dispersion comprising compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof. In some embodiments, a spray-dried dispersion or granulated solid dispersion component is prepared using crystalline compound 1-A. In an alternative embodiment, compound 1 or a pharmaceutically acceptable salt (e.g., compound 1-A) or compound 2 or a pharmaceutically acceptable salt may be delivered as an amorphous compound.

[0213] In other embodiments, the solid dispersion also contains at least one excipient selected from copovidone, poloxamer, and HPMC-AS. In one embodiment, the poloxamer is poloxamer 407 or a mixture of poloxamers that may include poloxamer 407. In one embodiment, HPMC-AS is HPMC-AS-L.

[0214] In other embodiments, the fixed-dose compositions prepared from compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof also comprise one or more of the following excipients: glyceryl phosphate; phosphatidylcholine; dipalmitoylphosphatidylcholine (DPPC); dioleoylphosphatidylethanolamine (DOPE); dioleoyloxypropyltriethylammonium (DOTMA); dioleoylphosphatidylcholine; cholesterol; cholesterol ester; dioleoylphosphatidylcholine ... Polyglycerol; diacylglycerol succinate; diphosphatidylglycerol (DPPG); hexanedecyl alcohol; fatty alcohols, such as polyethylene glycol (PEG); polyoxyethylene ethyl-9-lauryl ether; surfactant fatty acids, such as palmitic acid or oleic acid; fatty acids; fatty acid monoglycerides; fatty acid diglycerides; fatty acid amides; sorbitan trioleate (Span® 85); glyceryl esters; sorbitan monolaurate (Span® 20); polysorbate 20 (Tween® 20); polysorbate 60 (Tween® 60); polysorbate 65 (Tween® 65); polysorbate 80 (Tween® 80); polysorbate 85 (Tween® 85); Polyoxyethylene monostearate; Surfactants; Poloxamer; Sorbitan fatty acid esters, such as sorbitan trioleate; Lecithin; Lysophosphatidylserine; Phosphatidylinositol; Sphingomyelin; Phosphatidylethanolamine (cephalin); Cardiolipin; Phosphatidic acid; Cerebrosides; Diacetylphosphate; Dipalmitoylphosphatidylglycerin; Stearylamine; Dodecylamine; Hexadecylamine; Acetylpalmitate; Glyceryl ricinoleate; Hexadecyl stearate; Isopropyl myristate; Tetrabutylphenol; Poly(ethylene glycol) 5000-phosphatidylethanolamine; Poly(ethylene glycol) 400-monostearate; Phospholipids; Synthetic and / or natural detergents with high surfactant properties; Deoxycholates; Cyclodextrins; Chaotropic salts Salts; ion-pairing agents; glucose, fructose, galactose, ribose, lactose, sucrose, maltose, trehalose, cellbiose, mannose, xylose, arabinose, glucuronic acid, galacturonic acid, mannuronic acid, glucosamine, galactosamine, and neuraminic acid;Polyglucose, cellulose, microcrystalline cellulose, silicated microcrystalline cellulose, hydroxypropyl methylcellulose (HPMC), hydroxycellulose (HC), methylcellulose (MC), polydextrin, cyclodextrin, glycogen, hydroxyethyl starch, carrageenan, glycogen, amylose, chitosan, N,O-carboxymethyl chitosan, alginate and alginic acid, starch, chitin, inulin, konjac, glucommannan, pustulin, heparin, hyaluronic acid, curdlan and xanthan gum, mannitol, sorbitol, xylitol, erythritol, maltitol and lactitol. Poly(tol), pluronic polymers, polyethylene, polycarbonate (e.g., poly(1,3-dioxane-2-one)), polyanhydride (e.g., poly(sebacic anhydride)), polypropylfumerate, polyamide (e.g., polycaprolactam), polyacetal, polyether, polyester (e.g., polylactic acid, polyglycolic acid, polylactic acid-co-glycolic acid, polycaprolactone), polyhydroxy acid (e.g., poly(β-hydroxyalkanoate)), poly(orthoester), polycyanoacrylate, polyvinyl alcohol, polyurethane, polyphosphazene, polyacrylate, polymethacrylate, polyurea, polystyrene, and polyamine, polylysine, polylysine, polylysine-PEG copolymer and poly(ethylene ethylimide), poly(ethylene ethylimide)-PEG copolymer, glyceryl monooctyl decanoate, propylene glycol, vitamin E TPGS (also known as d-α-tocopherol polyethylene glycol 1000 succinate), gelatin, titanium dioxide, polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), methylcellulose (MC), block copolymers of ethylene oxide and propylene oxide (PEO / PPO), polyethylene glycol (PEG), sodium carboxymethyl cellulose (NaCMC), or hydroxypropyl methylcellulose acetate succinate (HPMCAS).

[0215] In other embodiments, the fixed-dose compositions prepared from compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof also comprise one or more of the following surfactants: polyethylene glycol, polyoxypropylene glycol, decyl glycoside, lauryl glycoside, octyl glycoside, polyethylene glycol octylphenol, Triton X-100, glyceryl alkyl ester, glyceryl laurate, cocoamide MEA, cocoamide DEA, dodecyl dimethylamine oxide, and poloxamer. Examples of poloxamers include poloxamer 188, 237, 338, and 407. These poloxamers are available under the trademark Pluronic® (available from BASF, Mount Olive, NJ) and correspond to Pluronic® F-68, F-87, F-108, and F-127, respectively. Poloxamer 188 (corresponding to Pluronic® F-68) is a block copolymer having an average molecular weight of about 7,000 to about 10,000 Da, or about 8,000 to about 9,000 Da, or about 8,400 Da. Poloxamer 237 (corresponding to Pluronic® F-87) is a block copolymer having an average molecular weight of about 6,000 to about 9,000 Da, or about 6,500 to about 8,000 Da, or about 7,700 Da. Poloxamer 338 (corresponding to Pluronic® F-108) is a block copolymer having an average molecular weight of about 12,000 to about 18,000 Da, or about 13,000 to about 15,000 Da, or about 14,600 Da. Poloxamer 407 (corresponding to Pluronic® F-127) is a triblock copolymer of polyethylene oxide and polypropylene oxide with a ratio of about E101 P56 E101 to about E106 P70 E106, or about E101 P56E101, or about E106 P70 E106, having an average molecular weight of about 10,000 to about 15,000 Da, or about 12,000 to about 14,000 Da, or about 12,000 to about 13,000 Da, or about 12,600 Da.

[0216] In other embodiments, the fixed-dose composition prepared from compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof also comprises one or more of the following surfactants: polyvinyl acetate, sodium cholate, sodium dioctyl sulfosuccinate, hexadecyltrimethylammonium bromide, saponin, glycoester, Triton. X series, sorbitan trioleate, sorbitan monooleate, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monooleate, oleyl polyoxyethylene (2) ether, stearyl polyoxyethylene (2) ether, lauryl polyoxyethylene (4) ether, block copolymers of oxyethylene and oxypropyl, diethylene glycol dioleate, tetrahydrofuranyl oleate, ethyl oleate, isopropyl myristate, glyceryl monooleate, glyceryl monostearate, glyceryl monoricinoleate, cetyl alcohol, stearyl alcohol, cetylpyridinium chloride, benzyl dimethyl ammonium chloride, olive oil, glyceryl monolaurate, corn oil, cottonseed oil and sunflower seed oil.

[0217] In an alternative embodiment, a fixed-dose composition prepared from compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof is prepared by a process including solvent or dry granulation as needed followed by compression or compaction, spray drying, nano-suspension treatment, hot melt extrusion, extrusion / spheronization, molding, spheronization, lamination (e.g., spray lamination of suspension or solution) or the like. Examples of such techniques include direct compression using suitable punches and dies, for example, wherein the punches and dies are mounted to a suitable press; wet granulation using suitable granulation equipment (such as a high-shear granulator) to form wetted granules to be dried into pellets; granulation followed by compression using suitable punches and dies, wherein the punches and dies are mounted to a suitable press; extrusion of wet mass to form cylindrical extrudates to be cut to desired lengths or broken into lengths under gravity and wear; extrusion / spheronization, wherein the extrudates are sphericalized into pellets and densified by spheronization; spraying suspensions or solutions onto inert cores using techniques such as conventional pans or Wurster columns; injection or compression molding using suitable dies mounted to a compression unit; and similar techniques.

[0218] Exemplary disintegrants include alginate, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose, croscarmellose sodium (croscarmellose sodium), powdered cellulose, chitosan, croscarmellose sodium, crospovidone, guar gum, low-substituted hydroxypropyl cellulose, methylcellulose, microcrystalline cellulose, sodium alginate, sodium starch glycolate, partially pregelatinized starch, pregelatinized starch, starch, sodium carboxymethyl starch, and similar or combinations thereof.

[0219] Exemplary lubricants include calcium stearate, magnesium stearate, glyceryl betaine, glyceryl palmitate stearate, hydrogenated castor oil, light mineral oil, sodium lauryl sulfate, magnesium lauryl sulfate, sodium stearyl fumarate, stearic acid, zinc stearate, silicon dioxide, colloidal silicon dioxide, silicon dioxide-treated dimethyl dichlorosilane, talc, or combinations thereof.

[0220] The dosage form core described herein may be coated to produce a coated tablet. The dosage from the core may be coated with a functional or non-functional coating, or a combination of functional and non-functional coatings. "Functional coating" includes tablet coatings that modify the release characteristics of the overall composition (e.g., sustained-release or delayed-release coatings). "Non-functional coating" includes coatings that are not functional coatings (e.g., cosmetic coatings). Non-functional coatings may have some effect on the release of active agents due to initial dissolution, hydration, coating perforation, etc., but this is not considered a significant deviation from the uncoated composition. Non-functional coatings may also mask the taste of the uncoated composition, including the active pharmaceutical ingredient. Coatings may include light-blocking materials, light-absorbing materials, or a combination of light-blocking and light-absorbing materials.

[0221] Exemplary polymethacrylates include copolymers of acrylates and methacrylates, such as a. aminomethacrylate copolymers USP / NF, such as poly(butyl methacrylate, (2-dimethylaminoethyl)methacrylate, methyl methacrylate) 1:2:1 (e.g., EUDRAGIT E 100, EUDRAGIT EPO, and EUDRAGIT E 12.5; CAS No. 24938-16-7); b. poly(methacrylic acid, ethyl acrylate) 1:1 (e.g., EUDRAGIT L30 D-55, EUDRAGIT L100-55, EASTACRYL 30D, KOLLICOAT MAE 30D AND 30DP; CAS No. 25212-88-8); c. poly(methacrylic acid, methyl methacrylate) 1:1 (e.g., EUDRAGIT L 100, EUDRAGIT L 12.5, and 12.5). P; also known as methacrylic acid copolymer, type A NF; CAS No. 25806-15-1); d. Poly(methacrylic acid, methyl methacrylate) 1:2 (e.g., EUDRAGIT S 100, EUDRAGIT S 12.5 and 12.5P; CAS No. 25086-15-1); e. Poly(methyl acrylate, methyl methacrylate, methacrylic acid) 7:3:1 (e.g., Eudragit FS 30 D; CAS No. 26936-24-3); f. Poly(ethyl acrylate, methyl methacrylate, trimethylammonium ethyl chloromethacrylate) 1:2:0.2 or 1:2:0.1 (e.g., EUDRAGITS RL 100, RL PO, RL 30 D, RL 12.5, RS 100, RS PO, RS 30 D or RS 12.5; CAS No. 33434-24-1); g. Poly(ethyl acrylate, methyl methacrylate) 2:1 (e.g. EUDRAGIT NE 30 D, Eudragit NE 40 D, Eudragit NM 30 D; CAS No. 9010-88-2); and similar or combinations thereof.

[0222] Suitable alkyl celluloses include, for example, methylcellulose, ethylcellulose, and the like or combinations thereof. Exemplary water-based ethyl cellulose coatings include AQUACOAT, a 30% dispersion further containing sodium lauryl sulfate and cetyl alcohol, available from FMC, Philadelphia, PA; SURELEASE, a 25% dispersion further containing stabilizers or other coating components (e.g., ammonium oleate, dibutyl sebacate, colloidal anhydrous silica, medium-chain triglycerides, etc.), available from Colorcon, West Point, PA; and ethyl cellulose, available from Aqualon or Dow Chemical Co (Ethocel), Midland, MI. Those skilled in the art will appreciate that other cellulose polymers, including other alkyl cellulose polymers, can replace some or all of the ethyl cellulose.

[0223] Other suitable materials for the preparation of functional coatings include hydroxypropyl methylcellulose acetate succinate (HPMCAS); cellulose acetate phthalate (CAP); polyvinyl acetate phthalate; natural or synthetic waxes; fatty alcohols (such as lauryl, myristyl, stearyl, cetyl, or especially cetearyl alcohol); fatty acids, including fatty acid esters, fatty acid glycerides (mono-, di-, and triglycerides), hydrogenated fatty acids, hydrocarbons, normal waxes, stearic acid, stearyl alcohol, hydrophobic and hydrophilic materials having a hydrocarbon backbone, or combinations thereof. Suitable waxes include beeswax, sugar wax, castor wax, carnauba wax, microcrystalline wax, candelilla wax, and wax-like substances (e.g., materials that are normally solid at room temperature and have a melting point of about 30°C to about 100°C), or combinations thereof.

[0224] In other embodiments, the functional coating may include digestible, long-chain (e.g., C8-C50, especially C12-C40), substituted or unsubstituted hydrocarbons, such as fatty acids, fatty alcohols, glycerides of fatty acids, mineral oils and vegetable oils, waxes, or combinations thereof. Hydrocarbons having a melting point between about 25°C and about 90°C may be used. Specifically, long-chain hydrocarbon materials and aliphatic alcohols may be used.

[0225] Such coatings may contain additional pharmaceutically acceptable excipients, such as plasticizers, stabilizers, water-soluble components (e.g., pore-forming agents), anti-adhesion agents (e.g., talc), surfactants, and similar or combinations thereof, as needed.

[0226] Functional coatings may include release modifiers that affect the release characteristics of the functional coatings. Release modifiers may, for example, be used as pore-forming agents or matrix disruptors. Release modifiers may be organic or inorganic and include materials that can be dissolved, extracted, or leached from the coating in the application environment. Release modifiers may contain one or more hydrophilic polymers, including cellulose ethers and other celluloses such as hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, methylcellulose, cellulose phthalate acetate, or hydroxypropyl methylcellulose phthalate; povidone; polyvinyl alcohol; acrylic polymers such as stomach-soluble Eudragit FS 30D, pH-sensitive Eudragit L30D 55, L 100, S 100, or L 100-55; or combinations thereof. Other exemplary release modifiers include povidone; sugars (e.g., lactose and the like); metal stearates; inorganic salts (e.g., dicalcium phosphate, sodium chloride and the like); polyethylene glycols (e.g., polyethylene glycol (PEG) 1450 and the like); sugar alcohols (e.g., sorbitol, mannitol and the like); basic alkyl sulfates (e.g., sodium lauryl sulfate); polyoxyethylene ethyl sorbitan fatty acid esters (e.g., polysorbate); or combinations thereof. Exemplary matrix disruptors include water-insoluble organic or inorganic materials. Organic polymers include (but are not limited to) cellulose, cellulose ethers (such as ethyl cellulose), cellulose esters (such as cellulose acetate, cellulose acetate butyrate, and cellulose acetate propionate); and starch can be used as matrix disruptors. Examples of inorganic disruptors include many calcium salts, such as monocalcium phosphate, dicalcium phosphate, and tricalcium phosphate; silica and talc.

[0227] The coating may contain plasticizers as needed to improve its physical properties. For example, since ethyl cellulose has a relatively high glass transition temperature and does not form a flexible film under normal coating conditions, it is advantageous to add a plasticizer to ethyl cellulose before using the same material as the coating. Generally, the amount of plasticizer contained in the coating solution is based on the concentration of the polymer, for example, from about 1% to about 200%, depending on the polymer, but most often from about 1% by weight to about 100% by weight of the polymer. However, the concentration of the plasticizer can be determined by routine experiments.

[0228] Examples of plasticizers used in ethyl cellulose and other celluloses include plasticizers such as dibutyl sebacate, diethyl phthalate, triethyl citrate, tributyl citrate, triacetin, or combinations thereof, although other water-insoluble plasticizers (such as acetylated monoglycerides, phthalates, castor oil, etc.) may be used.

[0229] Examples of plasticizers used in acrylic polymers include citrate esters, such as triethyl citrate NF, tributyl citrate, dibutyl phthalate, 1,2-propanediol, polyethylene glycol, propylene glycol, diethyl phthalate, castor oil, triacetin, or combinations thereof, although other plasticizers (such as acetylated monoglycerides, phthalates, castor oil, etc.) may be used.

[0230] Suitable methods may be used to apply the coating material to the surface of the formulation core. Processes that may be used include simple or complex coagulation, interfacial polymerization, liquid drying, thermal and ionic gelation, spray drying, spray cooling, fluidized bed coating, pot coating, or electrostatic deposition.

[0231] In some embodiments, an optional intermediate coating is used between the dosage form core and the outer coating. This intermediate coating may be used to protect the active agent or other components of the core subunit from the influence of materials used in the outer coating or to provide other properties. Exemplary intermediate coatings typically comprise a water-soluble film-forming polymer. Such intermediate coatings may comprise film-forming polymers such as hydroxyethyl cellulose, hydroxypropyl cellulose, gelatin, hydroxypropyl methylcellulose, polyethylene glycol, polyethylene oxide, and the like or combinations thereof; and plasticizers. Plasticizers may be used to reduce brittleness and increase tensile strength and elasticity. Exemplary plasticizers include polyethylene glycol, propylene glycol, and glycerin. Combination and Alternating Therapies

[0232] Drug resistance can sometimes occur due to mutations in genes encoding enzymes used in viral replication. The efficacy of combination therapy against HCV infection can be prolonged, enhanced, or restored by adding additional compounds to the combination therapy. Such further combination therapy may be administered together with or alternately with another, and possibly two or three, antiviral compounds that induce different mutations or actions through pathways different from the main combination. Alternatively, the pharmacokinetics, biodistribution, half-life, or other parameters of the combination may be altered by such combination therapy (which may include alternating therapy, where considered synergistic).

[0233] This invention provides a favorable combination therapy for treating HCV or HCV-related conditions by administering selected NS5B inhibitors and NS5A inhibitors. Further therapeutic effects can be achieved by adding co-formulated or separately supplied third, fourth, or even fifth active agents.

[0234] Since compounds 1 and 1-A are NS5B polymerase inhibitors and compound 2 is an NS5A inhibitor, administering compounds 1 and 2 to the host in combination with, for example, the following: (1) a protease inhibitor, such as an NS3 / 4A protease inhibitor; (2) another NS5A inhibitor; (3) another NS5B polymerase inhibitor; (4) an NS5B non-receptor inhibitor; (5) interferon α-2a, which may be polyethylene glycol-modified or otherwise modified, and / or ribavirin; (6) a non-receptor inhibitor; (7) a helicase inhibitor; (8) an antisense oligodeoxyribonucleotide (S-ODN); (9) an aptamer; (10) a nuclease-resistant ribozyme; (11) iRNA, including microRNA and siRNA; (12) a viral antibody, partial antibody or domain antibody, or (13) a viral antigen or partial antigen that induces a host antibody response.

[0235] Non-limiting examples of other anti-HCV agents that can be further combined with or alternately administered with the present invention include (i) protease inhibitors, such as Incivek®, Victrelis™, Olysio™, pariprevir (ABT-450), gcapipevir (ABT-493), Norvir, ACH-2684, AZD-7295, BMS-791325, danoprevir, filibuvir, GS-9256, GS-9451, MK-5172, Setrobuvir, Sovaprevir, Tegobuvir, VX-135, VX-222, ALS-220, and voxilaprevir. (ii) NS5A inhibitors, such as ACH-2928, ACH-3102, IDX-719, daclatasvir, ledipasvir, velpatasvir, elbasvir (MK-8742), gzopivir (MK-5172), and opiativir (ABT-267); (iii) NS5B inhibitors, such as AZD-7295, clemizole, dasabvir (Exviera), ITX-5061, PPI-461, PPI-688, sofosbuvir (Sovaldi®), MK-3682, and mericitabine; (iv) NS5B inhibitors, such as ABT-333 and MBX-700; (v) antibodies, such as GS-6624; (vi) combination therapies, such as Harvoni. (ledipasvir / sofosbuvir); Viekira Pak (opittivir / paripvir / ritonavir / dasabuvir); Viekirax (opittivir / paripvir / ritonavir); G / P (paripvir and gcapipvir); TechnivieTM (opittivir / paripvir / ritonavir), Epclusa (sofosbuvir / velpatasvir), Zepatier (elbavir and gzopivir), Mavyret (gcapipvir and pibupatasvir) and Vosevi (sofosbuvir, velpatasvir and vorciravir).

[0236] If the combination is administered to treat advanced hepatitis C virus-induced liver cancer or cirrhosis, in one embodiment, the compound may be administered in combination with or alternately with another drug commonly used to treat hepatocellular carcinoma (HCC), for example, as described by Andrew Zhu in "New Agents on the Horizon in Hepatocellular Carcinoma" Therapeutic Advances in Medical Oncology, V 5(1), January 2013, 41-50. Examples of suitable compounds for combination therapy in hosts at or at risk of HCC include anti-angiogenic agents, sunitinib, brivanib, linifanib, ramucirumab, bevacizumab, cediranib, pazopanib, TSU-68, lenvatinib, anti-EGFR antibodies, mTor inhibitors, MEK inhibitors, histone deacetylace inhibitors, capecitabine, cisplatin, carboplatin, doxorubicin, 5-fluorouracil, gemcitabine, irinotecan, oxaliplatin, topotecan, and other topoisomerases. General Methods

[0237] 1H, 19F, and 31P NMR spectra were recorded on a Brücker Fourier transform spectrometer at 400 MHz. DMSO-d6 spectra were obtained unless otherwise specified. Spin multiplicity is indicated by the symbols s (singleton), d (doublet), t (triplet), m (multiplex), and br (broad peak). Coupling constants (J) are reported in Hz. These reactions were generally carried out using Sigma-Aldrich anhydrous solvents under a dry nitrogen atmosphere. All common chemicals were obtained from commercially available sources. The following abbreviations are used in the examples: BID: twice daily; DCM: dichloromethane; EtOAc: ethyl acetate; EtOH: ethanol; GT: genotype; HPLC: high-performance liquid chromatography; LD: loading dose; NaOH: sodium hydroxide; Na2SO4: sodium sulfate (anhydrous); MeOH: methanol; Na2SO4: sodium sulfate; NH4Cl: ammonium chloride; PE: petroleum ether silica gel (230 to 400 mesh, adsorbent); t-BuMgCl: tertiary butylmagnesium chloride; THF: tetrahydrofuran (THF), anhydrous; TP: triphosphate. Example 1. Synthesis of compound 1 and compound 1-A. Part A: Synthesis of (2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purine-9-yl)-4-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3-ol (1-7)

[0238] In step 1, compound 1-1 is dissolved in DCM and the reaction is cooled to 10°C before the addition of benzyl chloroformate followed by NEt3. The reaction is allowed to rise to room temperature and stirred for 12 to 14 hours. Compound 1-2 is isolated under suitable treatment and purification conditions. In step 2, compound 1-2 is dissolved in acetonitrile and cooled to -15 to 5°C before the addition of Morpho DAST. The reaction is allowed to be stirred for 6 hours. Compound 1-3 is isolated under suitable treatment and purification conditions. In step 3, compound 1-3 is dissolved in toluene and the reaction is cooled to 0 to 10°C before the addition of Red Al. Compound 1-4 is isolated as a diastereomer having (R)- stereochemistry at the hydroxyl position under suitable treatment and purification conditions. In step 4, compound 1-4 is dissolved in acetonitrile and cooled to -15 to 5°C before the addition of CBr4 and PPh3. Compound 1-5 is isolated under suitable treatment and purification conditions. In step 5, compounds 1-5 are dissolved in acetonitrile and t-BuOH, t-BuOK, and 6-chloro-9H-purine-2-amine are added. The reaction is heated to 40-50°C. Compounds 1-6 are isolated under suitable treatment and purification conditions. In step 6, compounds 1-6 are dissolved in MeOH and MeNH2 is added. The reaction is heated to 20-30°C. Compounds 1-7 are isolated under suitable treatment and purification conditions. Part B: Synthesis of the dihydroquinine salt of (hydroxy(phenoxy)phosphatidyl)-L-propanolate isopropyl (1-12)

[0239] Phenyl dichlorophosphate (1-8, 150 g, 1.0 equivalent) was added to 1300 mL of isopropyl acetate. The solution was cooled to -10 °C ± 5 °C and then a solution of benzyl alcohol (1-9, 80.6 g, 1.05 equivalent) and Et3N (86.3 g, 1.2 equivalent) was added. The mixture was stirred at -10 ± 5 °C for 3 hours. The endpoint of the reaction was monitored by TLC.

[0240] L-isopropyl alanine hydrochloride (1-10, 125 g, 1.05 equivalents) and Et3N (152 g, 2.1 equivalents) were added at -10 °C ± 5 °C. The reaction mixture was stirred at -10 ± 5 °C for 2 hours. The endpoint of the reaction was monitored by TLC.

[0241] The reaction mixture was filtered, and the filter cake was washed with 20 mL of isopropyl acetate. The filtrate was washed with 1N HCl, water, and an aqueous sodium bicarbonate solution. The separated organic layer was dried with anhydrous Na₂SO₄ and then concentrated to dryness under vacuum at 40°C to 50°C to give 240 g of crude product 1-11 as a mixture of diastereomers (approximately 1:1). (Pale yellow oil; yield: 89.6% mol / mol; HPLC purity: 83.4% by area; HPLC analysis: 86.2% w / w). This product contains approximately 6% to 7% residual benzyl alcohol. The crude 1-4 series was used directly in the next step.

[0242] Compounds 1-11 (135 g, 1.0 equivalent, 86.2% analytical) and quinine (100 g, 1.0 equivalent) were added to 650 mL of i-PrOH. After the addition of 5% Pd / C (19.2 g, 60% water, based on KF), hydrogenation was carried out in a closed system using a hydrogen bag at 20°C to 25°C for 8 hours. After the reaction was complete, the mixture was filtered through a Büchner funnel. The filtrate was concentrated under vacuum to remove the solvent.

[0243] 300 mL of TBME was added to the above residue. The mixture was concentrated under vacuum at 40°C to 45°C to remove the solvent, and then the step was repeated with another 300 mL of MTBE. 600 mL of MTBE was added to the mixture, and the mixture was stirred at 40°C to 45°C for 1 hour and then stirred again at 0°C to 5°C for 1 hour. The mixture was filtered, and the filter cake was washed with 100 mL of MTBE. The filter cake was dried without vacuum at 45°C for 16 hours to give 152 g of dihydroquinine salt of (hydroxy(phenoxy)phosphatidyl)-L-propanoate isopropyl (1-12, white solid; yield: 69.5% mol / mol; HPLC purity: 97.91%). Part C: Synthesis of Compound 1

[0244] Dihydroquinine salt of (hydroxy(phenoxy)phosphatidyl)-L-propanoic acid isopropyl ester (1-12, 5.9 g, 1.5 equivalents), compounds 1-7 (2.0 g, 1.0 equivalents), DIPEA (0.83 g, 1.0 equivalents), and HATU (3.65 g, 1.5 equivalents) were added to 100 mL of dichloromethane. The mixture was heated to 40 °C and stirred for 18 hours. The reaction was monitored by TLC and HPLC.

[0245] After the reaction was complete, the reaction mixture was cooled to room temperature and washed with 1N hydrochloric acid (100 mL x 2), water (100 mL x 2), and 5% sodium bicarbonate aqueous solution (15 mL x 1). The separated organic phase was dried with 2 g of anhydrous sodium sulfate, filtered, and then concentrated under vacuum at 40°C to 45°C to obtain a yellow oil.

[0246] Add (10 mL) isopropyl acetate. After stirring, concentrate the mixture under vacuum. Then, add 25 mL of isopropyl acetate. Heat the mixture to 45°C to provide a clear solution. After stirring at room temperature for 2 hours, filter the solid precipitate and dry it at 45°C without vacuum for 15 hours to give 2.0 g of crude compound 1 (yield: 53.8% mol / mol; HPLC purity: 93.1%, based on area (containing 3.7% of compounds with opposite Rp-configurations)).

[0247] A mixture of crude compound 1 (2.0 g) and 15 mL of isopropyl acetate was heated to 80°C to 85°C to obtain a solution. The solution was cooled to 20°C to 25°C and stirred for 1 hour. The precipitated solid was filtered, washed with isopropyl acetate (1 mL), and then dried at 50°C without vacuum for 16 hours to give 1.7 g of compound 1 (yield: 45.7% mol / mol; HPLC purity: 98.99%). The structure of compound 1 was confirmed by 1H NMR, 19F NMR, and 31P NMR spectroscopy. Example 2. Characterization of amorphous and crystalline compound 1

[0248] Amorphous compound 1 and crystalline compound 1 were initially analyzed by XRPD, 1H NMR, and HPLC. The XRPD patterns of both compounds are shown in Figure 1A, and the HPLC traces confirming purity are shown in Figures 1B and 2A, respectively. Table 1 lists the XRPD peaks from crystalline compound 1, and Table 2 lists the relative residence times (RTT) from the HPLC traces. Amorphous compound 1 was 98.61% pure, and crystalline compound 1 was 99.11% pure. Both compounds were white solids. Figure 2B shows the TGA and DSC chromatograms of crystalline compound 1. For crystalline compound 1, endothermic reaction was observed at 88.6 °C, with a 7.8% mass loss from 80 to 110 °C.

[0249] A sample of compound 1 was recrystallized from EtOAc / hexane and plotted using ORTEP. The absolute structure of compound 1 was confirmed by recrystallization of a single crystal. Figure 3 shows the ORTEP plot of compound 1. Crystallographic data and measurement data are shown in Table 3. The absolute stereochemistry of compound 1 based on X-ray crystallography is shown below:

[0250] DSC data were collected on a TA Instruments Q2000 equipped with a 50-position autosampler. Heat capacity calibration was performed using sapphire, and energy and temperature calibration were performed using qualified indium. Typically, approximately 3 mg of each sample was heated from 25°C to 200°C at 10°C / min in a pinhole aluminized pan. Dry nitrogen purge at 50 ml / min was maintained over the samples. The instrument control software was Advantage Q series v2.8.0.394 and Thermal Advantage v5.5.3, and Universal Analysis v4.5A was used for data analysis.

[0251] TGA data were collected on a TA Instruments Q500 TGA equipped with a 16-position autosampler. The instrument was calibrated for temperature using qualified alumel and nickel. Typically, 5 to 10 mg of each sample was loaded into a pre-tared aluminum DSC vessel and heated from ambient temperature to 350°C at 10°C / min. A nitrogen purge of 60 ml / min was maintained over the samples. The instrument control software was Advantage Q series v2.5.0.256 and Thermal Advantage v5.5.3, and Universal Analysis v4.5 was used for data analysis. Amorphous compound 1 (1-1): ¹H NMR (400 MHz, DMSO-d6) δ ppm 1.01 - 1.15 (m, 9H), 1.21 (d, J=7.20 Hz, 3H), 2.75 - 3.08 (m, 3H), 3.71 - 3.87 (m, 1H), 4.02 - 4.13 (m, 1H), 4.22 - 4.53 (m, 3H), 4.81 (s, 1H), 5.69 - 5.86 (m, 1H), 6.04 (br d, J=19.33 Hz, 4H), 7.12 - 7.27 (m, 3H), 7.27 - 7.44 (m, 3H), 7.81 (s, 1H) Crystalline compound 1 (1-2): ¹H NMR (400 MHz, DMSO-d⁶) δ ppm 0.97 - 1.16 (m, ¹⁶ H), 1.21 (d, J=7.07 Hz, ³ H), 2.87 (br s, ³ H), 3.08 (s, ² H), 3.79 (br d, J=7.07 Hz, ¹ H), 4.08 (br d, J=7.58 Hz, ¹ H), 4.17 - 4.55 (m, ³ H), 4.81 (quin, J=6.25 Hz, ¹ H), 5.78 (br s, ¹ H), 5.91 - 6.15 (m, ⁴ H), 7.10 - 7.26 (m, ³ H), 7.26 - 7.44 (m, 3 H), 7.81 (s, 1 H) Table 1. Peak list of crystalline compound 1 Angle / °2θ d spacing / Å Intensity / Count strength / % 6.03 14.64 1005 39.0 7.36 12.00 315 12.2 7.94 11.13 1724 66.9 9.34 9.47 2500 97.0 9.51 9.29 860 33.4 9.77 9.05 1591 61.8 11.08 7.98 2576 100.0 12.02 7.36 171 6.6 12.95 6.83 319 12.4 13.98 6.33 241 9.4 14.30 6.19 550 21.4 14.69 6.03 328 12.7 15.20 5.82 2176 84.5 15.94 5.56 1446 56.1 16.75 5.29 1009 39.2 17.29 5.13 700 27.2 17.72 5.00 1213 47.1 18.11 4.89 1565 60.8 18.46 4.80 302 11.7 18.89 4.69 385 14.9 19.63 4.52 636 24.7 20.37 4.36 1214 47.1 20.74 4.28 1198 46.5 21.24 4.18 640 24.8 22.31 3.98 961 37.3 22.88 3.88 806 31.3 23.43 3.79 355 13.8 24.08 3.69 573 22.2 24.49 3.63 159 6.2 25.00 3.56 351 13.6 25.36 3.51 293 11.4 26.09 3.41 235 9.1 26.26 3.39 301 11.7 26.83 3.32 696 27.0 27.35 3.26 436 16.9 27.46 3.25 363 14.1 28.07 3.18 200 7.8 28.30 3.15 195 7.6 28.82 3.10 599 23.3 29.85 2.99 217 8.4 30.26 2.95 186 7.2 30.75 2.91 333 12.9 31.12 2.87 149 5.8 31.85 2.81 238 9.2 33.28 2.69 261 10.1 34.77 2.58 171 6.6 35.18 2.55 175 6.8 36.83 2.44 327 12.7 37.41 2.40 172 6.7 Table 2. Relative retention times from HPLC chromatograms of amorphous compound 1 and crystalline compound 1 Amorphous compound 1 Crystalline compound 1 RRT area% RRT area(%) 0.48 0.15 0.48 0.17 0.51 0.04 0.48 0.17 0.48 0.15 0.94 0.12 0.51 0.04 1.00 99.11 0.94 0.13 1.04 0.22 0.98 0.21 1.37 0.07 1.00 98.61 1.04 0.29 1.37 0.31 Table 3. Crystallography and data measurement of Compound 1 Key precision CC = 0.0297 Å, wavelength = 1.54184 Å unit cell a=10.1884(3) b=28.6482(9) c=12.9497(5) α=90 β=113.184(4) γ=90 temperature 150K Calculated value Report value volume 3474.5(2) 3474.5(2) Space Group P21 P 1 21 1 Hall Group P 2yb P 2yb Partial C24 H34 F N7 O7 P 2(C24H34FN7O7P) Total C24 H34 F N7 O7 P C48 H68 F2 N14 O14 P2 Mr 582.55 1165.10 Dx, g cm -1 1.114 1.114 Z 4 2 Mu (mm -1 ) 1.139 1.139 F000 1228.0 1228.0 F000' 1233.21 h, k, l max 12,34,15 12,34,15 N ref 12742 [ 6510] 8259 T min T max 0.790, 0.815 0.808, 1.000 T min’ 0.716 Correction method #Report's T Limit: T min = 0.808 T max = 1.00 AbsCorr MULTI-SCAN Data completeness 1.27 / 0.65 θ (max) 68.244 R (reflection) 0.2091 (7995) wR2 (reflection) 0.5338 (8259) S 2.875 Npar 716

[0252] Following this initial characterization, the compounds were analyzed by HPLC and XRPD after 14 days, 7 days, and 14 days of storage at 25°C / 60% relative humidity (RH). Figure 4A shows the XRPD after 14 days at 25°C / 60% (RH). Amorphous compound 1 (sample 1-1) remained poorly crystallized, while crystalline compound 1 (sample 1-2) maintained its crystallinity, but both compounds were stable after 14 days at 25°C / 60% (RH). Example 3. Formation of oxalate compound 1-B

[0253] Initially, oxalate compound 1-B of compound 1 was formed by mixing oxalate with a solvent (5 volumes, 100 μL) and allowing any solution to evaporate at room temperature. Any suspension was allowed to mature (room temperature – 50°C) for 3 hours to obtain crystallinity.

[0254] Table 4 shows the different solvents used in the preparation of compound 1-B. All solvents (except two (cyclohexane and n-heptane)) provided crystalline products. Although compound 1-B has high crystallinity and solubility, oxalate is unacceptable for clinical development due to its potential to form kidney stones, and other salts of compound 1 are being explored. Table 4. Formation of oxalate compound 1-B solvent Observation after acid addition at room temperature Observations after ripening / evaporation EtOH solution OXA – Form 1 IPA solution OXA – Form 1 acetone solution OXA – Form 1 MEK solution OXA – Form 1 EtOAc suspension OXA – Form 1 iPrOAc suspension OXA – Form 1 THF solution OXA – Form 1 Toluene solution OXA – Form 1 MeCN solution OXA – Form 1 IPA: 10% water solution OXA – Form 1 TBME suspension OXA – Form 1 Cyclohexane suspension Amorphous n-Heptane suspension Amorphous Example 4. Salt compound of amorphous compound 1

[0255] Because oxalate compound 1-B (Example 3) could not be used in clinical trials due to its potential to form kidney stones, the counterions listed in Table 5 were used to form an amorphous salt of compound 1. Compound 1 was dissolved in terbutanol (20 volumes, 6 ml) and the solution was treated with an acid counterion (equivalent to each sample 1, except for samples 1-9 which were treated with 0.5 equivalents of sulfate). The samples were then frozen, with the solvent removed by lyophilization. The residual solids in samples 1-4, 1-5, 1-6, 1-7, 1-8, and 1-9 were initially analyzed by XRPD and HPLC. Table 5. Details of amorphous salt formation Sample ID Sample details Detailed information on the stock solution Observation NMR 1-4 HCl (1:1) THF 1M White solid 3 fewer protons Approximately 0.3 equivalent t-BuOH 1-5 Sulfuric acid (1:1) THF 1M White solid 3 fewer protons Approximately 0.3 equivalent t-BuOH 1-6 Fumaric acid (1:1) MeOH:THF (1:1) 0.5M glassy solid 1.05 equivalent fumaric acid 0.84 equivalent t-BuOH 1-7 Benzoic acid (1:1) THF 1M White solid 1.0 equivalent benzoic acid 0.34 equivalent t-BuOH 1-8 Succinic acid (1:1) MeOH 1M sticky white solid Approximately 1.1 equivalents of succinic acid 0.37 equivalent t-BuOH 1-9 Sulfuric acid (0.5:1 acid:API) THF 1M White solid Three fewer protons Approximately 0.3 equivalent t-BuOH

[0256] Obtain the 1H NMR spectra of all samples. Sample 1-4, HCl (1:1) salt: 1H NMR (400 MHz, DMSO-d6) δ ppm 0.93 - 1.39 (m, 16 H), 2.97 (br s, 2 H), 3.70 - 3.88 (m, 1 H), 4.10 (br s, 1 H), 4.18 - 4.49 (m, 3 H), 4.70 - 4.88 (m, 1 H), 5.71 - 5.94 (m, 1 H), 6.07 (br d,J=19.07 Hz, 2 H), 7.14 - 7.27 (m, 3 H), 7.29 - 7.44 (m, 2 H), 7.83 - 8.19 (m, 1H) Samples 1-5, sulfate (1:1) salt: ¹H NMR (400 MHz, DMSO-d6) δ ppm 0.97 - 1.38 (m, 15 H), 2.96 (br s, 2 H), 4.06 - 4.18 (m, 1 H), 4.19 - 4.49 (m, 3 H), 4.66 - 4.91 (m, 1 H), 5.70 - 5.95 (m, 1 H), 5.96 - 6.16 (m, 2 H), 7.10 - 7.27 (m, 3 H), 7.30 - 7.43 (m, 2 H), 7.88 - 8.19 (m, 1 H) Samples 1-6, fumaric acid (1:1) salt: ¹H NMR (400 MHz, DMSO-d6) δ ppm 0.97 - 1.38 (m, 15 H), 2.96 (br s, 2 H), 4.06 - 4.18 (m, 1 H), 4.19 - 4.49 (m, 3 H), 4.66 - 4.91 (m, 1 H), 5.70 - 5.95 (m, 1 H), 5.96 - 6.16 (m, 2 H), 7.10 - 7.27 (m, 3 H), 7.30 - 7.43 (m, 2 H), 7.88 - 8.19 (m, 1 H) MHz,DMSO-d6) δ ppm 0.95 - 1.31 (m, 21 H), 2.87 (br s, 3 H), 3.79 (br d,J=7.20 Hz, 1 H), 4.01 - 4.13 (m, 1 H), 4.16 - 4.23 (m, 1 H), 4.16 - 4.24 (m, 1 H), 4.20 (s, 1 H), 4.18 - 4.23 (m, 1 H), 4.24 - 4.52 (m, 1 H), 4.24 - 4.52 (m, 1 H), 4.24 - 4.49 (m, 1 H), 4.72 - 4.88 (m, 1 H), 5.68 - 5.86 (m, 1 H), 6.04 (br d,J=19.33 Hz, 4 H), 6.63 (s, 1 H), 6.61 - 6.66 (m, 1 H), 7.12 - 7.27 (m, 3 H), 7.27 - 7.45 (m, 3 H), 7.81 (s, 1 H), 13.16 (br s, 2 H) Samples 1-7, benzoic acid (1:1) salt: 1H NMR (400 MHz, DMSO-d6) δ ppm 0.96 - 1.30 (m, 15 H), 2.87 (br s, 3 H), 3.79 (br d, J=7.07 Hz, 1 H), 4.07 (br s, 1 H), 4.20 (s, 1 H), 4.25 - 4.52 (m, 3 H), 4.81 (s, 1 H), 5.71 - 5.85 (m, 1 H), 6.04 (br d, J=19.33 Hz, 4 H), 7.08 - 7.27 (m, 3 H), 7.27 - 7.43 (m, 3 H), 7.45 - 7.57 (m, 2 H), 7.63 (s, 1 H), 7.81 (s, 1 H), 7.95 (dd, J=8.27, 1.33 Hz, 2 H), 12.98 (br s, 1 H) Samples 1-8, benzoic acid (1:1) salt: 1H NMR (400 MHz, DMSO-d6) δ ppm 0.98 - 1.28 (m, 15 H), 2.42 (s, 5 H), 2.87 (br s, 3 H), 3.57 - 3.62 (m, 1 H), 3.70 - 3.86 (m, 1 H), 4.02 - 4.14 (m, 1 H), 4.20 (s, 1 H), 4.24 - 4.51 (m, 3 H), 4.70 - 4.88 (m, 1 H), 5.69 - 5.86 (m, 1 H), 6.04 (br d, J=19.33 Hz, 4 H), 7.12 - 7.27 (m, 3 H), 7.27 - 7.44 (m, 3 H), 7.81 (s, 1 H), 11.95 - 12.58 (m, 2 H) Samples 1-9, sulfate (0.5:1) salt: 1H NMR (400 MHz, DMSO-d6) δ ppm 1.02 - 1.31 (m, 15 H), 2.94 (br s, 3 H), 3.79 (br d, J=7.20 Hz, 2 H), 4.09 (br s, 1 H), 4.22 - 4.48 (m, 3 H), 4.72 - 4.90 (m, 1 H), 5.71 - 5.92 (m, 1 H), 6.07 (br d,J=19.07 Hz, 2 H), 7.12 - 7.28 (m, 3 H), 7.31 - 7.44 (m, 2 H), 7.75 - 8.19 (m, 1 H). .

[0257] The samples were then stored at 25°C / 60% relative humidity (RH) for 14 days, and analyzed by HPLC and XRPD after 7 days (Fig. 4B) and 14 days (Fig. 5A). All prepared salts remained amorphous, and these observations are shown in Table 6. During the study, monosulfates (samples 1-5) and succinates (samples 1-8) were found to be physically unstable and deliquescent or turned into gums. Fumarates (samples 1-6) and benzoates (samples 1-7) were found to be glassy solids. HCl salts (samples 1-4) retained their physical appearance. Surprisingly, unlike the monosulfate compounds (samples 1-5) (which were sticky gums), hemisulfates (samples 1-9) also retained their physical appearance as white solids. The results are shown in Table 6. After two weeks of storage at 25°C / 60% relative humidity (RH), both the monoHCl salt (samples 1-4) and the hemisulfate (samples 1-9) were found to be physically and chemically stable. Although both salts were stable within two weeks, the hemisulfate was superior to the HCl salt because the HCl salt is hygroscopic, making it less suitable for long-term storage or use compared to the hemisulfate. Table 6. Stability of samples after 7 and 14 days at 25°C / 60% RH. Sample ID Time (days) of exposure to 25°C / 60% RH 0 7 14 HPLC Observation HPLC Observation HPLC Observation 1-1 98.6 White solid 98.7 White solid 98.5 White solid 1-2 99.1 White solid 99.2 White solid 99.0 White solid 1-3 99.7 White solid 99.6 White solid 99.4 White solid 1-4 98.7 White solid 98.8 White solid 98.6 White solid 1-5 98.4 White solid 55.7 sticky white solid - adhesive 1-6 98.7 glassy solid 98.6 Clear glassy solid 98.4 White glassy solid 1-7 98.8 White solid 98.8 Clear glassy solid 98.7 Clear glassy solid 1-8 98.7 sticky white solid - Deliquescent / Viscous Oil - deliquescence 1-9 98.7 White solid 98.1 White solid 96.4 White solid Example 5. Characterization of amorphous compound 1-A

[0258] Amorphous compound 1-A was initially analyzed by XRPD, 1H NMR, DSC, TGA, and HPLC. The XRPD pattern of amorphous compound 1-A overlapping with amorphous compound 1 and crystalline compound 1 is shown in Figure 1A, and the XRPD pattern of amorphous compound 1-A alone is shown in Figure 5B. Table 7 is a list of peaks from the XRPD pattern shown in Figure 5B. The HPLC traces confirming purity are shown in Figure 6A. Table 8 is a list of relative retention times (RTT) for the HPLC traces shown in Figure 6A. Amorphous compound 1-A was 99.68% pure. Figure 6B shows the TGA and DSC chromatograms of amorphous compound 1-A. Detailed experimental information for the TGA and DSC experiments is given in Example 2. Table 7. Peak List of Amorphous Compound 1-A Angle / °2θ d spacing / Å Intensity / Count strength / % 4.20 21.03 486 81.8 4.67 18.91 482 81.0 5.16 17.10 595 100.0 9.13 9.68 547 92.0 Table 8. HPLC chromatograms of amorphous compound 1-A Amorphous compound 1-A RRT area% 0.48 0.02 0.48 0.02 0.67 0.01 0.94 0.13 1.00 99.68 1.04 0.06 Amorphous compound 1-A: ¹H NMR (400 MHz, DMSO-d6) δ ppm 0.93 - 1.29 (m, ¹³H), 2.94 (br s, ³H), 3.79 (td, J=10.04, 7.07 Hz, ²H), 4.05 - 4.19 (m, ¹H), 4.19 - 4.50 (m, ³H), 4.81 (quin, J=6.25 Hz, ¹H), 5.71 - 5.94 (m, ¹H), 5.97 - 6.16 (m, ²H), 7.14 - 7.28 (m, ³H), 7.31 - 7.44 (m, ²H), 7.82 - 8.09 (m, ¹H) Example 6. Crystallization of amorphous compound 1-A

[0259] Because the hemisulfate was found to remain solid after a 14-day stability study, as shown in Table 6, preliminary tests were conducted using 11 different solvents to investigate crystallization conditions. Amorphous compound 1-A was suspended in 5 volumes of solvent (samples 2-1, 2-2, 2-3, 2-4, 2-5, 2-6, 2-7, 2-8, 2-9, 2-10, and 2-11) at 25°C. Another 5 volumes of solvent were added to the non-free-flowing samples (2-1, 2-2, 2-3, 2-4, 2-5, 2-6, 2-7, 2-8, and 2-10). These samples were then allowed to mature for 6 days at 25–50°C (1°C / min between temperatures and 4 hours at each temperature), except for sample 2-1, which was observed to be a clear solution after 1 day and allowed to evaporate under ambient conditions. The results are shown in Table 9. Crystallization patterns were generated using isobutanol (sample 2-1), acetone (sample 2-2), EtOAc (sample 2-6), and iPrOAc (sample 2-7). Two poorly crystallized samples were identified using MEK (sample 2-4) and MIBK (sample 2-5). XRPD patterns are shown in Figure 7A. Table 9. Crystallization conditions for compound 1-A Sample ID solvent Observation after 5 volumes Observation after 10 volumes Observation after 1 day of maturity XRPD 2-1 IPA Solid – Non-free flow free-flowing suspension The solution evaporates at RT to produce a gel. glue 2-2 Isobutanol Solid – Non-free flow free-flowing suspension suspension Crystallization – Pattern 2 2-3 acetone Solid – Non-free flow free-flowing suspension suspension Crystallization – Pattern 3 2-4 MEK Solid – Non-free flow free-flowing suspension suspension Poor crystallization – Figure 4 2-5 MIBK Solid – Non-free flow free-flowing suspension suspension Poor crystallization – Figure 4 2-6 EtOAc Solid – Non-free flow free-flowing suspension suspension Crystallization – Pattern 1 2-7 iPrOAc Solid – Non-free flow free-flowing suspension suspension Crystallization – Pattern 1 2-8 THF Solid – Non-free flow free-flowing suspension suspension Poor crystallinity 2-9 TBME free-flowing suspension - suspension Amorphous 2-10 Toluene Solid – Non-free flow free-flowing suspension suspension Amorphous 2-11 heptane free-flowing suspension - suspension Amorphous

[0260] Seven samples (samples 2-2, 2-3, 2-4, 2-5, 2-6, 2-7, and 2-8) were analyzed by DSC, TGA, 1H-NMR, and IC (Table 10, Figures 8A, 8B, 9A, 9B, 10A, 10B, 11A, and 11B) and by XRPD after 6 days of storage at 25°C / 60% relative humidity (RH). (All samples remained crystalline / poorly crystalline after stabilization). All samples retained approximately half the equivalent of sulfate but contained a relatively large amount of residual solvent. The overlay of the X-ray diffraction patterns of amorphous samples 2-9, 2-10, and 2-11 is shown in Figure 7B. Table 10. Characterization of crystalline compound 1-A sample. Sample ID solvent DSC TGA 1 HNMR IC (For TGA calibration) 2-2 Isobutanol Internal temperature 113.8℃ 8.3% environment to 140℃ 1.1 equivalent of isobutanol 0.45 equivalent 2-3 acetone Internal temperature 30 to 95°C Internal temperature 100 to 145°C 7.6% ambient temperature up to 140℃ 0.5 equivalent acetone 0.46 equivalent 2-4 MEK Wide and complex internal temperature 30 to 115°C Internal temperature 115 to 145°C 8.5% ambient temperature up to 140℃ 0.8 equivalent MEK 0.45 equivalent 2-5 MIBK Wide internal temperature 30 to 105℃, internal temperature 114.7℃ 5.2% ambient temperature up to 110℃ 0.2 equivalent MIBK 0.46 equivalent 2-6 EtOAc Sharp interior 113.6℃ 2.0% ambient temperature up to 100°C 0.9 Equivalent EtOAc 0.46 equivalent 2-7 iPrOAc Internal temperature 30 to 90°C 1.6% environment to 90℃ 0.8 equivalent iPrOAc 0.45 equivalent 2-8 THF Internal temperature 30 to 100°C A sharper internal temperature of 115.6℃ 4.2% environment to 130℃ 0.7 equivalent THF 0.45 equivalent

[0261] The 1H NMR spectra of all samples were obtained and are listed below. Sample 2-2: 1H NMR (400 MHz, DMSO-d6) δ ppm 0.83 (d,J=6.69 Hz, 7 H), 0.99 - 1.26 (m, 14 H), 1.61 (dt,J=13.26, 6.63 Hz, 1 H), 3.73 - 3.87 (m, 2 H), 4.03 - 4.18 (m, 1 H), 4.18 - 4.51 (m, 4 H), 4.66 - 4.92 (m, 1 H), 4.70 - 4.90 (m, 1 H), 4.72 - 4.88 (m, 1 H), 5.81 (br s, 1 H), 5.93 - 6.11 (m, 2 H), 7.10 - 7.26 (m, 3 H), 7.14 - 7.26 (m, 1 H), 7.30 - 7.41 (m, 2 H), 7.94 (br s, 1 H) Sample 2-3: 1H NMR (400 MHz, DMSO-d6) δ ppm 1.00 - 1.26 (m, 13 H), 2.09 (s, 3 H), 3.74 - 3.87 (m, 2 H), 4.10 (br d,J=7.70 Hz, 1 H), 4.22 - 4.50 (m, 3 H), 4.81 (quin,J=6.28 Hz, 1 H), 5.71 - 5.90 (m, 1 H), 5.96 - 6.15 (m, 2 H), 7.12 - 7.26 (m, 3 H), 7.31 - 7.41 (m, 2 H), 7.79 - 8.07 (m, 1 H) Sample 2-4: 1H NMR (400 MHz, DMSO-d6) δ ppm 0.91 (t,J=7.33 Hz, 3 H), 1.01 - 1.28 (m, 13 H), 2.08 (s, 2 H), 3.72 - 3.89 (m, 2 H), 4.10 (br d,J=8.08 Hz, 1 H), 4.23 - 4.47 (m, 3 H), 4.81 (quin,J=6.25 Hz, 1 H), 5.69 - 5.89 (m, 1 H), 5.94 - 6.13 (m, 2 H), 7.14 - 7.25 (m, 3 H), 7.32 - 7.41 (m, 2 H), 7.79 - 8.Samples 2-5: 1H NMR (400 MHz, DMSO-d6) δ ppm 0.86 (d, J = 6.69 Hz, 1 H), 0.98 - 1.33 (m, 13 H), 2.02 - 2.09 (m, 1 H), 4.03 - 4.17 (m, 1 H), 4.22 - 4.50 (m, 3 H), 4.81 (quin, J = 6.25 Hz, 1 H), 5.81 (br s, 1 H), 5.93 - 6.15 (m, 2 H), 7.11 - 7.27 (m, 3 H), 7.31 - 7.41 (m, 2 H), 7.77 - 8.21 (m, 1 H) Samples 2-6: 1H NMR (400 MHz, DMSO-d6) δ ppm 0.98 - 1.28 (m, 15 H), 2.00 (s, 3 H), 3.99 - 4.14 (m, 3 H), 4.21 - 4.49 (m, 3 H), 4.81 (quin, J = 6.22 Hz, 1 H), 5.82 (br s, 1 H), 5.93 - 6.14 (m, 2 H), 7.11 - 7.26 (m, 3 H), 7.29 - 7.42 (m, 2 H), 7.79 - 8.17 (m, 1 H) Samples 2-7: 1H NMR (400 MHz, DMSO-d6) δ ppm 0.92 - 1.28 (m, 17 H), 1.97 (s, 2 H), 4.04 - 4.16 (m, 1 H), 4.20 - 4.51 (m, 3 H), 4.71 - 4.93 (m, 2 H), 5.82 (br s, 1 H), 5.95 - 6.14 (m, 2 H), 7.11 - 7.28 (m, 3 H), 7.31 - 7.43 (m, 2 H), 7.75 - 8.21 (m, 1 H) Samples 2-8: 1H NMR (400 MHz, DMSO-d6) δ ppm 0.81 - 1.11 (m, 13 H), 1.19 (s, 1 H), 1.53 - 1.66 (m, 1 H), 3.87 - 4.01 (m, 1 H), 4.06 - 4.32 (m, 3 H), 4.64 (quin, J = 6.25 Hz, 1 H), 5.55 - 5.75 (m, 1 H), 5.77 - 5.97 (m, 2 H), 6.94 - 7.10 (m, 3 H), 7.13 - 7.26 (m, 2 H), 7.66 - 7.96 (m, 1 H) Example 7. Failed to crystallize amorphous malonate (compound 1-B).

[0262] As shown in Example 3, crystalline oxalate was identified when determining a suitable salt for compound 1, but oxalate compound 1-B could not be used in clinical trials due to its potential to cause kidney stones. Therefore, the chemistry-related malonate (compound 1-E) was crystallized using the same 11 solvents as the hemisulfate. Compound 1 (12 × 50 mg, samples 3-1, 3-2, 3-3, 3-4, 3-5, 3-6, 3-7, 3-8, 3-9, 3-10, 3-11 and 3-12) was dissolved in terbutanol (20 volumes) and the solutions were treated with 1 equivalent of malonic acid stock solution (1M contained in THF). The samples were then frozen, with the solvent removed by lyophilization. The relevant solvent (5 volumes) was added to samples 3-1, 3-2, 3-3, 3-4, 3-5, 3-6, 3-7, 3-8, 3-9, 3-10 and 3-11 at room temperature. Any resulting solution was allowed to evaporate under ambient conditions, while the gel or solid was allowed to mature for 5 days at 25–50 °C (1 °C / min between temperatures and 4 hours at each temperature). Solid analysis was performed by XRPD (Figure 12B), but all samples were found to form gels or be amorphous (Figure 12B). The results are shown in Table 11. Analysis of one solid (amorphous) sample (3-12) by 1H-NMR and HPLC revealed approximately 1 equivalent of malonic acid (peak overlap) and 0.6 equivalents of t-BuOH. The compound was 99.2% pure (Figure 13A). Figure 12A shows the XRDP of sample 3-12, and Figure 13A shows the HPLC chromatogram of sample 3-12. Samples 3-12: ¹H NMR (400 MHz, DMSO-d6) δ ppm 0.81 - 1.11 (m, ¹³H), 1.19 (s, ¹H), 1.53 - 1.66 (m, ¹H), 3.87 - 4.01 (m, ¹H), 4.06 - 4.32 (m, ³H), 4.64 (quin, J=6.25 Hz, ¹H), 5.55 - 5.75 (m, ¹H), 5.77 - 5.97 (m, ²H), 6.94 - 7.10 (m, ³H), 7.13 - 7.26 (m, ²H), 7.66 - 7.96 (m, ¹H) Table 11. Crystallization conditions of amorphous malonate compound 1-E Sample ID solvent Observation after 5 volumes Observation after 5 days of ripening / evaporation XRPD 3-1 IPA Clarified solution* Clarifying gum - 3-2 Isobutanol Clarified solution* Clarifying gum - 3-3 acetone Clarified solution* Clarifying gum - 3-4 MEK Clarified solution* Clarifying gum - 3-5 MIBK Solution and a certain glue Clarifying gum - 3-6 EtOAc Clarified solution* Clarified gum and crystalline appearance Amorphous 3-7 iPrOAc glue Clarifying gum - 3-8 THF Clarified solution* Clarifying gum - 3-9 TBME Thick suspension Clarifying gum - 3-10 Toluene White glue / solid White glue Amorphous 3-11 heptane White solid (static) White glue Amorphous 3-12 - (White solid – solvent-free) (Viscous white solid – environmental conditions) Amorphous *Evaporation at room temperature, example 8. Insufficient salt formation cannot be achieved using liquid-assisted milling (LAG).

[0263] Liquid-assisted grinding (LAG) studies were conducted to determine suitable salts other than hemisulfates using 14 acidic counterions listed in Table 12. Table 12. Counterion stock solutions used in LAG crystallization. Counterions Solvent (1M) Pyruvic acid DMSO malonic acid THF D-glucuronic acid water DL-mandelate THF D-gluconic acid THF glycolic acid THF L-lactic acid THF Oleic acid THF L-Ascorbic Acid water adipic acid THF (heat) hexanoic acid THF stearic acid THF Palmitic acid THF mesylate THF

[0264] Compound 1 (30 mg) was placed in an HPLC vial with two 3 mm ball bearings. The materials were wetted with solvents (15 µl ethanol, samples 4-1, 4-2, 4-3, 4-4, 4-5, 4-6, 4-7, 4-8, 4-9, 4-10, 4-11, 4-12, 4-13, and 4-14) and 1 equivalent of acid counterions were added. The samples were then ground at 650 rpm for 2 hours using a Fritsch grinding system with an Automaxion connector. Most of the ground samples were found to be clear gels and were not further analyzed (Table 13). XRPD analysis revealed the presence of solids, and in all cases, the obtained patterns matched those of the crystalline acid counterions, with no additional peaks (Figure 13B). Table 13. Observation of LAG and XRPD results for Compound 1. Sample ID acid Observation after grinding XRPD 4-1 Pyruvic acid Yellow glue / solid Phenylic acid and amorphous halo 4-2 malonic acid Clarifying gum - 4-3 D-glucuronic acid White glue / solid D-glucuronic acid and amorphous halo 4-4 DL-mandelate Clarifying gum - 4-5 D-gluconic acid Clarifying gum - 4-6 glycolic acid Clarifying gum 4-7 L-lactic acid Clarifying gum - 4-8 Oleic acid Clarifying gum - 4-9 L-Ascorbic Acid White glue / solid L-Ascorbic acid and amorphous halo 4-10 adipic acid Clarifying gum - 4-11 hexanoic acid Clarifying gum - 4-12 stearic acid White glue / solid Stearic acid and amorphous halo 4-13 Palmitic acid White glue / solid Palmitic acid and amorphous halo 4-4 mesylate Clarifying gum - Example 9. Sufficient salt formation cannot be obtained using methyl ethyl ketone (MEK).

[0265] Next, methyl ethyl ketone (MEK) was used as a solvent to investigate suitable salts other than hemisulfates. This study was conducted by dissolving Compound 1 (50 mg) in MEK (20 vol) at room temperature using 14 acidic counterions from Table 12. The solutions were treated with 1 equivalent of the selected counterions (Table 12). The samples were then cooled to 5°C at 0.1°C / min and stirred overnight at that temperature. All samples were allowed to evaporate under ambient conditions, and any solids observed by XRPD analysis were allowed. This evaporation primarily produced a gel, except for samples containing stearic acid (samples 4-12) and palmitic acid (samples 5-13), which provided a glassy solvent. By XRPD, these solids were amorphous, but no crystalline form of the salt was obtained. The results are shown in Table 14 (Figure 13A). Table 14. Results of dissolving Compound 1 in MEK (20 vol). Sample ID acid 1 M is used as a solvent for acids Observation after acid addition Observation after cooling Observations after evaporation 5-1 Pyruvic acid DMSO Yellow solution Yellow solution Yellow glue 5-2 malonic acid THF solution solution Clarifying gum 5-3 D-glucuronic acid water solution solution Clarifying gum 5-4 DL-mandelate THF solution solution Clarifying gum 5-5 D-gluconic acid THF White sediment Turbid solution Clarifying gum 5-6 glycolic acid THF solution solution Clarifying gum 5-7 L-lactic acid THF solution solution Clarifying gum 5-8 Oleic acid THF solution solution Clarifying gum 5-9 L-Ascorbic Acid water solution solution Yellow glue 5-10 adipic acid THF (heat) solution solution Clarifying gum 5-11 hexanoic acid THF solution solution Clarifying gum 5-12 stearic acid THF solution Turbid solution Clear, glassy solid* 5-13 Palmitic acid THF solution solution Clear, glassy solid* 5-14 mesylate THF solution solution Clarifying gum The stock solution prepared before adding acid* was analyzed by XRPD and the amorphous pattern of the acid counterion was given, along with peaks.

[0266] Since all samples were amorphous, all samples were redissolved in MEK (5 volumes) and cyclohexane (20 volumes of antisolvent) was added at room temperature, followed by stirring at 25°C for 1 hour. The samples were then allowed to mature between 50°C and 5°C (1°C / min for 4 hours at each temperature) for 2 days, and then the cycle was repeated between 50°C and 25°C for another 4 days. The samples were visually observed after maturation. The results are shown in Table 15. After maturation, all samples except 5-1 (containing pyruvic acid) were found to be gels. Sample 5-1 (yellow solid) was analyzed by XRPD, and the pattern matched the known form of pyruvic acid (Fig. 14B), therefore no crystalline form of the salt was obtained. Table 15. Results of redissolving compound 1 in MEK (5 volumes) and antisolvent. Sample ID Immediate observation Observation after 10 minutes Observation after 60 minutes Observation after maturity 5-1 precipitation glue glue Yellow suspension** 5-2 precipitation glue glue glue 5-3 Precipitate / gel glue glue glue 5-4 precipitation glue glue glue 5-5 Precipitate / gel glue glue glue 5-6 precipitation glue glue glue 5-7 precipitation glue glue glue 5-8 precipitation Light suspension glue glue 5-9 precipitation glue glue glue 5-10 precipitation glue glue glue 5-11 precipitation Light suspension glue glue 5-12 precipitation Light suspension glue glue 5-13 precipitation Light suspension glue glue 5-14 precipitation glue glue glue **XRPD analysis showed that the sample had a pattern matching that of pyruvic acid in its known form (no additional peaks). Example 10. Sufficient salt formation was not obtained using ethyl acetate.**

[0267] Next, ethyl acetate was used to study suitable salts other than hemisulfates. This study was conducted using 14 acidic counterions from Table 12, by dissolving Compound 1 (50 mg) in ethyl acetate (20 volumes) at 50 °C. The solutions were treated with 1 equivalent of the selected counterions (Table 12). The samples were then cooled to 5 °C at 0.1 °C / min and stirred at that temperature for 4 days. The solutions were allowed to evaporate under ambient conditions while any solids were analyzed by XRPD. The results of crystallization using ethyl acetate are shown in Table 16. In contrast to Example 8, where MEK was used as the solvent, most samples were observed as suspensions after cooling the acid:compound mixture (allowing for the solutions to evaporate under ambient conditions). However, XRPD diffraction patterns were generally found to match those of crystalline Compound 1. Samples 6-2, 6-4, and 6-5 showed some slight differences (Figs. 14A and 15A). No crystalline form of the salt was obtained. Table 16. Results of dissolving Compound 1 in EtOAc (20 volumes). Sample ID acid Solvents for 1M acid Observation after acid addition Observation after cooling XRPD Observations after evaporation 6-1 Pyruvic acid DMSO Yellow solution Yellow solution* - glue 6-2 malonic acid THF solution White suspension Slight difference from free base - 6-3 D-glucuronic acid water solution Solution* - glue 6-4 DL-mandelate THF solution White suspension Slight difference from free base - 6-5 D-gluconic acid THF White sediment Possible white glue Slight difference from free base - 6-6 glycolic acid THF solution White suspension Free base - 6-7 L-lactic acid THF solution White suspension Free base - 6-8 Oleic acid THF solution White suspension Free base - 6-9 L-Ascorbic Acid water solution Solution* - Side view / Yellow adhesive carrying white solid - amorphous 6-10 adipic acid THF (heat) solution White suspension Free base - 6-11 hexanoic acid THF solution White suspension Free base - 6-12 stearic acid THF solution White suspension Free base - 6-13 Palmitic acid THF solution White suspension Free base - 6-14 mesylate THF White sediment Solution / Clarifying Gel* - Clarifying gum Example 11. Determination of chemical purity by HPLC

[0268] Purity analyses in Examples 2 and 4 were performed on an Agilent HP1100 series system equipped with a diode array detector and using ChemStation software vB.04.03, using the methods shown in Table 17. Table 17. HPLC Methods for Determination of Chemical Purity parameter value Method type Using the reverse phase of gradient elution Sample preparation 0.5 mg / ml in acetonitrile:water 1:1 tubular Supelco Ascentis Express C18, 100 x 4.6 mm, 2.7 μm Tube temperature (°C) 25 Injection (μl) 5 Wavelength, bandwidth (nm) 255, 90 Flow rate (ml / min) 2 Phase A 0.1% TFA contained in water Phase B 0.085% TFA is contained in acetonitrile. schedule Time (minutes) Phase A% Phase B% 0 95 5 6 5 95 6.2 95 5 8 95 5 Example 12. X-ray Powder Diffraction (XRPD) Technology

[0269] XRPD patterns in Examples 2, 3, 4, 5, 6, 7, 8, and 9 were collected in transmission geometry using a PANalytical Empyrean diffractometer employing Cu Kα radiation (45 kV, 40 mA). A 0.5° slit, a 4 mm shield, and a 0.4° Redsole slit with a focusing lens were used based on the incident beam. A PIXcel3D detector positioned on the diffracted beam was equipped with a receiving slit and a 0.04° Redsole slit. The instrument was checked weekly using a silicon powder check. The software used for data collection was X'Pert Data Collector v. 5.3, and data was analyzed and presented using DiffracPlusEVA v. 15.0.0.0 or Highscore Plus v. 4.5. Samples were prepared and analyzed in transmission mode in metal or Millipore 96-well plates. X-ray transmission membranes are used between metal sheets on a perforated metal plate, and powder (approximately 1 to 2 mg) is used as is. Millipore plates are used to separate and analyze solids from suspensions by adding a small amount of suspension directly to the plate before filtration under optical vacuum.

[0270] The scanning mode for the metal plate used the Gonio scanning axis, while 2θ scanning was used for the Millipore plate. Performance checks were performed using silicon powder (metal perforated plate). Data collection details included an angle range of 2.5 to 32.0° 2θ, a step size of 0.0130° 2θ, and a total collection time of 2.07 minutes.

[0271] Samples were also collected using a Bruker D8 diffractometer employing Cu Kα radiation (40 kV, 40 mA), an θ-2θ goniometer, and V4 and receiving slit divergence, a Ge monochromator, and a Lynxeye detector. The instrument was tested for performance according to the certified Corundum standard (NIST 1976). The software used for data collection was DiffracPlusXRD Commander v2.6.1, and the data was analyzed and presented using DiffracPlusEVA v15.0.0.0.

[0272] The sample was run as a flat plate specimen using powder under ambient conditions. The sample was gently filled into the cavity and cut into polished zero-background (510) silicon wafers. During the analysis, the sample was rotated on its own plane. Data collection details included an angle range of 2 to 42° 2θ, a step size of 0.05° 2θ, and a collection time of 0.5 s / step. Example 13. Synthesis of amorphous compound 1-A

[0273] Add MeOH (151 mL) to a 250 mL flask and cool the solution to 0 to 5 °C. Add a concentrated solution of H2SO4 dropwise over 10 minutes. Add compound 1 (151 g) and acetone (910 mL) to a separate flask and add H2SO4 / MeOH solution dropwise over 2.5 hours at 25 to 30 °C. A large amount of solid precipitates. After stirring the solution at 25 to 30 °C for 12 to 15 hours, filter the mixture, wash with MeOH / acetone (25 mL / 150 mL), and then dry under vacuum at 55 to 60 °C to give compound 1-A (121 g, 74%). 1HNMR: (400 MHz, DMSO-d6): δ 8.41 (br, 1H), 7.97 (s, 1H), 7.36 (t,J= 8.0 Hz, 2H), 7.22 (d,J= 8.0 Hz, 2H), 7.17 (t,J= 8.0 Hz, 1H), 6.73 (s, 2H), 6.07 (d,J= 8.0 Hz, 1H), 6.00 (dd,J= 12.0, 8.0 Hz, 1H), 5.81(br, 1H), 4.84-4.73 (m, 1H), 4.44-4.28 (m, 3H), 4.10 (t,J= 8.0 Hz, 2H), 3.85-3.74 (m, 1H), 2.95 (s, 3H), 1.21 (s,J= 4.0 Hz, 3H), 1.15-1.10 (m, 9H).

[0274] Analytical method for compound 1-A: The purity of compound 1-A was obtained using an Agilent 1100 HPLC system with a Waters XTerra Phenyl 5µm 4.6*250 mm column under the following conditions: flow rate 1 mL / min, readout at 254 nm, column temperature 30 °C, injection volume 10 μL, and run time 30 min. The sample was dissolved in ACN:water (90:10, v / v). The gradient method used for separation is shown below. The Rt (min) for compound 1-A was approximately 12.0 min. Time (minutes) 0.1% H3PO4 is contained in water (A)%. Acetonitrile (B)% 0 90 10 20 20 80 20.1 90 10 30 90 10 1HNMR: (400 MHz, DMSO-d6): δ 8.41 (br, 1H), 7.97 (s, 1H), 7.36 (t,J= 8.0 Hz, 2H), 7.22 (d,J= 8.0 Hz, 2H), 7.17 (t,J= 8.0 Hz, 1H), 6.73 (s, 2H), 6.07 (d,J= 8.0 Hz, 1H), 6.00 (dd,J= 12.0, 8.0 Hz, 1H), 5.81(br, 1H), 4.84-4.73 (m, 1H), 4.44-4.28 (m, 3H), 4.10 (t,J= 8.0 Hz, 2H), 3.85–3.74 (m, 1H), 2.95 (s, 3H), 1.21 (s, J = 4.0 Hz, 3H), 1.15–1.10 (m, 9H). Example 14. Characterization of compound 1-A

[0275] Compound 1-A was further characterized by microscopy, 1H NMR, 13C NMR, 19F NMR, MS, HPLC, and XRPD (Figure 15B). Residual solvent was determined by GC. Water content was determined by Karl Fischer titration, and the water content was only 0.70%. The data are summarized in Table 18. Table 18. Summary of further characterization data for compound 1-A test result Appearance White solid NMR 1 HNMR peaks are listed in Example 4. MS MS(ESI+ve) [M+H) + = 582.3 – Conformal Structure HPLC 99.8%, by AUC at 254 nm (average of the two formulations). Residual solvent, through GC Methanol – 57 ppm Acetone – 752 ppm Dichloromethane – 50 ppm Ethyl acetate – 176 ppm Water content 0.70% Example 15. Solubility of Compound 1 and Compound 1-A

[0276] The solubility of Compound 1 and Compound 1-A in biologically relevant test media, including simulated gastric juice (SGF), fasting simulated gastric juice (FaSSIF), and satiated gastric juice (FeSSIF), was tested. Results for Compound 1 are shown in Table 19, and results for Compound 1-A are shown in Table 20. Samples were stirred at room temperature (20 to 25°C). At 2 hours, Compound 1-A was more than 40 times more soluble in water than Compound 1, and at 24 hours, it was more than 25 times more soluble. Under SGF conditions, at 24 hours, Compound 1-A had a solubility of 84.2 mg / mL, compared to 15.6 mg / mL of Compound 1 at the same time point. At 2 hours, Compound 1-A was also more soluble in SGF conditions than Compound 1, and its solubility was sufficient to allow testing even after 48 hours, although the 48-hour test was not performed using Compound 1. Table 19. Solubility Test Results of Compound 1 Test medium Solubility (in mg / mL) Appearance Descriptive terms 2 hours 24 hours water 1.5 2.5 Clarified solution* Slightly soluble SGF 13.8 15.6 Remove the glue solution from the bottom. Slightly soluble FaSSIF 1.7 1.7 turbid Slightly soluble FeSSIF 2.8 2.9 turbid Slightly soluble *The sample appeared clear, yet achieved a solubility of only 1.5 mg / mL. Further investigation revealed the formation of a colloidal film on the stir bar. During standard preparation, the active pharmaceutical ingredient of Compound 1 formed colloidal spheres in the diluent (90% water / 10% acetonitrile), requiring prolonged ultrasonic treatment for complete dissolution. Table 20. Solubility test results for Compound 1-A Test medium Solubility (mg / mL salt matrix) Appearance Descriptive terms 2 hours 24 hours 48 hours water 65.3 68.0 N / A turbid soluble SGF 89.0 84.2 81.3 turbid soluble FaSSIF 1.9 2.0 N / A turbid Slightly soluble FeSSIF 3.3 3.4 N / A turbid Slightly soluble Example 16. Chemical stability of compound 1-A

[0277] The chemical stability of compound 1-A was assessed by monitoring organic purity, water content, 1H NMR, DSC, and Raman IR at 25°C and 40°C for 6 months. The container sealing system used in this study was a combination medical valve bag with a pharmaceutical laminate on the bag and a desiccant silicone between the two layers. Compound 1-A (1 g) was measured into each container. The bags were then stored at 25°C / 60%RH (relative humidity) and 40°C / 75%RH (relative humidity). Organic purity, water content, 1H NMR, DSC, and Raman IR were determined at 0, 1 month, 2 months, 3 months, and 6 months.

[0278] The purity of compound 1-A was obtained using a Shimadzu LC-20AD system with a Waters XTerra Phenyl, 5 µm, 4.6 x 250 mm column, under the following conditions: flow rate 1 mL / min, readout at 254 nm, column temperature 35 °C, and injection volume 10 μL. The sample was dissolved in acetonitrile-water (90:10) (v / v). The gradient method is shown below. Time (minutes) A% (ACN) B% (water) 0 90 10 20 20 80 20.1 90 10 30 90 10

[0279] The water content of compound 1-A (250 mg) was determined by water titration using the Karl Fischer titration method.

[0280] The results are shown in Tables 21 and 22. The degradation rate was minimal when compound 1-A was stored at 25°C and 40°C for 6 months. At 3 months, compound 1-A had a purity of 99.75% at 25°C and 99.58% at 40°C. At 6 months, compound 1-A remained at 99.74% purity at 25°C and 99.30% purity at 40°C. At 25°C, the percentage of degradation products increased from 0.03% on day 0 to 0.08% after 6 months. At 40°C, the percentage of degradation products increased from 0.03% to 0.39%. Over the 6-month period, the percentage of water increased by approximately 0.6% at 25°C and by approximately 0.7% at 40°C.

[0281] The characterization of compound 1-A by 1H NMR, Raman, and DSC at 1 month, 2 months, 3 months, and 6 months was the same as that of compound 1-A under both temperature conditions on day 0 (Table 22), highlighting the long-term stability of compound 1-A. Table 21. Degradation rate of compound 1-A at 25 and 40 °C over 6 months. Test time Water percentage Purity percentage Percentage of degradation products Maximum impurity percentage 25℃ Day 0 1.2 99.82 0.03 0.12 Month 1 1.9 99.77 0.04 0.12 2nd month 1.8 99.75 0.06 0.12 3rd month 1.8 99.75 0.06 0.12 6th month 1.8 99.74 0.08 0.13 40℃ Day 0 1.2 99.82 0.03 0.12 Month 1 2.0 99.71 0.09 0.12 2nd month 1.9 99.63 0.15 0.12 3rd month 1.9 99.58 0.20 0.12 6th month 1.9 99.30 0.39 0.14 Table 22. Characterization of compound 1-A during the degradation study Test time 1 HNMR Raman DSC 25℃ Day 0 Initial test Initial test Initial test Month 1 Same as day 0 Same as day 0 Same as day 0 2nd month Same as day 0 Same as day 0 Same as day 0 3rd month Same as day 0 Same as day 0 Same as day 0 6th month Same as day 0 Same as day 0 Same as day 0 40℃ Day 0 Initial test Initial test Initial test Month 1 Same as day 0 Same as day 0 Same as day 0 2nd month Same as day 0 Same as day 0 Same as day 0 3rd month Same as day 0 Same as day 0 Same as day 0 6th month Same as day 0 Same as day 0 Same as day 0

[0282] Further chemical stability studies of compound 1-A were conducted to determine impurities and water content. Three conditions were tested: accelerated stability over a 6-month period (40 ± 2 °C / 75 ± 5% RH), environmental stability over a 9-month period (25 ± 2 °C / 60 ± 5% RH), and stability under refrigerator conditions (5 ± 3 °C) over a 9-month period. The results for accelerated stability, environmental stability, and refrigerator conditions are shown in Tables 23, 24, and 25, respectively. Based on these results, compound 1-A is extremely chemically stable.

[0283] In the accelerated stability study (Table 23), at each time point (month 1, month 3, and month 6) when compound 1-A was measured, compound 1-A was consistently a white solid, and its IR matched the reference standard. After six months, the total related substance 1 impurity was only 0.08%, and related substance 2 and isomers were not detected. Table 23. Accelerated stability of compound 1-A (40 ± 2 °C / 75 ± 5% RH) item Specification Test time point 0 months Month 1 3rd month 6th month Appearance White or off-white solid White solid White solid White solid White solid IR Consistent with reference standards Consistent with reference standards / Consistent with reference standards Consistent with reference standards water ≤2.0% 0.45% 0.21% 0.36% 0.41% Related substance 1 Impurity A ≤0.15% ND ND ND ND Impurity B ≤0.15% ND ND ND ND impurity F ≤0.15% ND ND ND 0.01% impurity H ≤0.15% ND ND ND ND Any other single impurity ≤0.10% 0.01% 0.02% 0.01% 0.05% Total impurities ≤0.2% 0.01% 0.02% 0.02% 0.08% Related substance 2 Impurity G ≤0.15% ND ND ND ND Isomers Impurity C ≤0.15% ND / ND ND Impurity D ≤0.15% ND / ND ND Impurity E ≤0.15% ND / ND ND analyze 98.0%~102.0% 98.8% 101.5% 99.6% 99.5% Microbial testing TAMC ≤1000 cfu / g <1 cfu / g / / / molds and yeasts ≤100 cfu / g <1 cfu / g / / / Escherichia coli (E. coli) Not detected ND / / / ND: Not detected

[0284] In the nine-month environmental stability study, which measured appearance, IR, water content, and impurity content, compound 1-A consistently appeared as a white solid and its IR consistently corresponded to the reference sample. The results (Table 24) highlight the chemical stability of compound 1-A. After 9 months, the percentage of water in the sample was only 0.20%, and the total related substance 1 impurity was only 0.02%. Similar to the accelerated stability study, no related substance 2 or any isomers of compound 1-A were detected. Table 24. Environmental stability of compound 1-A (25±2℃ / 60±5% RH) item Specification Test time point 0 months Month 1 3rd month 6th month 9th month Appearance White or off-white solid White solid White solid White solid White solid grayish-white solid IR Consistent with reference standards Consistent with reference standards / Consistent with reference standards Consistent with reference standards Consistent with reference standards water ≤2.0% 0.45% 0.19% 0.29% 0.46% 0.20% Related substance 1 Impurity A ≤0.15% ND ND ND ND ND Impurity B ≤0.15% ND ND 0.03% ND ND impurity F ≤0.15% ND ND 0.02% 0.01% ND impurity H ≤0.15% ND ND ND ND ND Any other single impurity ≤0.10% 0.01% 0.01% 0.03% 0.02% 0.02% Total impurities ≤0.2% 0.01% 0.02% 0.11% 0.05% 0.02% Related impurities 2 Impurity G ≤0.15% ND ND ND ND ND Isomers Impurity C ≤0.15% ND / ND ND ND Impurity D ≤0.15% ND / ND ND ND Impurity E ≤0.15% ND / ND ND ND analyze 98.0% to 102.0% 98.8% 101.1% 99.6% 99.7% 100.9% Microbial testing TAMC ≤ 1000cfu / g <1 cfu / g / / / / molds and yeasts ≤100 cfu / g <1 cfu / g / / / / E. coli Not detected ND / / / / ND: Not detected

[0285] The results of stability tests conducted under refrigerator conditions are shown in Table 25. Even after 9 months, the only impurities detected were from related substance 1 and water. After 9 months, the water content was 0.32%, and the total impurities of related substance 1 were only 0.01% of the sample. Compound 1-A is extremely chemically stable under refrigerator conditions. Table 25. Stability of Compound 1-A under refrigerator conditions (5 ± 3 °C) item Specification Test time point 0 months Month 1 3rd month 6th month 9th month Appearance White or off-white solid White solid White solid White solid White solid Grayish-white solid. IR Consistent with reference standards Consistent with reference standards / Consistent with reference standards Consistent with reference standards Consistent with reference standards water ≤2.0% 0.45% 0.19% 0.32% 0.42% 0.32% Related substance 1 Impurity A ≤0.15% ND ND ND ND ND Impurity B ≤0.15% ND ND 0.01% ND ND impurity F ≤0.15% ND ND ND ND ND impurity H ≤0.15% ND ND ND ND ND Any other single impurity ≤0.10% 0.01% 0.01% 0.01% 0.01% 0.01% Total impurities ≤0.2% 0.01% 0.01% 0.03% 0.03% 0.01% Related impurities 2 Impurity G ≤0.15% ND ND ND ND ND Isomers Impurity C ≤0.15% ND / ND ND ND Impurity D ≤0.15% ND / ND ND ND Impurity E ≤0.15% ND / ND ND ND analyze 98.0% to 102.0% 98.8% 101.1% 100.2% 98.6% 101.4% Microbial testing TAMC ≤1000 cfu / g <1 cfu / g / / / / molds and yeasts ≤100 cfu / g <1 cfu / g / / / / E. coli Not detected ND / / / / ND: No plasma levels of metabolites of compound 1-A were detected after a single oral dose in Example 17.

[0286] A single oral dose of compound 1-A was administered to rats, dogs and monkeys, and the plasma levels of certain metabolites shown in Scheme 1 were determined.

[0287] The conversion of compound 1-A to compound 1 and metabolites 1-7 is shown in Table 26, and the results for metabolites 1-8 and metabolites 1-2 are shown in Table 27. In rats, low levels of compound 1 exposure were observed, but high levels of metabolites 1-7, i.e., nucleoside metabolites of active triphosphates (metabolites 1-6), were observed. In monkeys, approximate dose-proportional exposure to compound 1 was determined. In dogs, overproportional exposure to compound 1 was determined, indicating first-pass metabolic clearance in the liver. Throughout the study, vomiting was observed significantly more frequently in dogs (5 / 5 in the high-dose group) than in monkeys (1 / 5 in the high-dose group). Table 26. Plasma concentrations of compound 1 and metabolites 1-7 after a single oral dose of compound 1-A. Species Dosage* (mg / kg) Compound 1 Metabolites 1-7 C max (ng / mL) T max (Hour) AUC 0-last (hr*ng / mL) C max (ng / mL) AUC 0-last (hr*ng / mL) rats a 500 70.5 0.25 60.9 748 12000 dog b 30 1530 0.25 to 1 1300 783 9270 100 8120 0.5 to 1 10200 2030 24200 300 21300 204 44300 4260 60800 monkey b 30 63.5 0.5 to 2 176 42.5 1620 100 783 1 to 2 1100 131 3030 300 501 204 1600 93.6 3660 Three males per species, per dose; *Dosage formulation: a) 0.5% CMC, 0.5% Tween 80 in water; b) Powder in capsules. Table 27. Plasma content of metabolites 1-8 and 1-2 after a single oral dose of compound 1-A. Species Dosage* (mg / kg) Metabolites 1-8 Metabolites 1-2 C max (ng / mL) AUC 0-last (hr*ng / mL) C max (ng / mL) AUC 0-last (hr*ng / mL) rats a 500 5060 35100 9650 20300 dog b 30 291 905 196 610 100 1230 4370 886 2830 300 5380 35300 2380 8710 monkey b 30 209 5690 300 1730 100 406 12300 1350 8160 300 518 16800 1420 11400 3. Number of males per species at each dose; *Dosage formulation: a. 0.5% CMC, 0.5% Tween 80 in water; b. Powder in capsules. Example 18. Tissue exposure of active triphosphate after oral dose of compound 1-A.

[0288] The content of active triphosphate (TP) of compound 1-A (metabolites 1-6) in heart and liver tissues was determined 4 hours after an oral dose of compound 1-A. Liver and heart samples were obtained 4 hours after a single dose of compound 1-A, rapidly frozen, homogenized, and then the intracellular level of active TP was analyzed by LC-MS / MS. Tissue contents were determined in rats, dogs, and monkeys, as shown in Figure 16A. High levels of active TP were detected in the livers of all species tested. Relatively low levels of active TP were detected in the hearts of dogs due to the saturation of first-pass hepatic metabolism, and TP levels that could not be quantified were detected in the hearts of rats and monkeys, indicating liver-specific formation of active TP. Although not shown, administration of compound 1-A improved TP distribution compared to administration of compound 1. Example 19. Pharmacological comparison of compound 1 and compound 1-A in dogs.

[0289] A head-to-head comparison was conducted in dogs administered compound 1 and compound 1-A. This study measured plasma concentrations of compound 1 and metabolites 1-7 (from protocol 1) up to 4 hours after administration of compound 1 (25 mg / kg) and compound 1-A (30 mg / kg) (Table 28), and the AUC (0-4hr) of metabolites 1-7 was twice that of compound 1-A compared to compound 1. Dose-normalized exposures of compound 1 and metabolites 1-7 are shown in Table 28. The AUC (0-4hr) of compound 1, metabolites 1-7, and the sum of compound 1 and metabolites 1-7 was greater after administration of compound 1-A. Table 28. Comparison of plasma concentrations after administration of compound 1 and compound 1-A. Compounds for administration The following mean dose standardized AUC (0-4hr) a (μM*hr): Compound 1 Metabolites 1-7 Compound 1 + Metabolites 1-7 Compound 1 (25 mg / kg) 0.2 1.9 2.1 Compound 1-A (30 mg / kg) 1.0 4.1 5.1 aAUC(0-4hr) value, standardized to a dose of 25 mg / kg

[0290] The liver / heart ratio of triphosphate concentrations indicates that, compared with compound 1, administration of compound 1-A increases the selective delivery of triphosphate to the liver, as shown in Table 29. The AUC (0-4hr) of active guanine metabolites (1-6) after administration of compound 1 in the heart was 174 μM*hr, while the AUC (0-4hr) of active guanine metabolites (1-6) after administration of compound 1-A in the heart was 28 μM*hr. The liver / heart ratio of compound 1-A was 20 compared to the liver / heart ratio of 3.1 for compound 1. Table 29. Comparison of liver and heart exposure after administration of compound 1 and compound 1-A. The given compound The following mean dose standardized AUC (0-4hr) a (μM*hr): liver heart Liver / Heart Compound 1-A 565 28 b 20 Compound 1 537 174 3.1 a) Active TP concentration (1-6; Scheme 1), standardized to a dose of 25 mg / kg; b) Extrapolated to a dose below the lower limit of quantitation of the calibration curve.

[0291] The increased selectivity of compound 1-A over the heart compared to compound 1 is also shown in Figure 16B. The tissue contents of active triphosphate in the heart and liver after a dose of compound 1-A (30 mg / kg) were compared with the tissue contents of active triphosphate after a dose of compound 1 (25 mg / kg). For both compound 1 and compound 1-A, the concentration of active TP in the liver was higher than that in the heart, but when compound 1-A was administered, active TP was more selective for the liver than for the heart compared to compound 1. Example 20. Plasma profile of metabolites of compound 1-A in rats and monkeys.

[0292] Male Sprague-Dawley rats and cynomolgus monkeys (n=3 per dose group) were administered a single oral dose of compound 1-A. The concentrations of compound 1 and metabolites 1-7 (nucleoside metabolites of the active triphosphate of compound 1-A shown in Protocol 1) in aliquots of plasma prepared from dichlorvos-treated blood samples were analyzed by LC-MS / MS, and pharmacokinetic parameters were determined using WinNonlin. Results for a single 500 mg / kg dose in rats are shown in Figure 17, and results for single 30, 100, or 300 mg / kg doses in monkeys are shown in Figure 18. These results are also summarized in Table 30.

[0293] High plasma levels of metabolites 1-7 (i.e., metabolites of the active triphosphate (TP) of compound 1-A) indicate the formation of high levels of TP, even in rats where extremely low plasma levels of the parent nucleotide prodrug were observed due to the short half-life (<2 minutes) of compound 1 in rat blood. Sustained plasma levels of metabolites 1-7 reflect the long half-life of TP.

[0294] In monkeys, plasma exposure (AUC) of compound 1 was approximately dose-proportional, while exposure of metabolites 1-7 was slightly less dose-proportional, although the AUC values ​​of the parent drug and the nucleotide metabolites of active TP continued to increase up to the highest dose tested (300 mg / kg).

[0295] Oral administration of compound 1-A to rats and monkeys resulted in high and dose-dependent plasma exposure to metabolites 1-7 (nucleoside metabolites of the intracellular active triphosphate of compound 1-A); exposure to metabolites 1-7 continued to increase up to the highest dose tested, reflecting substantial formation of active TP in these species. Table 30. Plasma concentrations of compounds 1 and 1-7 after a single oral dose of compound 1-A. Species rats a monkey b Dosage (mg / kg) 500 30 100 300 Compound 1 C max (ng / mL) 60.8 63.5 783 501 T max (Hour) 0.25 0.5 to 2 1 to 2 204 AUC 0-last (hr*ng / mL) 78.2 176 1100 1600 Metabolites 1-7 C max (ng / mL) 541 42.5 131 93.6 AUC 0-last (hr*ng / mL) 9640 1620 3030 3660 T max (Hour) 6 to 8 12 to 24 4 4 to 24 T 1 / 2 (Hour) 15.3 11.5 15.0 18.8 Dosage formulation: a) 0.5% CMC, 0.5% Tween 80 contained in water; b) powder contained in capsules. Example 21. Effects of the active triphosphates of compound 1 and compound 1-A on mitochondrial integrity.

[0296] The relative efficiency of incorporation of active triphosphates (TP) of compounds 1 and 1-A (i.e., metabolites 1-6 (Scheme 1)) by human mitochondrial RNA polymerase was compared with the relative efficiency of active TP of sofosbuvir and INX-189. Compounds 1 and 1-A were unlikely to affect mitochondrial integrity because their active triphosphates were poorly incorporated by human mitochondrial RNA polymerase at an efficiency similar to that of sofosbuvir triphosphates; the relative efficiency of incorporation of INX-189 triphosphates was as high as 55-fold. The results are shown in Table 31. Incorporation of these analogues by human mitochondrial RNA-dependent RNA polymerase (POLRMT) was determined according to Arnold et al. (Sensitivity of Mitochondrial Transcription and Resistance of RNA Polymerase II Dependent Nuclear Transcription to Antiviral Ribonucleotides. PLoS Pathog., 2012, 8, e1003030). Table 31. Kinetic parameters of nucleotide analogs evaluated by human mitochondrial RNA polymerase Nucleotide analogues K pol (s -1 ) K d,app (μM) K pol / Kd,app (μM -1 s -1 ) Relative efficiency* 2'-Deoxy-2'-F-2'-C-methylUTP (the active TP of sofosbuvir) 0.00034 + 0.00005 590+250 5.8 x 10 -7 +2.6 x 10 -7 1.0 x10 -6 2'-C-methyl GTP (Active TP of INX-189) 0.051+0.002 240+26 2.1 x 10 -4 +0.2 x 10 -4 5.5 x 10 -5 The active TP of compound 1 and compound 1-A (metabolites 1-6) 0.0017 + 0.0002 204+94 8.3 x 10 -6 +4.0 x 10 -6 2.2 x10 -6 *Relative efficiency = (Kpol / Kd,app) analog nucleotide / (Kpol / Kd,app) native nucleotide. Example 22. Activity of compound 1 against replicons containing the NS5B sequence.

[0297] A set of replicons containing the NS5B sequence from various HCV genotypes derived from six laboratory reference strains (GT1a, 1b, 2a, 3a, 4a and 5a) (Fig. 19) and from eight HCV patient plasma samples (GT1a, 1b, 2a, 2b, 3a-1, 3a-2, 4a and 4d) (Fig. 20) were used to determine the potency of compound 1 and sofosbuvir.

[0298] Compound 1 was more effective than sofosbuvir against clinical and laboratory strains of HCV. Compound 1 showed effective pangenotypic antiviral activity against wild-type clinical isolates at EC95 < 80 nM, which was 4 to 14 times more effective than sofosbuvir. As shown in Figure 20, the EC95 value of compound 1 was 7 to 33 times lower than that of sofosbuvir against all tested HCV genotypes of clinical isolates. The EC50 value of compound 1 was 6 to 11 times lower than that of sofosbuvir against laboratory strains of HCV genotypes 1 to 5 (Figure 19). Example 23. Single escalation dose (SAD) study of compound 1-A in healthy volunteers (part A) and GT1-HCV infected patients (part B).

[0299] Compound 1-A was tested in a single escalation dose (SAD) study to determine its safety, tolerability, and pharmacokinetics in healthy individuals (Part A). Part A was a randomized, double-blind, placebo-controlled SAD study. Healthy individuals in Part A received a single dose of compound 1-A or placebo while fasting. Individuals were restricted to clinic settings from Day -1 to Day 6.

[0300] Dosing in each group was staggered so that, 48 hours after dosing, two individuals (one active and one placebo) in each group were assessed prior to administration of the remaining dose. Compound 1-A was received in ascending order across groups. Sequential dosing was conducted based on a review of available safety data (up to day 5) and plasma pharmacokinetic data (up to 24 hours) from previous groups.

[0301] Following a satisfactory review of these data, the dosage was increased. Due to the availability of pharmacokinetic and safety data in previous groups, the dosages evaluated in groups 3a and 4a were adjusted by increments not exceeding 100 mg. The total maximum dose evaluated in part A did not exceed 800 mg. The dosing regimen for part A is shown in Table 32. Table 32. Dosing regimens of compound 1-A in part A Team group N (Active agent: Placebo) Compound 1-A (Compound 1)* 1a healthy 6:2 50 (45) mg x 1 day 2a healthy 6:2 100 (90) mg x 1 day 3a healthy 6:2 200 (180) mg x 1 day 4a healthy 6:2 400 (360) mg x 1 day *Clinical dosage is based on compound 1-A, where the values ​​in parentheses are approximate base equivalents of compound 1.

[0302] The healthy volunteers in Part A of this study were male and female individuals aged 18 to 65 years. The active agent and placebo recipient groups were also included in each Part A group to maintain study blinding.

[0303] Compound 1-A was also tested in a single escalation dose (SAD) study to determine its safety, tolerability, pharmacokinetics, and antiviral activity in patients with GT1-HCV infection (Part B). Individuals in Part B received a single dose of compound 1-A on an empty stomach. From day -1 to day 6, patients were confined to an outpatient setting.

[0304] Part B begins after reviewing the safety (up to day 5) and plasma pharmacokinetics (up to 24 hours) data for Group 3a in Part A. The available safety data (up to day 5) and pharmacokinetics data (up to 24 hours) for Group 1 (Group 1b) in Part B are reviewed before inclusion in subsequent Part B groups. Subsequent Part B groups are only administered after reviewing the available safety and pharmacokinetics data for each dose in Part A and the available safety data (up to day 5) for the previous Part B groups.

[0305] Following a satisfactory review of this data, the dosage increase to up to 600 mg continued in HCV-infected patients. Dosing regimens for part B are shown in Table 33. Table 33. Dosing regimens for compound 1-A in part B. Team group N (Active Agent) Compound 1-A (Compound 1)* 1b Infected by GT1 HCV 3 100 (90) mg x 1 day 2b Infected by GT1 HCV 3 300 (270) mg x 1 day 3b Infected by GT1 HCV 3 400 (360) mg x 1 day 4b Infected by GT1 HCV 3 600 (540) mg x 1 day *Clinical dosage is based on compound 1-A, where the values ​​in parentheses are approximate base equivalents of compound 1.

[0306] Patients infected with HCV are treatment-naïve, non-hard GT1 infected patients with viral replication of >5 log10 IU / mL.

[0307] No serious adverse events were recorded in either part A or part B, and premature discontinuation was not necessary. All adverse effects were mild to moderate in intensity and dose-related patterns (including laboratory parameters), vital signs, and ECGs were not significant. Example 24. Results of a single escalation dose (SAD) study of compound 1-A.

[0308] Pharmacokinetics of compound 1 and nucleoside metabolites 1-7 were determined after a single dose of compound 1-A. In HCV-infected patients following a 600 mg dose of compound 1-A, the C24 plasma trough concentration (C24h) of metabolite 1-7 was 25.8 ng / mL, which was twice the plasma concentration following a 300 mg dose of compound 1-A. Metabolite 1-7 (shown in Protocol 1) is produced solely via dephosphorylation of intracellular phosphate metabolites 1-4, 1-5, and 1-6, and is the active species. Therefore, metabolite 1-7 can be considered a substitute for the active species. Pharmacokinetic data for the groups used are shown in Tables 34 and 35. Values ​​are reported as mean ± SD, except for Tmax of the reported range. Pharmacokinetic parameters were comparable in healthy and HCV-infected patients. Table 34. Pharmacokinetics of Compound 1 and Metabolites 1-7 after a single dose of Compound 1-A in healthy volunteers. Dosage (mg) C max (ng / mL) T max (Hour) AUC tot (ng*h / mL) T 1 / 2 (h) C 24h (ng / mL) Part A, healthy individuals Compound 1 50 46.4 ±17.6 0.5 (0.5 to 0.5) 36.4 ± 12.3 0.32 ± 0.02 -- 100 156 ± 96.3 0.5 (0.5 to 1.0) 167 ± 110 0.53 ± 0.24 -- 200 818 ± 443 0.5 (0.5 to 3.0) 656 ± 255 0.71 ± 0.16 -- 400 1194 ± 401 0.5 (0.5 to 1.0) 1108 ± 326 0.86 ± 0.15 -- Metabolites 1-7 50 27.9 ± 5.62 3.5 (3.0 to 4.0) 285 ± 69.4 7.07 ± 4.59 2.28 ± 0.95 100 56.6 ± 14.0 4.0 (3.0 to 6.0) 663 ± 242 17.7 ± 14.7 4.45 ± 1.87 200 111 ± 38.8 5.0 (3.0 to 6.0) 1524 ± 497 15.9 ± 7.95 13.7 ± 5.09 400 153 ± 49.4 6.0 (4.0 to 8.0) 2342 ± 598 15.6 ± 6.37 23.5 ± 6.31 *Based on 24-hour overview. Table 35. Pharmacokinetics of Compound 1 and Metabolites 1-7 in Human Patients Infected with GT1-HCV Following Administration of Compound 1-A. dose (mg) C max (ng / mL) T max (Hour) AUC tot (ng*h / mL) T 1 / 2 (Hour) C 24h (ng / mL) Compound 1 100 212 ± 32.0 0.5 (0.5 to 1.0) 179 ± 54.4 0.54 ± 0.12 -- 300 871 ± 590 0.5 (0.5 to 1.0) 818 ± 475 0.64 ± 0.20 -- 300 2277 ± 893 0.5 (0.5 to 1.0) 1856 ± 1025 0.84 ± 0.18 -- 400 2675 ± 2114 1.0 (1.0 to 2.0) 2408 ± 1013 0.86 ± 0.18 -- 600 3543 ± 1649 1.0 (0.5 to 1.0) 4132 ± 1127 0.70 ± 0.13 -- Metabolites 1-7 100 50.2 ± 15.4 6.0 (4.0 to 6.0) 538 ± 103* 8.4 ± 4.3* 3.60 ± 0.40 300 96.9 ± 38.9 6.0 (from 3.0 to 6.0) 1131 ± 273* 8.1 ± 2.4* 10.9 ± 3.51 300 123 ± 16.6 4.0 (3.0 to 6.0) 1420 ± 221 -- 18.0 ± 8.83 400 160 ± 36.7 4.0 (4.0 to 4.0) 2132 ± 120 11.6 ± 1.21 22.5 ± 3.29 600 198 ± 19.3 4.0 (4.0 to 6.0) 2176 ± 116 -- 25.8 ± 4.08 *Based on a 24-hour overview.

[0309] Mean plasma concentration-time curves for compound 1 and metabolites 1-7 were also calculated for all groups in Part A and Part B of this study. Figure 21 shows the mean plasma concentration of compound 1 after a single dose of compound 1-A, and Figure 22 shows the mean plasma concentration of metabolites 1-7 after a single dose of compound 1-A. As shown in Figure 21, compound 1 was rapidly absorbed and rapidly / extensively metabolized in all groups from Part B. As shown in Figure 22, metabolites 1-7 were the major metabolites and exhibited sustained plasma concentrations. Plasma exposure to compound 1 was dose-dependent, while exposure to metabolites 1-7 was dose-proportional.

[0310] For individuals with HCV infection in the GT1b group, HCV RNA quantification was performed before, during, and after administration of compound 1-A. Plasma HCV RNA was measured using a validated commercially available assay. Baseline was defined as the average of day -1 and day 1 (before administration). In individuals with GT1b-HCV infection, a single 300 mg dose of compound 1-A (equivalent to 270 mg of compound 1) resulted in significant antiviral activity. In individuals with GT1a HCV infection, the mean maximum HCV RNA reduction was 1.7 log10 IU / mL 24 hours after a single 300 mg dose and compared to a reduction of -2 log10 IU / mL after a 400 mg sofosbuvir monotherapy on day 1. The mean maximum HCV RNA reduction was 0.8 log10 IU / mL 24 hours after a single 100 mg dose. After a single 400 mg dose, the mean maximum HCV RNA reduction was 2.2 log10 IU / mL. Individual pharmacokinetic / pharmacodynamic analyses of individual individuals from Part B of this study are shown in Figures 23A-23F. The concentrations of metabolites 1-7 are plotted relative to the reduction in HCV RNA, and as shown in Figures 23A-23F, plasma HCV RNA reduction is associated with plasma exposure to metabolites 1-7. Viral response is maintained at plasma concentrations of metabolites 1-7 greater than the EC95 value for GT1b. The correlation between plasma concentration and the degree of HCV RNA reduction indicates that a more significant response could be achieved using higher doses of compound 1-A. Example 25. Predicted steady-state trough levels of metabolites 1-7 exceed the EC95 value of compound 1 against clinical isolates of HCV GT1-4.

[0311] As shown in Figure 24, the steady-state plasma trough concentrations (C24, ss) of metabolites 1-7 after administration of compound 1-A (600 mg QD (550 mg free base equivalent) and 450 mg QD (400 mg free base equivalent)) to humans were predicted and compared with the EC95 of compound 1 in all tested clinical isolates in vitro to determine whether the steady-state plasma concentration was consistently higher than the EC95. This result will provide evidence for the high efficacy against any or all tested clinical isolates in vivo. The EC95 of compound 1 is the same as that of compound 1-A. For compound 1-A to be effective, the steady-state plasma trough concentrations of metabolites 1-7 should exceed the EC95.

[0312] As shown in Figure 24, compound 1-A targets EC95 in the range of approximately 18 to 24 nM for all tested clinical isolates.

[0313] As shown in Figure 24, at a dose of 450 mg QD (400 mg free base equivalent), compound 1-A provides a predicted steady-state plasma trough concentration (C24, ss) of approximately 40 ng / mL in humans. At a dose of 600 mg QD (550 mg free base equivalent), compound 1-A provides a predicted steady-state plasma trough concentration (C24, ss) of approximately 50 ng / mL in humans.

[0314] Therefore, against all tested clinical isolates (even the refractory GT3a), the predicted steady-state plasma concentrations of alternative metabolites 1-7 were almost twice that of EC95, indicating superior performance.

[0315] Conversely, among all the HCV clinical isolates tested, the EC95 of the care standard nucleotide sofosbuvir ranged from 50 to 265 nM, with only two isolates, GT2a and GT2b, showing EC95 values ​​lower than predicted steady-state concentrations at a commercially available 400 mg dose. The EC95 of the commercially available 400 mg dose of sofosbuvir was higher than the predicted steady-state concentrations of the other clinical isolates, GT1a, GT1b, GT3a, GT4a, and GT4d.

[0316] The steady-state plasma trough concentration (C24, ss) of compound 1-A at 450 mg was predicted using the 300 mg steady-state plasma trough concentration (C24, ss). The mean steady-state plasma trough concentration (C24, ss) at 300 mg was 26.4 ng / mL, and therefore the calculation was 26.4 * 450 / 300 = 39.6 ng / mL.

[0317] Three methods were used to predict the steady-state plasma trough concentration (C24, ss) at 600 mg: 1) The average C24 on day 1 of 600 mg was 25.8 ng / mL, and it was assumed that it would increase by 60% to reach steady state. Therefore, the calculation was 25.8 * 1.6 = 41.3 ng / mL; 2) The average C24 on day 1 of 400 mg was 22.5 ng / mL, and it was assumed that it would increase by 60% to reach steady state. Considering the dose-proportional PK, the calculation was 22.5 * 1.6 * 600 / 400 = 54 ng / mL; and 3) The steady-state plasma trough concentration (C24, ss) at 300 mg was 26.4 ng / mL, assuming proportional PK. Therefore, the calculation was 26.4 * 2 = 52.8 ng / mL. The steady-state plasma trough concentration (C24, ss) at 600 mg is the average of three data points ((41.3+54+52.8) / 3=49.3 ng / mL). Compared with the C24 after a single dose, the steady-state C24 generally increases by about 60%.

[0318] A comparison of the efficacy and pharmacokinetic steady-state parameters in Figure 24 clearly demonstrates the unexpected therapeutic importance of compound 1-A for the treatment of hepatitis C. In fact, the predicted steady-state plasma concentrations after administration of compound 1-A were at least twice the EC95 for all tested genotypes, and 3-5 times more effective for GT2. This data indicates that compound 1-A has effective pan-genotypic antiviral activity in humans. As shown in Figure 24, the EC95 of sofosbuvir is greater than 100 ng / mL at GT1, GT3, and GT4. Therefore, surprisingly, compound 1-A is active against HCV at a lower steady-state trough concentration (40 to 50 ng / mL) compared to the steady-state trough concentration (approximately 100 ng / mL) achieved with similar formulations of sofosbuvir. Example 26. Three-part study evaluating the safety / tolerability, pharmacokinetic (PK), and antiviral activity of compound 1-A.

[0319] Compound 1-A was used in a three-part study to evaluate safety / tolerability, pharmacokinetics (PK), and antiviral activity. The three parts included: 1) once-daily (QD) administration of up to 600 mg of compound 1-A (equivalent to 550 mg of compound 1) for 7 days in patients with non-cirrhotic GT1 HCV infection (part C); 2) once-daily (QD) administration of 600 mg of compound 1-A (equivalent to 550 mg of compound 1) for 7 days in patients with non-cirrhotic GT3 HCV infection (part D); and 3) once-daily (QD) administration of 600 mg of compound 1-A (equivalent to 550 mg of compound 1) for 7 days in a cohort of patients with cirrhotic Child-Pugh A (CPA) infection with GT1, GT2, or GT3 HCV (part E). Doses were administered in the form of compound 1-A saline. The free base equivalent of compound 1 is often given in parentheses.

[0320] Part C is a randomized, double-blind, placebo-controlled MAD study, divided into three groups. Individuals received 150 mg, 300 mg, or 600 mg of compound 1-A or placebo for 7 days in a fasting state. Dose increases were only made after a satisfactory review of the data. Parts D and E are open-label studies in which patients received 600 mg of compound 1-A (equivalent to 550 mg of compound 1) for 7 days in a fasting state.

[0321] HCV-infected patients who had not received treatment with HCV RNA > 5 log10 IU / mL. HCV RNA was quantified using COBAS® AmpliPrep TaqMAN® v2.0 with an LLQ of 15 IU / mL. Plasma drug levels were determined using LC-MS / MS. The mean baseline HCV RNA was > 6 logs in all patient groups receiving 500 mg of compound 1-A. Cirrhosis was confirmed by prior liver biopsy or Fibroscan > 12.5 kPa. In Parts C, D, and E, the mean baseline Fibroscan in patients receiving a 600 mg equivalent of compound 1-A was 6.3, 6.8, and 17.6 kPa, respectively. The mean ages of enrolled individuals were 44 years, 39 years, and 56 years in the non-cirrhotic GT1b 600 mg dose group, the non-cirrhotic GT3 group, and the cirrhotic group, respectively.

[0322] Parts A and B have been previously conducted and described in WO 2018 / 144640. Parts A and B were single escalation dose (SAD) studies. In Part A, healthy individuals were given up to 400 mg of compound 1-A (equivalent to 367 mg of compound 1), and in Part B, GT1 NC HCV-infected individuals were given up to 600 mg of compound 1-A as a single dose (equivalent to 550 mg of compound 1). Example 27. Results of the study of compound 1-A

[0323] No serious adverse events (AEs), dose-limiting toxicities, or premature discontinuation were reported. Compound 1-A was well tolerated for 7 days up to the highest dose tested (600 mg saline form). The only observed pattern was a higher incidence of most low-grade lipid abnormalities (increased cholesterol and triglycerides) in individuals receiving compound 1-A compared to placebo. However, this observation is consistent with previously published data showing a rapid increase in lipids and HCV clearance after initiation of DAA therapy in HCV-infected individuals. Furthermore, no indication of liver injury was found. In individuals receiving compound 1-A, ALT / AST values ​​increased over time during the treatment period. Ultimately, no other clinically relevant, dose-related patterns were found after analysis of AEs, laboratory parameters, ECGs, and vital signs.

[0324] In Part B, a single dose of Compound 1-A equivalent to 92 mg, 275 mg, 368 mg, or 550 mg of Compound 1 was administered to non-hardened GT1b HCV-infected individuals isolated into treatment groups (n=3 per group) to determine the mean maximum reduction in HCV RNA. The results are shown in Figure 25 and Table 36. A single dose of 600 mg of Compound 1-A (equivalent to 550 mg of Compound 1) administered to non-hardened GT1b HCV-infected individuals (n=3) resulted in a mean maximum reduction in HCV RNA of 2.3 log10 IU / mL, with individual maximum HCV RNA reductions of 2.1, 2.3, and 2.6 log10 IU / mL in this group. Table 36. Changes in HCV RNA from baseline in GT1b HCV patients after a single dose of Compound 1-A. Drug administration team (Compound 1-A equivalent to Compound 1) Average (individual) maximum reduction (log 10 IU / ml) 92 mg 0.8 (0.6, 0.8, 0.9) 275 mg 1.7 (1.1, 1.8, 2.2) 368 mg 2.2 (1.8, 2.2, 2.6) 550 mg 2.3 (2.1, 2.3, 2.6)

[0325] In part C, dose-related antiviral activity was observed 7 days after administration of a mean maximum reduction in HCV RNA up to 4.4 log10 IU / mL in non-hardened GT1b HCV-infected individuals (n=6). 50% of individuals achieved HCV RNA < LOQ. Figure 26 shows the change in mean HCV RNA from baseline in individuals receiving placebo, 150 mg, 300 mg, or 600 mg of compound 2 once daily (QD). The mean maximum reduction was observed 7 days after administration in the three groups receiving 150 mg, 300 mg, or 600 mg of compound 1-A once daily (QD).

[0326] In part D, effective antiviral activity was observed in non-hardened GT3 HCV-infected individuals (n=6), with a mean maximum HCV RNA reduction of 4.5 log10 IU / mL. Following an initial dose of 600 mg of compound 1-A (equivalent to 550 mg of compound 1), the mean HCV RNA reduction was 2.4 log10 IU / mL, and one individual achieved HCV RNA < LOQ within four days of the initial dose.

[0327] The antiviral activity in HCV-infected individuals with CPA sclerosis in the E group was similar to that in the non-sclerotic GT1b and GT3 groups. In the E group, the mean maximum HCV RNA in sclerotic HCV-infected patients was reduced to 4.6 log10 IU / mL. The change in mean HCV RNA from baseline in these populations is shown in Figure 27. For comparison, the curves for the escalation dose groups (part C, non-sclerotic GT1b HCV-infected patients) are shown in Figure 26, and the curves for all 600 mg QD groups (part C / D / E) are included in Figure 27. The antiviral activity of metabolites 1–7 observed in each group is summarized in Tables 39A, 39B, and 39C.

[0328] The mean maximum HCV RNA changes in portions C, D, and E are shown in Table 37. Figures 28A to 28C compare the mean maximum reduction in non-hardened individuals with GT1 HCV infection from portion C, non-hardened individuals with GT3 HCV infection from portion D, and hardened individuals with GT1 / GT2 / GT3 HCV infection from portion E. For individuals, the mean maximum reduction was similar after 7 days of administration, regardless of whether the individual was infected with GT1 or GT3 HCV or whether the individual was hardened or non-hardened. An overview of antiviral activity in all these groups is shown in Tables 37 and 38. A significant early viral response was observed in hardened individuals, resulting in a reduction of 2.4 and 2.2 log10 HCV RNA in GT1 and GT3 HCV individuals, respectively, within the first 24 hours. In this study, five individuals receiving metabolites 1-7 at a dose of 600 mg QD (3 individuals (50%) in part C and 1 individual each (17%) in parts D and E) achieved HCV RNA levels below the lower limit of quantification. Table 37. Maximum HCV RNA changes in parts B, C, D, and E. End point, log 10 IU / mL Part C Part D Part E placebo N = 6 Compound 2, 150 mg / day N= 6 300 mg / day Compound 2 N= 6 600 mg / day Compound 2 N= 6 600 mg / day Compound 2 N= 6 600 mg / day Compound 2 N= 6 Mean ± SD HCV RNA variation from baseline to 24 hours 0.0 ± 0.2 1.2 ± 0.3 1.9 ± 0.2 2.1 ± 0.2 2.3 ± 0.3 2.4 ± 0.2 Mean ± SD HCV RNA maximum change from baseline 0.4 ± 0.1 (0.2 to 0.5)* 2.6 ± 1.1 (1.5 to 3.7)* 4.0 ± 0.4 (3.5 to 4.4)* 4.4 ± 0.7 (3.7 to 5.1)* 4.5 ± 0.3 (4.1 to 5.0)* 4.6 ± 0.5 The largest change in individual HCV RNA from baseline 0.3, 0.3, 0.4, 0.4, 0.5, 0.6 1.7, 1.8, 1.8, 2.7, 3.0, 4.5 3.4, 3.7, 3.9, 4.2, 4.2, 4.5 3.5, 4.0, 4.1, 4.3, 5.2, 5.3 4.2, 4.4, 4.4, 4.5, 4.5, 5.0 GT1b: 4.0, 4.0, 4.5 GT2: 4.8 GT3: 5.0, 5.2 *95% CI Table 38. Overview of the antiviral activity of compound 1-A against 600 mg of compound 1-A in portions C, D, and E. Drug administration team Average reduction after 24 hours (log 10 IU / mL) Average (individual) maximum reduction (log 10 IU / mL) HCV RNA < LOQ (15 IU / mL) GT1, non-hard-shifting (n=6) 2.1 4.4 (3.5, 4.0, 4.1, 4.3, 5.2, 5.3) 3 / 6 GT3, non-hard-shift (n=6) 2.4 4.5 (4.2, 4.4, 4.5, 4.5, 5.0) 1 / 6 GT1, Child-Pugh A (n=3) 2.4 4.2 (4.0, 4.1, 4.5) 1 / 3 GT3, Child-Pugh A (n=1) 2.2 4.8 (n=1) 0 / 1

[0329] Compound 1 (the free base of compound 1-A) is rapidly and well absorbed, with an estimated absorption fraction close to 50% based on urinary recovery. After repeated QD administration for seven days in a fasting state, compound 1 is rapidly absorbed and then rapidly metabolized and activated.

[0330] In part C, after 7 days of daily dosing, compound 1 exhibited a short half-life and did not accumulate over time. Plasma exposure of compound 1 was slightly higher than dose-proportional amounts from 150 mg to 300 mg and mostly slightly higher than dose-proportional amounts thereafter. Although peak plasma exposure and total exposure of metabolites 1-7 were dose-proportional amounts from 150 to 300 mg and less than dose-proportional amounts from 300 mg to 600 mg, trough levels of metabolites 1-7 were mostly dose-proportional amounts within the studied dose range. Based on the trough levels of metabolites 1-7, steady-state PK was essentially reached after the third or fourth dose. The formation of metabolites 1-7 peaked approximately 6 hours after dosing and exhibited a long half-life (approximately 13 to 30 hours) that supported once-daily (QD) dosing. This long half-life resulted in the desired higher trough levels of metabolites 1-7 (50% to 60%) after reaching steady state. (Active triphosphates 1-6 are not measurable in plasma because they do not leave the cells, and therefore 1-7 (which are measurable in plasma) serves as a substitute for triphosphates 1-6 and reflects the intracellular active triphosphates.)

[0331] Steady-state concentrations of metabolites 1-7 were reached by day 3 or 4 in NC individuals and by day 5 in individuals with cirrhosis. Overall, mild hepatic impairment did not significantly affect the p-value of compound 1-A based on plasma exposure. No food effects were observed on total exposure to metabolites 1-7 or trough exposure.

[0332] Figure 29 is a graph showing the mean plasma concentration-time curves of metabolites 1-7 under steady state, comparing non-hardened individuals with GT1 HCV infection who received 138 mg / d QD equivalent of compound 1-A, non-hardened individuals with GT1 HCV infection who received 275 mg / d QD equivalent of compound 1-A, non-hardened individuals with GT3 HCV infection who received 600 mg of compound 1-A (equivalent to 550 mg of compound 1), and hardened individuals with GT1 or GT3 HCV infection who received 600 mg of compound 1-A (equivalent to 550 mg of compound 1). The plasma concentrations of metabolites 1-7 were determined using LC-MS / MS.

[0333] Tables 39A, 39B, and 39C show the mean PK results for individuals included in this study. As shown in Tables 39A to 39C and Figure 29, the PK of metabolites 1-7 were similar in both non-hardened and hardened individuals. Table 39A. Cmax and Tmax of compound 1 and metabolites 1-7 on day 1 and at steady state (SS) Analytes part Dosage (n) C max (ng / mL) T max (h) (mg / d) Day 1 SS Day 1 SS Compound 1 C 150 (6) 573 ± 280 462 ± 409 0.5 (0.5 to 1.0) 1.0 (0.5 to 1.0) 300 (6) 2277 ± 893 1834 ± 1313 0.5 (0.5 to 0.9) 0.5 (0.4 to 1.0) 600 (6) 4211 ± 2302 3604 ± 1742 0.5 (0.5 to 0.5) 0.5 (0.5 to 1.0) D 600 (6) 3971 ± 1943 4144 ± 2280 0.5 (0.5 to 0.5) 0.5 (0.5 to 1.0) E 600 (6) 3412 ± 2175 3192 ± 2085 0.5 (0.5 to 1.0) 0.5 (0.5 to 1.0) Metabolites 1-7 C 150 (6) 75.6 ± 15.4 81.1 ± 33.9 4.0 (4.0 to 6.0) 4.0 (4.0 to 8.0) 300 (6) 123 ± 16.6 220 ± 203 4.0 (2.9 to 6.0) 4.0 (2.0 to 5.9) 600 (6) 197 ± 57.1 233 ± 42.9 5.0 (4.0 to 6.0) 4.0 (4.0 to 6.0) D 600 (6) 195 ± 42.9 263 ± 104 5.0 (3.0 to 6.0) 4.0 (4.0 to 6.0) E 600 (6) 201 ± 68.1 255 ± 95.4 5.0 (3.0 to 6.0) 6.0 (4.0 to 6.0) Table 39B. AUC and T1 / 2 of compound 1 and metabolites 1-7 on day 1 and at steady state (SS). Analytes part Dosage (n) AUC # (ng / mL xh) T 1 / 2 (hours) (mg / d) Day 1 SS Day 1 SS Compound 1 C 150 (6) 492 ± 141 475 ± 301 0.62 ± 0.11 0.64 ± 0.20 300 (6) 1947 ± 1120 1510 ± 976 0.80 ± 0.18 0.73 ± 0.15 600 (6) 3335 ± 1502 4036 ± 2093 0.86 ± 0.11 0.85 ± 0.12 D 600 (6) 3333 ± 1241 3754 ± 2275 0.73 ± 0.12 0.83 ± 0.06 E 600 (6) 3323 ± 1467 3527 ± 1605 0.86 ± 0.18 0.81 ± 0.12 Metabolic products 1-7 C 150 (6) 800 ± 213 962 ± 409 12.5 ± 6.33 300 (6) 1414 ± 220 1828 ± 453 24.5 ± 15.3 600 (6) 2204 ± 486 2839 ± 572 28.9 ± 14.4 D 600 (6) 2253 ± 595 3117 ± 1048 27.9 ± 18.3 E 600 (6) 2625 ± 873 3569 ± 1214 24.4 ± 9.81 #AUCinf of compound 1 and AUCτ of metabolites 1-7 Table 39C. C24h of compound 1 and metabolites 1-7 on day 1 and at steady state (SS) Analytes part Dosage (n) C 24h * (ng / mL) (mg / d) Day 1 SS * Compound 1 C 150 (6) 300 (6) 600 (6) D 600 (6) E 600 (6) Metabolites 1-7 C 150 (6) 8.08 ± 3.48 12.8 ± 4.45 300 (6) 18.0 ± 8.83 26.1 ± 7.56 600 (6) 27.5 ± 5.21 46.9 ± 15.5 D 600 (6) 30.1 ± 10.9 37.8 ± 11.4 E 600 (6) 41.6 ± 12.9 69.9 ± 18.5 *C24 is reported only for metabolites 1-7; C24 at steady state is the average of C24 at 72, 96, 120, 144 and 168 hours.

[0334] Figures 30A to 30D show the PK / PD analysis of individuals with GT1 HCV infection (non-hardened) (Figure 30A), GT3 HCV infection (non-hardened) (Figure 30B), GT1 HCV infection (hardened) (Figure 30C), and GT3 HCV infection (hardened) (Figure 30D). The left y-axis represents the mean concentration of metabolites 1-7, and the right y-axis represents the mean reduction in HCV RNA. The dashed horizontal line (-----) represents the EC95 value of compound 1, and the dots represent Cτ, i.e., the steady-state plasma trough content of metabolites 1-7 after 600 mg of compound 1-A (equivalent to 550 mg of compound 1). As shown in Figures 30A to 30D, in the inhibition of HCV GT1 and GT3 in both non-hardened and hardened individuals, the steady-state plasma trough content of metabolites 1-7 consistently exceeded the EC95 of compound 1. In patients with sclerosis, the steady-state plasma trough level of metabolites 1-7 was 45.7 ng / mL, and the EC95 of compound 1 in HCV GT1, GT2, and GT3 were approximately 21.7 ng / mL, 11.6 ng / mL, and 17.5 ng / mL equivalents, respectively. Figures 30A to 30D also confirm antiviral activity associated with plasma exposure.

[0335] An Emax model based on the AUC of metabolites 1-7 relative to HCV RNA reduction was used to predict that exposure to metabolites 1-7 at >2000 ng / mL xh would result in a maximum viral load reduction of at least 4 log units 7 days after QD administration of compound 1-A (Figure 31). In both non-hardened and hardened individuals, a 600 mg dose of compound 1-A (equivalent to 550 mg of compound 1) consistently reached this threshold, confirming that 550 mg of QD compound 1 (equivalent to 600 mg of compound 1-A) would result in a maximum viral load reduction. Example 28. Description and manufacture of compound 1-A formulations.

[0336] Representative non-limiting batch formulations of Compound 1-A tablets (50 mg and 100 mg) are presented in Table 40. Tablets 32 were produced from the co-blender using a direct compression process as shown in Figure 32. The active pharmaceutical ingredient (API) was adjusted based on as-is assay, with adjustments made for the percentage of microcrystalline cellulose. The API and excipients (microcrystalline cellulose, lactose monohydrate, and croscarmellose sodium) were screened, placed in a V-type blender (PK Blendmaster, 0.5 L bowl), and mixed at 25 rpm for 5 minutes. Magnesium stearate was then screened, added, and the blend was mixed for another 2 minutes. The co-blender was split to produce 50 mg and 100 mg tablets. The lubricated blend was then compressed using a single-punch experimental tablet press (Korsch XP1) and a gravity powder feeder at a rate of 10 tablets / minute. A 50 mg tablet was prepared using a 6 mm circular concave tool and a force of 3.5 kN. A 100 mg tablet was prepared using an 8 mm circular concave tool and a force of 3.9 to 4.2 kN. Table 40. Formulations of 50 mg and 100 mg Compound 1-A tablets. raw materials w / w% g / batch Mg / unit 50 mg tablets 100 mg tablets Compound 1-A 50.0 180.0 50.0 100.0 Microcrystalline cellulose, USP / NF, EP 20.0 72.0 20.0 40.0 Lactose monohydrate, USP / NF, BP, EP, JP 24.0 86.4 24.0 48.0 Sodium croscarmellose, USP / NF, EP 5.0 18.0 5.0 10.0 Magnesium stearate, USP / NF, BP, EP, JP 1.0 3.6 1.0 2.0 total 100.0 200.0

[0337] Compound 1-A was adjusted based on the original analysis, with the adjustment made in the percentage of microcrystalline cellulose. Compound 1-A and excipients (microcrystalline cellulose, lactose monohydrate, and croscarmellose sodium) were screened, placed in a V-type blender (PK Blendmaster, 0.5L bowl), and mixed at 25 rpm for 5 minutes. Magnesium stearate was then screened, added, and the blend was mixed for another 2 minutes. The co-blended compound was split to produce 50 mg and 100 mg tablets. The lubricated blend was then compressed at a rate of 10 tablets / minute using a single-punch research tablet press (Korsch XP1) and a gravity powder feeder. 50 mg tablets were produced using a 6 mm circular standard concave tool and a force of 3.5 kN. 100 mg tablets were produced using an 8 mm circular standard concave tool and a force of 3.9 to 4.2 kN. The specifications of the 50 mg and 100 mg tablets are shown in Table 41. Table 41. Specifications of 50 mg and 100 mg tablets of compound 1-A 50 mg tablets 100 mg tablets Average weight (n=10) 100+5 mg 200+10 mg Individual weight 100+10 mg 200+20 mg hardness 5.3 kp 8.3 kp Disintegration < 15 minutes < 15 minutes Fragility NMT 0.5% NMT 0.5%

[0338] The 50 mg and 100 mg tablets produced as described above underwent a 6-month stability study under three conditions: 5°C (refrigeration), 25°C / 60% RH (ambient), and 40°C / 75% RH (accelerated). The 50 mg and 100 mg tablets were chemically stable under all three tested conditions.

[0339] Under refrigeration conditions (5°C), both 50 mg and 100 mg tablets remained white solids, showing no change in appearance from T=0 to T=6 months. No impurities greater than 0.05% were reported for either the 50 mg or 100 mg tablets throughout the 6-month study. The water content was also less than 3.0% w / w for both tablets after 6 months. Similar results were reported when the tablets were subjected to environmental conditions (25°C / 60% RH); no impurities greater than 0.05% were reported for either tablet within 6 months, and the water content did not exceed 3.0% w / w under the 6-month mark. When the tablets were subjected to accelerated conditions (40°C / 75% RH), the appearance of both the 50 mg and 100 mg tablets did not change from white, round tablets. One impurity was reported after 3 months, but the impurity level was only 0.09%. A second impurity was reported after 6 months, but the total impurity percentage for both the 50 mg and 100 mg tablets was only 0.21%. At 6 months, the water content of the 50 mg tablets was 3.4% w / w and that of the 100 mg tablets was 3.2% w / w.

[0340] In an independent study, the stability of 50 mg and 100 mg tablets of compound 1-A under ambient conditions (25°C / 60% RH) was determined over a 9-month period. During the 9-month period, the appearance of the 50 mg and 100 mg tablets did not change from white, round tablets. After 9 months, the impurities in the 50 mg tablets were less than 0.10% and the impurities in the 100 mg tablets were less than 0.05%. After 9 months, the water content of the 50 mg and 100 mg tablets was only 2.7% w / w and 2.6%, respectively. Example 29: Synthesis of Compound 2 Synthesis of Compounds 2-9

[0341] 3-Chloro-5-chlorophenol (compound 2-1) and 2-(2-bromo-5-chlorophenyl)acetic acid (compound 2-2, 20.02 g, 80.0 mmol) were added to a 250 mL round-bottom flask, mixed with TfOH (91 mL), and heated to 60 °C under a nitrogen atmosphere. After stirring at this temperature for 16 hours, the mixture was cooled to room temperature and poured into isopropanol (500 mL), which had been cooled in an ice / water bath, over a period of 20 minutes. The resulting slurry was diluted with water (125 mL), which was added over a period of 10 minutes. After aging in an ice / water bath for 30 minutes, the mixture was filtered, and the collected solid was washed with 4:1 isopropanol / water (50 mL). The solid was dried under vacuum to provide compound 2-3.

[0342] Compounds 2-3 (2.03 g, 5.37 mmol) were dissolved in 2-methyltetrahydrofuran (20.3 mL, 10 eq.), and ammonia contained in methanol (11.51 mL 7N, 81 mmol, 15 eq.) was added to the solution. The resulting solution was aged at room temperature for 16 hours, then concentrated by removing 25 mL of solvent and treated with toluene (70 mL). The resulting solution was then distilled to remove an additional 35 mL of solvent, resulting in a final solution of compounds 2-5 in 20 eq. This solution was ready for use without further purification.

[0343] Compound 2-5 (25 g, 163 mmol), 4-methoxyaniline (22.1 g, 180 mmol), and isopropanol (250 mL) were added to a 1 L round-bottom flask equipped with an air condenser. The resulting slurry was heated to 50 °C and stirred for 3.5 h, during which time a precipitate formed. The resulting slurry was cooled to 0 °C, aged for 1 h, and then filtered. The flask and gasket were rinsed twice with 0 °C isopropanol (84 mL), and the solids were dried to constant weight in a vacuum oven at 50 °C to provide compound 2-6.

[0344] Add compound 2-6 (7.54 g, 29.2 mmol) and a solution of compound 2-4 in toluene (5.72 wt%, 174.8 g, 26.5 mmol) to a three-necked round-bottom flask equipped with a magnetic stir bar, temperature probe, and nitrogen inlet. Allow the resulting suspension to be stirred at room temperature until the solid dissolves, and cool the resulting solution using an ice / water bath. Add TFA (2.45 mL, 31.8 mmol) while maintaining the internal temperature below 5°C. Allow the resulting solution to be stirred in an ice / water bath for 16 hours, as it is heated to room temperature. Filter the resulting slurry, wash the flask and gasket with toluene (27 mL), and wash the organic solution with aqueous NaHCO3 (4 wt%, 54 mL) and water (54 mL). Concentrate the organic layer to about 25 mL under vacuum, dilute with isopropanol (110 mL), and then concentrate under vacuum to about 50 mL total volume. The resulting slurry was heated to 40°C, diluted with water (10 mL, added over 30 minutes), aged at 0°C for 1 hour, and then filtered. The flask and gasket were washed with 4:1 isopropanol / water (25 mL), and the solid was dried to constant weight in a vacuum oven at 50°C to provide compounds 2-7.

[0345] Degassed toluene (45 mL) was added to a solution of Pd(OAc)2 (219 mg, 0.98 mmol) and (R)-QuinoxP* (compounds 2-8) (343 mg, 1.03 mmol) in a 100 mL round-bottom flask. This solution was evaluated using three cycles of vacuum, backfilled with nitrogen, and then purified with nitrogen over the surface for 5 minutes. The catalyst solution was then allowed to age at 20°C for 2 hours. Compound 7 (25 g, 48.8 mmol), K3PO4 (41.4 g, 195 mmol), and toluene (700 mL) were then added to a 1 L 3-necked round-bottom flask equipped with a top stirrer. This mixture was subjected to three cycles of vacuum degassing and nitrogen backfilling, and then purified with nitrogen over the surface for 5 minutes. Then, degassed water (0.88 mL, 48.8 mmol) was added dropwise, followed by the addition of a pre-prepared catalyst solution, and the resulting reaction was heated to 50–55 °C and stirred at that temperature for 11 hours. During the first 6 hours of the reaction, additional water (5.28 mL, 293 mmol) was added hourly in six equal portions. After a total of 11 hours at 50–55 °C, the reaction mixture was cooled to 20 °C, and 75 mL of water and 5 mL of 50% w / v KOH (approximately 9N) were added. The aqueous layer was discarded, and the organic layer was washed with 100 mL of water. The organic layer was then filtered and concentrated under vacuum, and the residue was purified by rapid column chromatography to provide the free base of compounds 2–9.

[0346] Crude free alkali compound 10 was dissolved in about 50 mL of toluene and 128 mL of iPAC at 45 °C. (S)-camphorsulfonic acid (10.8 g, 46.4 mmol) was added in three fractions at 45 °C for 2.5 h. The mixture was cooled to room temperature and another (S)-camphorsulfonic acid (0.57 g, 2.4 mmol) was added. The mixture was aged at room temperature for 16 h and then filtered. The solid was washed with 50 mL of 1 / 2.5 toluene / isopropyl acetate and then with 50 mL of isopropyl acetate, and dried under vacuum to provide compounds 2-9. Synthesis of compound 2

[0347] In a 500 mL three-necked round-bottom flask equipped with a top stirrer, under nitrogen atmosphere, compound 2-9 ((S)-CSA salt, 10.0 g or equivalent free base), bis(pinacolyl)diboron (8.50 g), potassium acetate (8.78 g), and 5-chloroindole (0.46 g) were added. Degassed 2-Me-THF (130 mL) and water (0.54 mL) were added. In a separate container under nitrogen atmosphere, palladium acetate (0.067 g) and Xphos (2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl) (0.293 g) and degassed 2-Me-THF (20 mL) were added, and the mixture was stirred for 30 minutes, then added to the flask containing compound 2-9. The mixture was then heated to 75°C and allowed to age at this temperature for 1 hour or until complete conversion, then allowed to cool to room temperature. Water (30 mL) was added to the mixture, and the layers were separated. The organic layer was washed with 10% brine (30 mL) and then treated with Cuno-3-carbon (1.0 g) for about 15 hours. The mixture was filtered through a diatomaceous earth mat to remove the carbon. The solution was concentrated under vacuum to approximately 35 mL. Seeds were added to initiate crystallization. The mixture was allowed to age at room temperature for 10 minutes, and then acetonitrile (105 mL) was slowly added. The resulting slurry was filtered, and the collected solid was washed with a mixture of acetonitrile / 2-Me-THF (3:7, 30 mL) and then dried in a nitrogen stream to provide compound 2-10.

[0348] Compound 2-10 (10.0 g, 16.28 mmol, 1.0 equivalent), compound 2-11 (11.5 g, 2.15 equivalent), 2-Me-THF (90 mL), and K2CO3 (98 mL, 1 M, 6 equivalent) were added to a high-pressure vessel. This vessel was degassed. Pd(OAc)2 (0.11 g, 3%) and Xphos (0.58 g, 7.5%) were added to a second reaction vessel, which was then degassed, followed by the addition of degassed 2-Me-THF (20 mL). The resulting catalyst / ligand slurry was allowed to age at room temperature under a nitrogen atmosphere for 2 hours. It was then transferred to a reaction vessel containing compound 2-11 and rinsed with degassed 2-Me-THF (10 mL). The resulting reaction mixture was degassed again, and the reaction vessel was sealed and heated to 85 to 90 °C for about 8 hours until a conversion of >99.5% was achieved. The reaction was cooled to room temperature, and the organic layer was washed sequentially with 10% NaCl solution (18 mL) and 3% NaCl solution (18 mL). The organic layer was then concentrated under vacuum and dried by azeotropic distillation to provide the crude product.

[0349] MeOH (19.4 mL) and tri-n-butylphosphine (2.32 mL) were added to the crude product (14.66 g) contained in 2-Me-THF (135 mL). The mixture was heated to 70°C, and then (S)-mandelic acid (0.94 g) was added in a solution dissolved in 2-Me-THF (3.87 mL). After aging at 70°C for several hours, the reaction mixture was cooled to 60°C, and another portion of (S)-mandelic acid (3.06 g) contained in 2-Me-THF (12.58 mL) was added. The batch was inoculated with mandelate compound 2-12. The final portion of S-mandelic acid (35.41 g) contained in 2-Me-THF (22.25 mL) was added over 4 hours at 60°C. The reaction mixture was gradually cooled to 20°C over 8 hours and aged at 20°C for 1 hour. The slurry was filtered and washed with 2-Me-THF (containing 2% by weight (S)-mandelic acid). The collected solid was dried at 60°C to provide dimandelic acid salt compound 2-12 in solid form.

[0350] The dimantinate compound 2-12 (6 g) was mixed with ethyl acetate (48 mL) and water (25.7 mL). A 2M potassium carbonate solution (6 mL, 2.5 equivalents) was added to the two-phase mixture over 10 minutes, during which time a two-phase solution was formed. The lower aqueous layer was removed and washed successively with 8% saline solution (30 mL) and water (2 × 30 mL). The organic layer was dried by distillation azeotropic drying (final solution volume = 30 mL). Heptane (66 mL) was added to an inert flask. An ethyl acetate stream containing the product was added to the heptane over 2 hours. After aging for another 2 hours, the product slurry was filtered, and the wet filter cake was washed with a mixture of heptane (10.8 mL) and EtOAc (2 mL). The solid was dried under vacuum at 60°C for approximately 15 hours to provide compound 2. Example 30: Synergistic anti-HCV activity of compounds 1 and 2

[0351] The reporter cell line Huh-luc / neo-ET was obtained from Dr. Ralf Bartenschlager (Department of Molecular Virology, Hygiene Institute, University of Heidelberg, Germany) by lmQuest BioSciences under a protocol. This cell line contains a persistently replicating 13sgluc-ubi-neo / NS3-3' / ET replicon of NS3-5B HCV containing the firefly luciferase gene-ubiquitin-neomycin phosphotransferase fusion protein and ET tissue culture adaptive mutations (E1202G, T1208I, and K1846T) driving the EMCV IRES sequence. Huh-luc / neo-ET stock cultures were expanded by culturing in DMEM supplemented with 10% FCS, 2 mM glutamic acid, penicillin (100 IU / ml) / streptomycin (100 µg / ml), and 1X non-essential amino acids, plus 1 mg / ml G418. These cells were divided 1:4 and cultured in the same medium with 250 µg / ml G418 to obtain two passages. The cells were treated with trypsin, stained with trypan blue, and seeded at a cell culture density of 7.5 x 10³ cells / well in 96-well tissue culture plates and cultured at 37°C 5% CO2 for 24 hours.

[0352] Compound Addition—After 24 hours of culture, the medium was removed and replaced with the same medium minus G418, plus three copies of the diluted test compound. Six wells in each plate received separate medium as a non-treatment control. The cells were cultured at 37°C and 5% CO2 for another 72 hours, and anti-HCV activity was then determined by luciferase endpoint assay. Two copies of the plates were processed and cultured in parallel to assess cytotoxicity by XTT staining.

[0353] Cell Viability—Cell viability of the Huh-luc / neo-ET receptor cell line was assessed by staining cell culture monolayers from treated cells with tetrazolium dye XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide) after 72 hours of culture. XTT staining allows for rapid quantitative analysis of the inhibition of virus-induced cell kill by mitochondrial enzymes in metabolically active cells to soluble formazan products, enabling rapid quantification of antiviral assays. XTT solutions were prepared daily at 1 mg / ml stock in RPM11640. Phenyrazine methyl sulfate (PMS) solutions were prepared in PBS at 0.15 mg / ml and stored in the dark at -20°C. Prepare the XTT / PMS stock solution immediately before use by adding 40 µl of PMS per ml of XTT solution. Add 50 µl of XTT / PMS to each well of the plate and incubate the plate at 37 °C for another 4 hours. Seal the plate with an adhesive plate sealer and gently shake or invert several times to mix the soluble formazan product. Read the plate spectrophotometrically at 450 / 650 nm using a Molecular Devices Vmax plate reader.

[0354] Viral Replication from Replicon Analysis System - HCV Replication Assay was performed by measuring luciferase activity after 72 hours of culture using the britelite plus luminescent reporter gene kit according to the manufacturer's instructions (Perkin Elmer, Shelton, CT). In short, one vial of britelite plus lyophilized reagent was dissolved in 10 ml of britelite rehydration buffer and gently mixed by inversion. After incubation at room temperature for 5 minutes, 100 µL of britelite plus reagent was added to each well of a 96-well plate. The plates were sealed with an adhesive membrane and incubated at room temperature for approximately 10 minutes to lyse the cells. The well contents were transferred to a Bass 96-well plate, and luminescence was measured using a Wallac 1450 Microbeta Trilux liquid scintillation counter over 15 minutes. The data were entered into a customized Microsoft Excel 2010 spreadsheet to determine the 50% viral inhibition concentration (ECso) used for a single concentration assessment. Combination Therapy Analysis

[0355] Compound 2 was evaluated in the above anti-HCV assay using a high test concentration of 0.008 nM and a combination of four consecutive double dilutions and nine concentrations of compound 1. In the antiviral assay, 50 μL of each compound was added to a 96-well microtiter plate containing cells at a concentration four times (4x) of the desired level. 50 μL of analytical medium was added to the wells to evaluate the antiviral activity of the test compound as a single compound.

[0356] Data Analysis—Raw data were collected from Softmax Pro and imported into the Prichard and Shipman MacSynergy II software template (Prichard et al., 1993. Antiviral Research 14: 181-206). The combined effect of the drugs was calculated based on the activity of the two compounds when tested individually. The expected additive antiviral protection was subtracted from the experimentally determined antiviral activity at each combination concentration, resulting in a positive value (synergistic or enhancing effect), a negative value (antagonistic effect), or zero (additive effect). The results of the combination analysis are presented in three dimensions at each combination concentration, producing an active surface extending above (synergistic) or below (antagonistic) the additive plane. The volume of the surface is calculated and expressed as the synergistic volume (µM2%) calculated at a 95% confidence interval.

[0357] For these studies, synergy is defined as a combination of drugs producing a synergistic volume greater than 50 µM2% within a 95% confidence interval. Mild synergistic activity and high synergistic activity are defined as producing synergistic volumes of 50 to 100 µM2% and > 100 µM2%, respectively. Synergistic volumes between -50 and 50 µM2% are considered additive, and synergistic volumes less than -50 µM2% are considered antagonistic.

[0358] Evaluation of Anti-HCV Combination Therapy: The inhibition of HCV replication in Huh-luc / neo-ET replicon cells by the combination of compound 2 and compound 1 was evaluated. The percentage of viral replication inhibition exceeding the expected value was calculated for each dual-drug combination at each concentration within 95%, 99%, and 99.9% confidence intervals. Data obtained at 95% confidence levels were plotted in three dimensions, and synergistic volumes were calculated. The synergistic volumes of the combinations at 95% confidence levels are summarized in Table 42 below. Table 42: Evaluation of Combination Anti-HCV Activity compound HCV 1b replicon Synergistic / antagonistic effect volume (μM2 / %) Definition of interaction 20 nM compound 1 0.004 nM compound 2 103 / -6.01 Highly collaborative 40 nM compound 1 0.008 nM compound 2 255 / -25.1 Highly collaborative

[0359] The results of HCV replicon analysis confirmed that, within the concentration range used in the combined antiviral assay, compound 1 at 20 nM and 40 nM and compound 2 at 0.004 nM and 0.008 nM exhibited a synergistic interaction. No antagonistic or synergistic toxicity interactions were observed at the evaluated concentrations.

[0360] This specification has been described with reference to embodiments of the invention. However, those skilled in the art will understand that various modifications and variations can be made without departing from the scope of the invention as set forth in the following claims. Therefore, this specification should be considered illustrative rather than restrictive, and all such modifications are intended to be included within the scope of the invention. [Simplified Explanation of the Diagram]

[0079] Figure 1A is an overlay of XRPD diffraction patterns of samples 1-1 (amorphous compound 1), 1-2 (crystalline compound 1), and 1-3 (amorphous compound 1-A) prior to a stability study for characterization purposes, as described in Examples 2 and 5. The x-axis represents 2θ measured in degrees, and the y-axis represents intensity measured in counts.

[0080] Figure 1B is an HPLC chromatogram of amorphous compound 1 (sample 1-1) used to determine purity as described in Example 2. The purity of the sample is 98.7%. The x-axis represents time measured in minutes and the y-axis represents intensity measured in counts.

[0081] Figure 2A is an HPLC chromatogram of crystalline compound 1 (samples 1-2) used to determine purity as described in Example 2. The purity of the sample is 99.11%. The x-axis represents time measured in minutes and the y-axis represents intensity measured in counts.

[0082] Figure 2B is a DSC and TGA plot of crystalline compound 1 (samples 1-2) prior to any stability studies for characterization purposes, as described in Example 2. The x-axis represents the temperature measured in °C, the left y-axis represents the heat flow measured in (W / g), and the right y-axis represents the weight measured as a percentage.

[0083] Figure 3 is an X-ray crystallographic image of compound 1, which shows the absolute stereochemistry as described in Example 2.

[0084] Figure 4A is an overlay of XRPD diffraction patterns of samples 1-1 (amorphous compound 1), 1-2 (crystalline compound 1), and 1-3 (amorphous compound 1-A) after being stored at 25°C and 60% relative humidity for 14 days as described in Example 2. The x-axis represents 2θ measured in degrees and the y-axis represents the intensity measured in counts.

[0085] Figure 4B is an overlay of XRPD diffraction patterns of samples 1-4, 1-5, 1-6, 1-7 and 1-9 after being stored at 25°C and 60% relative humidity for 7 days as described in Example 4. The x-axis represents 2θ measured in degrees and the y-axis represents the intensity measured in counts.

[0086] Figure 5A is an overlay of the XRPD diffraction patterns of samples 1-4, 1-6, 1-7 and 1-9 after storage at 25°C and 60% relative humidity for 14 days as described in Example 4. The x-axis represents 2θ measured in degrees and the y-axis represents the intensity measured in counts.

[0087] Figure 5B is an XRPD plot of the amorphous compound 1-A (sample 1-3) as described in Example 5. The x-axis is 2θ measured in degrees and the y-axis is the intensity measured in counts.

[0088] Figure 6A is an HPLC chromatogram of amorphous compound 1-A (samples 1-3) used to determine purity as described in Example 5. The purity of the sample is 99.6%. The x-axis represents time measured in minutes and the y-axis represents intensity measured in counts.

[0089] Figure 6B shows the DSC and TGA plots of amorphous compound 1-A (samples 1-3) prior to any stability studies for characterization purposes, as described in Example 5. The x-axis represents the temperature measured in °C, the left y-axis represents the heat flow measured in (W / g), and the right y-axis represents the weight measured as a percentage.

[0090] Figure 7A is an overlay of XRPD diffraction patterns of crystalline samples (samples 2-2, 2-6 and 2-7) and poorly crystalline samples (samples 2-3, 2-4, 2-5 and 2-8) identified from the crystallization of compound 1-A (Example 6). The x-axis represents 2θ measured in degrees and the y-axis represents the intensity measured in counts.

[0091] Figure 7B is an overlay of XRPD diffraction patterns of amorphous samples (samples 2-9, 2-10 and 2-11) identified from the crystallization of compound 1-A (Example 6). The x-axis is 2θ measured in degrees and the y-axis is intensity measured in counts.

[0092] Figure 8A shows the overlap of XRPD diffraction patterns of samples (samples 2-2, 2-3, 2-4, 2-5, 2-6, 2-7 and 2-8) after being stored at 25°C and 60% relative humidity for 6 days (Example 6). The x-axis represents 2θ measured in degrees and the y-axis represents the intensity measured in counts.

[0093] Figure 8B shows the DSC and TGA plots of sample 2-2 (Example 6). The x-axis represents the temperature measured in °C, the left y-axis represents the heat flux measured in (W / g), and the right y-axis represents the weight measured as a percentage. The experimental procedure for DSC and TGA collection is given in Example 2.

[0094] Figure 9A shows the DSC and TGA plots of samples 2-3 (Example 6). The x-axis represents the temperature measured in °C, the left y-axis represents the heat flux measured in (W / g), and the right y-axis represents the weight measured as a percentage. The experimental procedure for DSC and TGA collection is given in Example 2.

[0095] Figure 9B shows the DSC and TGA plots of samples 2-4 (Example 6). The x-axis represents the temperature measured in °C, the left y-axis represents the heat flux measured in (W / g), and the right y-axis represents the weight measured as a percentage. The experimental procedure for DSC and TGA collection is given in Example 2.

[0096] Figure 10A shows the DSC and TGA plots of samples 2-5 (Example 6). The x-axis represents the temperature measured in °C, the left y-axis represents the heat flux measured in (W / g), and the right y-axis represents the weight measured as a percentage. The experimental procedure for DSC and TGA collection is given in Example 2.

[0097] Figure 10B shows the DSC and TGA plots of samples 2-6 (Example 6). The x-axis represents the temperature measured in °C, the left y-axis represents the heat flux measured in (W / g), and the right y-axis represents the weight measured as a percentage. The experimental procedure for DSC and TGA collection is given in Example 2.

[0098] Figure 11A shows the DSC and TGA plots of samples 2-7 (Example 6). The x-axis represents the temperature measured in °C, the left y-axis represents the heat flux measured in (W / g), and the right y-axis represents the weight measured as a percentage. The experimental procedure for DSC and TGA collection is given in Example 2.

[0099] Figure 11B shows the DSC and TGA plots of samples 2-8 (Example 6). The x-axis represents the temperature measured in °C, the left y-axis represents the heat flux measured in (W / g), and the right y-axis represents the weight measured as a percentage. The experimental procedure for DSC and TGA collection is given in Example 2.

[0100] Figure 12A is an XRPD pattern of amorphous compound 1-B (sample 3-12) as discussed in Example 7. The x-axis is 2θ measured in degrees and the y-axis is intensity measured in counts. No crystallization of malonate was observed regardless of the solvent used.

[0101] Figure 12B is an overlay of XRPD diffraction patterns of amorphous samples (samples 3-6, 3-10, 3-11 and 3-12) identified from compound 1 (Example 7) which were attempted to be crystallized using malonate. The x-axis is 2θ measured in degrees and the y-axis is intensity measured in counts.

[0102] Figure 13A is an HPLC chromatogram of samples 3-12 from which compound 1 was attempted to be crystallized using malonate as described in Example 7. The samples were 99.2% pure. The x-axis represents time measured in minutes and the y-axis represents intensity measured in mAu.

[0103] Figure 13B shows the XRPD diffraction patterns of solid samples (samples 4-13, 4-12, 4-9, 4-3, and 4-1) obtained using LAG crystallization as described in Example 8, compared with compound 1 (sample 1-2). All XRPDs match the patterns of the crystalline acid counterions without additional peaks. The x-axis represents 2θ in degrees, and the y-axis represents the intensity in counts.

[0104] Figure 14A shows the XRPD diffraction patterns of samples (samples 6-13, 6-12, 6-11, 6-10, 6-8, 6-7, 6-6, 6-5, 6-4, and 6-2) obtained using ethyl acetate as the crystallization solvent, as described in Example 10, compared to crystalline compound 1 (sample 1-2). Generally, the XRPD patterns are found to match those of compound 1, with slight differences observed in samples 6-2, 6-4, and 6-5. The x-axis represents 2θ measured in degrees, and the y-axis represents intensity measured in counts.

[0105] Figure 14B is an overlay of the XRPD diffraction patterns of sample 5-1 after a second dissolution in MEK as described in Example 9, with the addition of the antisolvents cyclohexane and pamioc acid. Sample 5-1, crystallized in pamioc acid, is a solid after maturation, but its XRPD pattern matches that of pamioc acid.

[0106] Figure 15A shows the XRPD diffraction patterns of samples (samples 6-5, 6-4, and 6-2) obtained using ethyl acetate as the crystallization solvent, as described in Example 10, compared to crystalline compound 1 (sample 1-2). Generally, the XRPD patterns are found to match those of compound 1, with slight differences observed in samples 6-2, 6-4, and 6-5. The x-axis represents 2θ measured in degrees, and the y-axis represents the intensity measured in counts and is labeled using the acid used in the crystallization.

[0107] Figure 15B is an XRPD pattern of compound 1-A as described in Example 14. The x-axis is 2θ measured in degrees and the y-axis is the intensity measured in counts.

[0108] Figure 16A is a graph showing the concentration levels of active TP (metabolites 1-6) in the liver and heart of rats, dogs, and monkeys (Example 18). The x-axis represents the dose measured in mg / kg for each species, and the y-axis represents the concentration of active TP measured in ng / g.

[0109] Figure 16B is a graph showing the concentration levels of active TP (metabolites 1-6) in the liver and heart of dogs (n=2) 4 hours after a single oral dose of compound 1 or compound 1-A (Example 19). The x-axis represents the dose of each compound measured in mg / kg and the y-axis represents the concentration of active TP measured in ng / g.

[0110] Figure 17 shows the plasma concentrations of compound 1 and metabolites 1-7 in rats that received a single oral dose of 500 mg / kg of compound 1-A 72 hours after administration (Example 20). The x-axis represents time measured in hours and the y-axis represents plasma concentration measured in ng / mL.

[0111] Figure 18 shows the plasma profile of compound 1 and metabolites 1-7 in monkeys given a single oral dose of 30 mg, 100 mg or 300 mg of compound 1-A, measured 72 hours after administration (Example 20). The x-axis represents time measured in hours and the y-axis represents plasma concentration measured in ng / mL.

[0112] Figure 19 shows the EC95 values ​​of sofosbuvir and compound 1 against HCV clinical isolates, measured in nM. The EC95 value of compound 1 was 7 to 33 times lower than that of sofosbuvir (Example 22). The x-axis represents the genotype marker and the y-axis represents the EC95 measured in nM.

[0113] Figure 20 shows the EC50 values ​​(in nM) of sofosbuvir and compound 1 against laboratory strains of HCV genotypes 1a, 1b, 2a, 3a, 4a, and 5a. Among genotypes 1-5, compound 1 was approximately 6 to 11 times more potent than sofosbuvir (Example 22). The x-axis represents the genotype marker, and the y-axis represents the EC50 (in nM).

[0114] Figure 21 is a graph showing the mean plasma concentration-time curves of compound 1 after a single dose of compound 1-A in all groups of Part B of this study, as described in Example 24. In all groups from Part B, compound 1 was rapidly absorbed and rapidly metabolized within approximately 8 hours. The x-axis represents time measured in hours and the y-axis represents the geometric mean plasma concentration measured in ng / mL.

[0115] Figure 22 is a graph showing the mean plasma concentration-time curves of compound 1-A after administration of a single dose of metabolites 1-7 to all groups in study part B as described in Example 24. Metabolites 1-7 represent the sustained plasma concentrations from all groups in part B. The x-axis represents time measured in hours and the y-axis represents the geometric mean plasma concentration measured in ng / mL.

[0116] Figure 23A shows the individual pharmacokinetic / pharmacodynamic analysis of individuals enrolled in team 1b as described in Example 24. This figure shows the extent of plasma metabolite 1-7 exposure and HCV RNA reduction. The dashed line represents the minimum concentration of metabolites 1-7 required to maintain a viral response greater than the EC95 value against GT1b. The x-axis represents time measured in hours. The left y-axis represents the plasma concentration of metabolites 1-7 measured in ng / mL, and the right y-axis represents the reduction in HCV RNA measured in log10 IU / mL.

[0117] Figure 23B shows the individual pharmacokinetic / pharmacodynamic analysis of individuals enrolled in team 1b as described in Example 24. This figure shows the extent of plasma metabolite 1-7 exposure and HCV RNA reduction. The dashed line represents the minimum concentration of metabolites 1-7 required to maintain a viral response greater than the EC95 value against GT1b. The x-axis represents time measured in hours. The left y-axis represents the plasma concentration of metabolites 1-7 measured in ng / mL, and the right y-axis represents the reduction in HCV RNA measured in log10 IU / mL.

[0118] Figure 23C shows the individual pharmacokinetic / pharmacodynamic analysis of individuals enrolled in team 1b as described in Example 24. This figure shows the extent of plasma metabolite 1-7 exposure and HCV RNA reduction. The dashed line represents the minimum concentration of metabolites 1-7 required to maintain a viral response greater than the EC95 value against GT1b. The x-axis represents time measured in hours. The left y-axis represents the plasma concentration of metabolites 1-7 measured in ng / mL, and the right y-axis represents the reduction in HCV RNA measured in log10 IU / mL.

[0119] Figure 23D shows the individual pharmacokinetic / pharmacodynamic analysis of individuals enrolled in group 3b as described in Example 24. Each figure shows the extent of plasma metabolite 1-7 exposure and HCV RNA reduction. The dashed line represents the minimum concentration of metabolites 1-7 required to maintain a viral response greater than the EC95 value against GT1b. The x-axis represents time measured in hours. The left y-axis represents the plasma concentration of metabolites 1-7 measured in ng / mL, and the right y-axis represents the reduction in HCV RNA measured in log10 IU / mL.

[0120] Figure 23E shows the individual pharmacokinetic / pharmacodynamic analysis of individuals enrolled in group 3b as described in Example 24. Each figure shows the extent of plasma metabolite 1-7 exposure and HCV RNA reduction. The dashed line represents the minimum concentration of metabolites 1-7 required to maintain a viral response greater than the EC95 value against GT1b. The x-axis represents time measured in hours. The left y-axis represents the plasma concentration of metabolites 1-7 measured in ng / mL, and the right y-axis represents the reduction in HCV RNA measured in log10 IU / mL.

[0121] Figure 23F shows the individual pharmacokinetic / pharmacodynamic analysis of individuals enrolled in group 3b as described in Example 24. Each figure shows the extent of plasma metabolite 1-7 exposure and HCV RNA reduction. The dashed line represents the minimum concentration of metabolites 1-7 required to maintain a viral response greater than the EC95 value against GT1b. The x-axis represents time measured in hours. The left y-axis represents the plasma concentration of metabolites 1-7 measured in ng / mL, and the right y-axis represents the reduction in HCV RNA measured in log10 IU / mL.

[0122] Figure 24 is a graph showing the EC95 values ​​of compound 1 and sofosbuvir against clinical isolates from patients with GT1, GT2, GT3, and GT4 HCV infections. The dashed horizontal line (- - - - -) represents the steady-state trough concentration (C24, ss) of sofosbuvir nucleoside after a dose of 400 mg QD. The full horizontal line (________) represents the steady-state trough concentration (C24, ss) of metabolites 1-7 after a dose of 600 mg of compound 1-A (equivalent to 550 mg of compound 1). The dashed horizontal line (---------) represents the steady-state trough concentration (C24, ss) of metabolites 1-7 after a dose of 450 mg of compound 1-A (equivalent to 400 mg of compound 1). As discussed in Example 25, the predicted steady-state trough plasma concentrations (C24, ss) of metabolites 1-7 following 600 mg and 450 mg of compound 1-A exceeded the in vitro EC95 of compound 1 against all tested clinical isolates. The steady-state trough plasma concentration (C24, ss) of sofosbuvir only exceeded the EC95 against the GT2 clinical isolate. The x-axis is labeled with the clinical isolate, and the table below the x-axis lists the EC95 values ​​of compound 1 and sofosbuvir. The y-axis represents the EC95 against the clinical isolate, measured in ng / mL. EC95 is expressed as nucleoside equivalents. Sofosbuvir and compound 1-A were administered daily (QD).

[0123] Figure 25 is a graph showing the change in mean HCV RNA from baseline after a single dose (92 mg, 275 mg, 368 mg or 550 mg of compound 1) of the equivalent of compound 1-A in individuals with confirmed non-hardening GT1b HCV infection as described in Examples 26 and 27. The x-axis represents the number of hours after administration and the y-axis represents the change in mean HCV RNA from baseline as measured in log10 IU / mL.

[0124] Figure 26 is a graph showing the change in mean HCV RNA from baseline in individuals with confirmed non-hardening GT1b HCV infection as described in Examples 26 and 27, following a 7-day QD administration of compound 1-A. The x-axis represents the number of days after the first dose and the y-axis represents the change in mean HCV RNA from baseline, measured at log10 IU / mL.

[0125] Figure 27 is a graph comparing the change in mean HCV RNA from baseline after a dose of compound 1-A (equivalent to 550 mg of compound 1) at a dose of 600 mg / day QD in individuals with non-cirrhotic GT1 HCV infection, individuals with non-cirrhotic GT3 HCV infection, and individuals with cirrhotic GT1 or GT3 HCV infection, as described in Examples 26 and 27. As shown in the figure, individuals with cirrhosis exhibit a similar change in mean HCV RNA as individuals without cirrhosis. The x-axis represents the number of days after the first dose and the y-axis represents the change in mean HCV RNA from baseline, measured at log10 IU / mL.

[0126] Figure 28A is a graph showing the change in individual HCV RNA from baseline in individuals with non-hardening GT1b HCV infection as described in Examples 26 and 27 after taking compound 1-A at a dose of 600 mg / day QD (equivalent to 550 mg compound 1). The dashed horizontal line (----) represents the limit of quantitation (LOQ = 15 IU / mL) and 50% of individuals achieved HCV RNA < LOQ. The x-axis represents the number of days after the first dose and the y-axis represents the change in HCV RNA from baseline as measured at log10 IU / mL.

[0127] Figure 28B is a graph showing the change in individual HCV RNA from baseline in individuals with non-hardening GT3 HCV infection as described in Examples 26 and 27 after administration of compound 1-A at a dose of 600 mg / day QD (equivalent to 550 mg of compound 1). The dashed horizontal line (----) represents the limit of quantitation (LOQ = 15 IU / mL). The x-axis represents the number of days after the first dose, and the y-axis represents the change in HCV RNA from baseline as measured at log10 IU / mL.

[0128] Figure 28C is a graph showing the change in individual HCV RNA from baseline in individuals with hardened GT1 or GT3 HCV infection as described in Examples 26 and 27 after taking compound 1-A at a dose of 600 mg / day QD (equivalent to 550 mg of compound 1). The dashed horizontal line (----) represents the limit of quantitation (LOQ = 15 IU / mL). The x-axis represents the number of days after the first dose and the y-axis represents the change in HCV RNA from baseline measured at log10 IU / mL.

[0129] Figure 29 shows the mean plasma concentration-time curves of metabolites 1-7 in calcified and non-calcified individuals infected with GT1 / GT3 HCV. As described in Examples 26 and 27, GT1-infected non-calcified individuals were given compound 1-A, equivalent to 138 mg / d, 275 mg / d, or 550 mg / d QD of compound 1; GT3-infected non-calcified individuals were given compound 1-A (550 mg / d compound 1) at 600 mg / d QD; and GT1 / GT3-infected calcified individuals were given compound 1-AQD (550 mg / d compound 1) at 600 mg. The x-axis represents time measured in hours, and the y-axis represents the mean plasma concentration measured in ng / mL.

[0130] Figure 30A is a plot of mean plasma concentrations of metabolites 1-7 (left y-axis) and mean reduction in HCV RNA (right y-axis) over time in individuals with non-hardening GT1b HCV infection as described in Examples 26 and 27 after a QD of compound 1-A at 600 mg / day (equivalent to 550 mg of compound 1). The EC95 of compound 1 in GT1b is shown as a horizontal dashed line (-----). These points represent the steady-state plasma trough concentration (Cτ) of metabolites 1-7, and as shown in the figure, (Cτ) was consistently higher than EC95 at all time points studied. The left y-axis represents the mean plasma concentrations of metabolites 1-7 measured in ng / mL, the right y-axis represents the reduction in HCV RNA after a QD of 550 mg compound 1 measured in log10 IU / mL, and the x-axis represents time measured in hours.

[0131] Figure 30B is a plot of mean plasma concentrations of metabolites 1-7 (left y-axis) and mean reduction in HCV RNA (right y-axis) over time in individuals with non-hardening GT3 HCV infection as described in Examples 26 and 27 after a QD of compound 1-A at 600 mg / day (equivalent to 550 mg of compound 1). The EC95 of compound 1 in GT3 is shown as a horizontal dashed line (-----). These points represent the steady-state plasma trough concentration (Cτ) of metabolites 1-7, and as shown in the figure, (Cτ) was consistently higher than EC95 at all time points studied. The left y-axis represents the mean plasma concentrations of metabolites 1-7 measured in ng / mL, the right y-axis represents the reduction in HCV RNA after a QD of 550 mg compound 1 measured in log10 IU / mL, and the x-axis represents time measured in hours.

[0132] Figure 30C is a plot of mean plasma concentrations of metabolites 1-7 (left y-axis) and mean reduction in HCV RNA (right y-axis) over time in individuals with calcified GT1b HCV infection as described in Examples 26 and 27 after a QD of compound 1-A at 600 mg / day (equivalent to 550 mg of compound 1). The EC95 of compound 1 in GT1b is shown as a horizontal dashed line (-----). These points represent the steady-state plasma trough concentration (Cτ) of metabolites 1-7, and as shown in the figure, (Cτ) was consistently higher than EC95 at all time points studied. The left y-axis represents the mean plasma concentrations of metabolites 1-7 measured in ng / mL, the right y-axis represents the reduction in HCV RNA after a QD of 550 mg compound 1 measured in log10 IU / mL, and the x-axis represents time measured in hours.

[0133] Figure 30D is a plot of mean plasma concentrations of metabolites 1-7 (left y-axis) and mean reduction in HCV RNA (right y-axis) against time in individuals with GT3 HCV infection and hardening as described in Examples 26 and 27 after a QD of compound 1-A (equivalent to 550 mg of compound 1) at a dose of 600 mg / day. The EC95 of compound 1 in GT1b is shown as a horizontal dashed line (-----). These points represent the steady-state plasma trough concentration (Cτ) of metabolites 1-7, and as shown in the figure, (Cτ) was consistently higher than EC95 at all time points studied. The left y-axis represents the mean plasma concentrations of metabolites 1-7 measured in ng / mL, the right y-axis represents the reduction in HCV RNA after a QD of 550 mg compound 1 measured in log10 IU / mL, and the x-axis represents time measured in hours.

[0134] Figure 31 is an Emax model in which the AUC of HCV RNA reduction measured against metabolites 1-7 is plotted on day 7 after QD administration of compound 1-A for individuals with non-hardened GT1b HCV infection, non-hardened GT3 HCV infection, hardened GT1b HCV, and hardened GT3 HCV infection. As described in Examples 26 and 27, individuals with non-hardened GT1b HCV were administered multiple escalating doses of compound 1-A (equivalent to 138 mg / d, 275 mg / d, or 550 mg / d of compound 1) for 7 days. Individuals with non-hardened GT3 and those with hardened GT1 / GT3 infection were administered 600 mg of compound 1-A (equivalent to 550 mg / d of compound 1) for 7 days. The model shows the 95% confidence interval range for non-cirrhotic GT1b HCV at doses of 138 mg / day, 275 mg / day, or 550 mg / day. The model predicts that exposure to metabolites 1-7 at a dose greater than or equal to 2000 ng / mL xh will result in a maximum viral load reduction of at least 4 logs after 7 days of administration. Following a 550 mg dose of compound 1, all individuals achieved exposure to metabolites 1-7 greater than 2000 ng / mL xh, regardless of whether they presented with cirrhosis or not. The x-axis represents the AUC of metabolites 1-7 measured in ng / mL xh, and the y-axis represents the reduction in HCV RNA on a log10 scale at day 7.

[0135] Figure 32 is a flow chart showing the manufacturing process of 50 mg and 100 mg tablets of compound 1-A as described in Example 31. In step 1, microcrystalline cellulose, compound 1-A, lactose monohydrate, and croscarmellose sodium are filtered through a 600 μM sieve. In step 2, the contents from step 1 are loaded into a V-type blender and mixed at 25 rpm for 5 minutes. In step 3, magnesium stearate is filtered through a 600 μM sieve. In step 4, magnesium stearate is loaded into a V-type blender containing the contents from step 2 (microcrystalline cellulose, compound 1-A, lactose monohydrate, and croscarmellose sodium) and mixed at 25 rpm for 2 minutes. The co-blended mixture is then separated to prepare 50 mg and 100 mg tablets. To prepare the 50 mg tablet, the mixture from step 4 is compressed using a 6 mm circular standard concave tool. To prepare 100 mg tablets, the blend from step 4 was compressed using an 8 mm circular standard concave tool. The tablets were then packaged into HDPE bottles containing a desiccant and induced-seal with PP caps.

[0136] Figure 33 shows NS5B polymerase inhibitor compound 1-A and NS5A inhibitor compound 2.

[0137] Figure 34 is a three-dimensional combination surface plot showing at which concentrations the combination of compounds 1 and 2 exhibits synergistic, additive, or antagonistic effects. The effect of the drug combination was calculated based on the activity of the two compounds when tested individually. The expected additive antiviral protection was subtracted from the experimentally determined antiviral activity at each combination concentration to obtain a positive value (synergistic or enhanced effect), a negative value (antagonistic effect), or zero (additive). The results of this combination analysis are presented in three dimensions at each combination concentration, thus producing an active surface extending above (synergistic) or below (antagonistic) additive planes. The combination of compounds 1 and 2 is synergistic across a wide concentration range of compounds 1 and 2. Synergistic effects were observed in compound 1 from about 0.156 to about 1 and 2.5 to 40 or higher nM. The range of compound 2 from about 0.001 nM to about 0.008 nM represents the range of compound 2 where most synergistic effects were observed.

Claims

1. Use of an effective amount of compound 1 or a pharmaceutically acceptable salt thereof in combination with an effective amount of compound 2 or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical product for the treatment of HCV in humans in need: .

2. Use of an effective amount of compound 1 or a pharmaceutically acceptable salt thereof for the preparation of a medicine for treating HCV in humans in need, wherein the medicine is used in combination with an effective amount of compound 2 or a pharmaceutically acceptable salt thereof.

3. Use of an effective amount of compound 2 or a pharmaceutically acceptable salt thereof for the preparation of a medicine for treating HCV in humans in need, wherein the medicine is used in combination with an effective amount of compound 1 or a pharmaceutically acceptable salt thereof.

4. As requested in claim 1, wherein compound 1 is compound 1-A: Compound 1-A.

5. As claimed in claim 2, wherein compound 1 is compound 1-A: Compound 1-A.

6. As requested in claim 3, wherein compound 1 is compound 1-A: Compound 1-A.

7. For any of the uses described in claims 1 to 6, wherein the pharmaceutical product is provided simultaneously, separately or sequentially with compound 1 or a pharmaceutically acceptable salt thereof and compound 2 or a pharmaceutically acceptable salt thereof.

8. The use as claimed in any of claims 1 to 6, wherein the pharmaceutical product is prepared for patients with non-cirrhotic diseases.

9. The use of any of claims 1 to 6, wherein the pharmaceutical product contains 100 mg to 800 mg of compound 1 or an equivalent amount of its pharmaceutically acceptable salt.

10. For any of the uses described in claims 1 to 6, wherein the pharmaceutical product contains at least 550 mg of compound 1 or an equivalent amount of its pharmaceutically acceptable salt.

11. For any of the uses described in claims 1 to 6, wherein the pharmaceutical product contains at least 275 mg of compound 1 or an equivalent amount of its pharmaceutically acceptable salt.

12. The use of any of claims 1 to 6, wherein the pharmaceutical product contains 90 mg to 360 mg of compound 2 or an equivalent amount of its pharmaceutically acceptable salt.

13. For any of the uses described in claims 1 to 6, wherein the pharmaceutical product contains at least 180 mg of compound 2 or an equivalent amount of its pharmaceutically acceptable salt.

14. For any of the uses described in claims 1 to 6, wherein the pharmaceutical product contains at least 90 mg of compound 2 or an equivalent amount of its pharmaceutically acceptable salt.

15. The use of any of the claims 1 to 6, wherein the pharmaceutical product is in a single dosage form.

16. The use of any one of claims 1 to 6, wherein the pharmaceutical product comprises: a dosage form comprising compound 1 or a pharmaceutically acceptable salt thereof, and a second dosage form comprising compound 2 or a pharmaceutically acceptable salt thereof.

17. The use of any of claims 1 to 6, wherein the pharmaceutical product is prepared for oral administration.

18. The use of any of claims 1 to 6, wherein the pharmaceutical product is prepared for non-enteral administration.

19. The use of any of claims 1 to 6, wherein the medicine is prepared for administration once daily.

20. The use of any of claims 1 to 6, wherein the medicine is prepared for administration twice daily.

21. The use as claimed in any of claims 1 to 6, wherein the pharmaceutical product is prepared for administration for a period of up to 12 weeks.

22. The use of any of claims 1 to 6, wherein the pharmaceutical product is prepared for administration for up to 8 weeks.

23. The use of any of claims 1 to 6, wherein the pharmaceutical product is prepared for administration for a period of up to 6 weeks.

24. The use of any of claims 1 to 6, wherein the pharmaceutical product is prepared for administration for a period of up to 4 weeks.

25. The use of any of the claims 1 to 6, wherein the HCV is genotype 1.

26. The use of any of the claims 1 to 6, wherein the HCV is genotype 2.

27. The use of any of the claims 1 to 6, wherein the HCV is genotype 3.

28. The use of any of the claims 1 to 6, wherein the HCV is genotype 4.

29. The use of any of the claims 1 to 6, wherein the HCV is genotype 5.

30. The use of any of the claims 1 to 6, wherein the HCV is genotype 6.

31. As used in claim 25, wherein the HCV is a resistance-related mutant.

Citation Information

Patent Citations

  • Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases

    EP2945952B1

  • Highly active drug combination for treatment of hepatitis c virus

    US20200179415A1

  • Treatment of HCV infected patients with cirrhosis

    WO2019200005A1